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PART I 
 
Abstract 
In the central nervous system, the Ras-ERK signaling module, triggered by the small GTPases of 
the Ras family, plays a key role in different forms of behavioural plasticity, including learning and 
consolidation of long-term memory. In particular, in the striatum the combined engagement of 
dopaminergic and glutamatergic pathways leads to a sustained activation of the Ras-ERK pathway, 
necessary for the normal striatal functions, including learning of procedural actions and habit 
formation, but also for the behavioural responses to the rewarding properties of drugs of abuse. In 
addition, an aberrant ERK hyperactivation is implicated in the development of L-DOPA- induced 
dyskinesia (LID), a severe and disabling pathology characterized by involuntary movements that 
develop as consequence of L-DOPA treatment in parkinsonian patients. 
In this work, I showed the development of a new experimental approach in which striatal slices 
acutely prepared from adult mice can be incubated in a perfusing chamber and challenged with 
appropriate agonists and antagonists. First, I validated our system by Western blot analysis 
performed on striatal slices stimulated for 10 min with glutamate and I confirmed a significant 
ERK1/2 activation.  Next, I developed a system to study ERK activation at a single cell definition 
monitoring by immunofluorescence analysis the phosphorylation state of two proteins downstream 
of ERK1/2: S6 ribosomal protein (cytoplasmic target) and histone H3 (nuclear target). I 
demonstrated that both these proteins are robustly activated upon the application of glutamate, the 
D1Rs agonist SKF38393 or the neurotrophin BDNF 100 µM and that this event is specifically 
regulated by the ERK cascade, thus demonstrating that these two proteins are reliable indicators of 
ERK induction.  
Having validated this experimental setting, I next investigated the integration between 
dopaminergic  and glutamatergic signaling specifically in the D1Rs-expressing neurons (direct 
pathway) and in the D2Rs-expressing neurons (indirect pathway) in adult striatal slices obtained 
from M4-EGFP mice, expressing EGFP in the direct pathway. My results indicate that an additive 
integration between glutamate and SKF38393 is necessary to elicit S6, but not histone H3 
phosphorylation, and this event is restricted to the direct pathway. Unexpectedly, the application of 
the D1Rs agonist activates S6 ribosomal protein also in the indirect pathway in a D1Rs-dependent 
manner. Further experiments will be necessary to clarify the exact mechanism, either direct or 
indirect, through which D1Rs stimulation mediates S6 activation in the indirect pathway. In 
addition, I demonstrated that, whereas D1Rs-mediated signalling depends on glutamatergic activity, 
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glutamatergic activity does not entirely depend on dopaminergic signalling since glutamate-
mediated S6 phosphorylation is only partially inhibited (48% of inhibition) following D1Rs 
blockade. In addition, in the direct pathway, S6 activation seems to be more inhibited (55%) by 
D1Rs antagonist with respect to the indirect pathway (41%). Further experiments will be performed 
also in A2A-EGFP mice, expressing EGFP in the indirect pathway, in order to confirm the results 
concerning the indirect pathway. 
In the last part of the project, I used the technique I developed to investigate the role of the Ras-
ERK signalling in LID. In particular, I demonstrated that the antidyskinetic property of the recent 
discovered NOP receptor agonist (N/OFQ) correlates with a negative modulation of D1Rs-mediated 
signalling in striatal slices obtained from naïve mice, highlighting NOP receptor as a possible drug 
target. Successively, since recent evidence has demostrated that ERK hyperactivation in dyskinetic 
mice is reduced by the loss of Ras-GRF1, a neuronal specific Ras exchange factor, ameliorating the 
dyskinetic symptoms, I wanted to further investigate the effect of Ras-GRF1 ablation on either S6 
and histone H3 activation in dyskinetic mice; my results have demonstrated that histone H3 
phosphorylation as well as ERK phosphorylation are reduced in dyskinetic Ras-GRF1 KO mice, 
whereas the level of S6 phosphorylation does not change in comparison to wild-type mice. These 
findings may indicate that the chronic treatment with L-DOPA produces some adaptive processes 
that bypass Ras-GRF1 and possibly ERK requirement. For instance, lack of Ras-GRF1 may be 
compensated by other calcium-sensitive Ras-GEFs, including the striatal-enriched members of Ras-
GRP/CalDAG GEFs family, although I cannot exclude that other pathways, including mTOR, 
converge to activate S6 in dyskinetic mice effectively bypassing ERK. In order to test our 
hypothesis, further experiments will be performed, for instance by treating dyskinetic wild-type and 
Ras-GRF1 KO mice or striatal slices obtained from these animals with a MEK inhibitor, to 
investigate the effect of ERK blockade on L-DOPA induced S6 hyperactivation. 
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Aim of the project 
The aim of the project is to characterize Ras-ERK pathway in the striatum by developing a new 
experimental approach based on single-cell analysis in mature striatal slices. This system will be 
composed by a chamber for pharmacological stimulation in which brain slices are acutely prepared 
from adult mice, challenged with the appropriate agonists and antagonists and then the induction of 
ERK cascade can be monitored by using specific antibodies against the phosphorylated form of 
ERK1/2 or target proteins downstream of the ERK signaling pathway. 
In an initial phase, I will validate our ex-vivo system : i) by Western blot analysis performed on 
striatal slices stimulated with glutamate to detect ERK activation; ii) by immunofluorescence 
analysis to target specific neuronal population, for instance in a mouse transgenic line available in 
our laboratory expressing EGFP specifically in the striatonigral pathway. 
Having validating the ex-vivo system, I will set out to further investigate the role of ERK cascade in 
the integration of glutamatergic and dopaminergic inputs, comparing the striatonigral and the 
striatopallidal neurons.  
In the last part of my thesis, I plan to use the ex-vivo technique I developed to further elucidate the 
role of Ras-ERK pathway in L-DOPA induced dyskinesia (LID). 
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State of the art 
The GTPases superfamily 
The GTPases superfamily includes a number of proteins with regulatory functions in cellular 
proliferation, differentiation, apoptosis and vesicular trafficking. The GTPases are composed by 
three distinct classes of proteins: i) the heterotrimeric G proteins; ii) the small GTPases Ras-like 
group, including the products of H(arvey)-Ras, N(euroblastoma)-Ras, K(irsten)-Ras genes: 
Ras/Rap, Rho/Rac, Rab, Sar1/Arf, Ran; iii) the inititiation and elongation factors. 
The scientific interest on Ras biology rose at the beginning of the 1980s, when it was demonstrated 
that almost 30% of all solid tumors in humans are associated to specific mutations in the Ras gene 
(Bos et al., 1998). These mutations produce oncogenic forms of Ras that become constitutively 
active and transduce signals leading to cellular proliferation, transformation and tumorigenesis.  
However, it is now known that Ras is implicated in many others cellular events; in particular, it has 
been shown that: i) Ras and Rho/Rac are involved in gene expression: ii) Rho is a key element for 
cytoskeletal reorganization; iii) Rab and Sar1/Arf control vesicular trafficking; iv) Ran is involved 
in the nucleocytoplasmatic transport during G1, S and G2 phases and microtubular organization 
during  mitosis (Wennerberg et al., 2005). 
Ras proteins are  molecular switches for intracellular signal transduction receiving, modulating and 
propagating extracellular signals downstream. They are mainly located at the inner face of the 
plasma membrane in close proximity to different types of receptors, including tyrosine kinase 
receptors (i.e. the Epidermal Growth Factor Receptor, EGFR, the Platelet Derived Growth Factor 
Receptor, PDGF or the Nerve Growth Factor Receptor, NGFR), G-protein Coupled Receptors 
(GPCRs), cytokines receptors, Voltage Gated Calcium Channels (VGCCs), and importantly, in the 
central nervous system, ionotropic glutamate receptors. Once activated, these receptors transmit the 
signals through the cell membrane to the monomeric GTPases that can interact with a number of 
effectors able to propagate the downstream signal, leading to a biological response (Barbacid, 1987; 
Campbell et al., 1998). 
Upon activation, GTPases cycle from an inactive state, GDP-bound, to an active state, GTP-bound. 
The conversion from the inactive to the active state is catalyzed by the Guanine Nucleotide 
Exchange Factors(GEFs) and the GTP binding is facilitated by the higher intracellular concentration 
of GTP with respect to GDP.  
Another class of proteins, named Guanine Dissociation Inhibitors (GDIs), stabilizes the binding 
between Ras and GDP. In addition, given the poor intrinsic GTPase activity of Ras proteins, the 
conversion from the active to the inactive state is catalyzed by GTPase Activating Proteins (GAPs ), 
that increase the rate of GTP hydrolysis (Barbacid, 1987; Bourne et al., 1990). 
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Fig. 1.  Ras activation cycle (From Coleman M. L. et al., 2004) 
 
Ras-mediated signalling pathways 
 
Upon activation, Ras proteins act as key molecular switches for multiple signaling pathways, by 
recruiting specific effector molecules.  Figure 2 summarizes the most studied Ras effectors, i.e. Raf-
1/B-Raf and A-Raf pathway,  the phosphatidylinositol 3-kinase (PΙ3K) and RalGDS cascades. 
Raf-1, also called MAPKKK, is the first serine/threonine kinase of the Mitogen Activated Protein 
Kinases (MAPKs) cascade. Once activated Raf-1 phosphorylates MEK (MAPKK) that in turn 
phosphorylates ERKs (MAPKs). Extracellular signal-Regulated Kinases (ERKs) produce both 
short-term effects, by phosphorylating several cytoplasmatic substrates, and long-term effects, by 
activating transcriptional regulators that modulate the expression of the Immediate Early Genes 
(IEGs). 
The phosphatidylinositol 3-kinase (PΙ3K) pathway is triggered by the direct interaction between Ras 
and the p110α subunit of PI3K  (Rodriguez-Viciana et al.,1996). Activated PI3K catalalyzes the 
phosphorylation of phosphatidylinositol-4,5-bisphosphate (PIP2) by generating the 
phosphatidylinositol-3,4.5-triphosphate (PIP3), that acts as second messenger involved in cell 
survival and in the regulation of gene expression and cellular metabolism. The activation of PI3K 
and the consequent release of PIP3 lead to the activation of several proteins such as Akt. This 
protein kinase promotes cell survival by phosphorylating and inactivating glycogen synthase 3 
(GSK-3) and BAD. Furthermore, activated PI3K provides a link between Ras and Rho/Rac 
GTPases signalling, by recruiting  the guanine nucleotide exchangers of Rac, that activate the SAP 
kinase pathway, another member of the MAPK kinase family. Another effector of Ras is RalGDS 
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that activates RalBP1, a member of the Guanine activating proteins of Rac, Cdc42 and 
phospholipase D.  In addition, it has been demonstrated that also phospholipase Cε (PLCε) directly 
interacts with Ras; the consequent activation of PLCε generates the second messengers inositol 
(1,4,5)trisphosphate (InsP3)  and diacylglycerol (DAG), that trigger calcium release from the 
intracellular stores and the activation of protein kinase C (PKC) (Citro S. et al., 2007). 
 
                                         
   
   Fig. 2. Ras-mediated signalling pathways (From Schubbert S. et al., 2007) 
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The MAPKs pathway  
The extracellular signal regulated kinase (ERK) pathway belongs to the mitogen-activated protein 
kinase (MAPK) superfamily, a class of serine/threonine kinases that are highly conserved among 
the eukaryotes, from yeast to mammals. In the recent years, considerable attention was pointed to 
this signaling module that has been shown to be a key element regulating a series of biological 
processes including not only cell proliferation and differentiation, but also neuronal plasticity, 
survival and apoptosis. On the other hand, a dysregulation of this pathway has been shown to be 
involved in various pathologies, including neurodegenerative diseases, developmental disorders, 
diabetes and cancer. 
The MAPK cascade is triggered by a wide variety of extracellular signals, including growth factors, 
cytokines and neurotransmitters, through many intracellular signaling molecules, such as calcium, 
protein kinase C, PI3-kinase or cAMP, depending on cellular context. This pathway is composed by 
three enzymes that act in a cascade of sequential phosphorylations; upon activation, the small 
GTPase Ras recruits Raf to the plasma membrane, inducing its activation; activated Raf is able to 
phosphorylate MEK which in turn phosphorylates ERK1/2. Once activated, ERKs translocate into 
the nucleus where they mediate genes transcription by activating  specific  transcription factors, 
such as CREB, c-Myc and Elk-1.  
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 Fig. 3. The Ras-ERK pathway (From Davis and Laroche, 2006) 
 
 
Raf  
The Raf family is composed by the Ser/Thr kinases A-Raf, B-Raf e Raf1. While A-Raf is mainly 
expressed in the urogenital apparatus, B-Raf expression is restricted to the central nervous system 
and testicles (Pearson et al., 2001). Raf proteins contain three conserved regions: CR1, CR2, 
localized in the regulatory domain at the N-terminus and CR3, localized in the ATP binding region 
at the C-terminus. Once activated, Raf phosphorylates MEK on Ser218 and Ser222. The exact 
mechanism of Raf activation has not been completely understood yet, but it might involve both 
homo- or hetero-dimerization and phosphorylation. Although the kinases involved in Raf 
phosphorylation are still under investigation, experimental evidence has shown that the activation of 
Raf-1 might be mediated by Ras via protein kinase C (PKC), while B-Raf is activated by Rap1 via 
protein kinase A (PKA). In addition, Rap-1 seems to have opposite effects on the two isoforms of 
Raf, by activating B-Raf and inhibiting Raf-1 (York et al., 1998). It has also been suggested that 
Ras and Rap might be involved in the modulation of ERK cascade activation; in fact, Rap-1 induces 
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a sustained phosphorylation of ERK, that is associated with cell differentiation; on the contrary, 
activation of Ras induces only transient activation of ERK that underlies cell proliferation (York et 
al., 1998, Marshall et al., 1996).  
Interestingly, in the central nervous system, it has been demonstrated that Ras and Rap1 pathways 
converge to activate the MAPKs via NMDA receptors with different kinetics. In fact, depolarization 
in cortical neurons induces a rapid and sustained Ras activation but at the same time a much weaker 
and delayed Rap1 response. This evidence suggests that Ras might act as a fast molecular switch 
involved in transient responses; on the contrary, Rap1 might be involved in the long-term 
modulation of the signal (Baldassa et al., 2003). 
 
MEK 
MEK kinases are dual specificity protein kinases that phosphorylate ERK1/2 on Thr183 e Tyr185, 
two residues located within the activation loop of ERK1/2. In mammalian cells, MEK kinases are 
present in two isoforms: MEK1 and MEK2 that share 80% of homology and are ubiquitously 
expressed. 
 
ERK1 and ERK2 
ERK1 and ERK2, also known as p44 and p42 MAPK, respectively, are highly homologous 
isoforms coded by two genes, erk1 (MAPK3) and erk2 (MAPK1). They share 85% sequence 
identity with much greater identity in the core kinase regions and are ubiquitously expressed, even 
if ERK2 is the predominant isoform in brain and hematopoietic cells (English and Sweatt, 1996). 
Phosphorylation by MEK in their activation loop (Tyr185 e Thr183) leads to a conformational 
change allowing their activation in the cytoplasm and subsequently their translocation into the 
nucleus, where they can activate transcription factors, either directly or indirectly, in order to induce 
the expression of several immediate early genes. 
In the cytosol, ERK1/2 phosphorylates a wide range of substrates including membrane proteins, 
such as  phospholipase A2, cytoskeletal proteins and several protein kinases such as p90 rsk (90 KDa 
ribosomal S6 Kinase). p90 rsk  kinases (there are three isoforms, Rsk 1,2 and 3) activate cAMP 
response element (CRE) binding factor (CREB), a member of leucine-zipper transcription factors 
that binds a specific sequence of DNA, called CRE, that can be found in the promoter of many 
genes, including  c-Fos, FosB and Zif268.  
In addition, in the nucleus, ERK1 and 2 can bind and activate serum response element (SRE) 
binding proteins, such as Elk-1, thus contributing more directly to transcriptional regulation. 
Finally, ERK1/2 can also regulate gene transcription more globally at the level of chromatin 
remodelling by phosphorylating histone H3 on Ser10 via the kinase MSK-1 (and MSK2).  
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The ERK cascade also controls protein translation by activating the p70 S6 kinase-1 (S6K-1), which 
is phosphorylated by mTOR. S6K1 can directly activate S6 ribosomal protein, that is located near 
the mRNA and tRNA binding sites on the 40S ribosomal subunit. Although the exact mechanism 
through which the phosphorylated S6K1 and S6 ribosomal protein are involved in translational 
regulation is not completely clear, it has been shown that S6 phosphorylation correlates with an 
increased translation rate. In addition, the ERK-dependent phosphorylation of MAPK-interacting 
serine/threonine kinase 1 (Mnk1), which can phosphorylate eIF4E, is associated with an enhanced 
translation initiation (Klann and Dever, 2004). 
Since ERK1 and ERK2 are activated by the same stimuli and they have identical substrate 
specificity, for a long time they have been considered as interchangeable.  However, recent 
experiments conducted on ERK1 and ERK2 knock-out mice highlighted important functional 
differences between the two isoforms. At the level of the whole organism, clear differences have 
been shown between ERK isoforms. Precisely, erk2 gene ablation results in early embryonic 
lethality, showing that ERK1 cannot compensate ERK2 (Saba-El-Leil et al., 2003; Pages et 
al.,1999), whereas genetic inactivation of ERK1 is fully compatible with adult life (Satoh et al., 
2007; Mazzucchelli et al., 2002). In addition, experiments conducted on mouse embryonic 
fibroblasts (MEFs) from ERK-1 KO mice and RNA interference approaches have given insight into 
the individual contribution of ERK1 and ERK2 in cell proliferation. In particular, ERK-1 knock out 
cells isolated from ERK-1 knock-out mice showed that the stimulus-dependent activation of ERK-2 
was enhanced without any increase in ERK2 protein (Vantaggiato et al., 2006; Mazzucchelli  et al., 
2002). 
Other studies demonstrated that ERK1 knock-down in culture cells leads to increased cell growth; 
importantly, the resulting enhancement of ERK2 activation is similar to what observed when 
constitutive active form of MEK1 is overexpressed via lentiviral vectors into MEFs. On the 
contrary, the ERK2 knock-down phenotype is similar to what observed with a dominant negative 
form of MEK1 (Vantaggiato et al., 2006; Indrigo et al., 2010). These results suggested a differential 
role of ERK1 and ERK2 in transducing intracellular signals; in particular, ERK2 is supposed to 
interact with MEK more efficiently and ERK1 is likely to act as partial agonist, providing a fine 
tuning of ERK2 activity (Vantaggiato et al., 2006). 
Despite these observations, other studies still claim that ERK isoforms contribute to ERK signalling 
according to the ratio of their expression levels and not to their specific properties. For instance, in 
2008 Lefloch and collaborators have reported that silencing of ERK2 expression slows the 
proliferation of NIH 3T3 fibroblasts, whereas reduction of ERK1 has no effect. Moreover, silencing 
of ERK1 further reduces cell proliferation in cells with a limiting level of ERK2 (Lefloch et al., 
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2008). More recently, another work have supported the idea that both ERK1 and ERK2 act as 
redundant and positive-regulators of cell proliferation, since MEFs genetically deficient for erk1 or 
erk2 show a slower proliferation rate to an extent reflecting the expression level of the kinase 
(Voisin et al., 2010). 
 
The role of the MAPKs in learning and memory formation  
In the central nervous systems, the ERK signaling cascade connects the stimuli deriving from 
ionotropic, metabotropic and neurotrophin receptors with cytosolic and nuclear events, leading to 
gene transcription and de novo protein synthesis. Recent evidence suggested the involvement of the 
Ras-ERK signaling module with many neuronal functions, such as different forms of plasticity 
including structural modifications at the synapses, learning and consolidation of long-term memory. 
Indeed, several components of the Ras-ERK pathway, including Ras and ERK1/2 themselves, but 
also Ras-GRF1, SynGAP and NF-1 are abundantly expressed in the central nervous system, in 
particular in brain regions involved in learning and memory (hippocampus, neocortex and 
cerebellum) (Kim et al., 2003; Zippel et al., 1997; ) 
In addition, the Ras-ERK cascade is coupled to diverse receptors (NMDARs, AMPARs, VGCCs) 
and it is potently activated by intracellular increase of calcium and cAMP (Kennedy et al., 2005; 
Farnsworth et al., 1995). 
 
Long term potentiation (LTP) is the classical cellular model of neuronal plasticity that underlies the 
formation and the storage of memory and involves both rapid and persistent remodelling of the 
synapses. Rapid synaptic changes rely on the insertion of AMPA receptors in the plasma membrane 
and the remodelling of actin cytoskeleton and they are regulated by local calcium, whereas the long 
lasting modifications require synthesis of new proteins that are involved in the loss or pruning of 
dendritic spines and the formation or elimination of synapses. LTP can be dependent or independent 
on NMDA receptors and it consists in two distinct temporal phases: the early LTP, which lasts up to 
30-60 minutes and depends on second messengers and kinases activity, and the late LTP, which 
lasts up to weeks and requires gene transcription and de-novo protein synthesis (Kennedy et al., 
2005; Martin et al., 2000). 
The molecular mechanisms underlying LTP induction and maintenance can be summarized in 
figure 4. First of all, glutamate is released as neurotransmitter from the presynaptic neurons and it 
specifically stimulates AMPA receptors. This event allows the post synaptic membrane to 
depolarise and Mg++ is removed from NMDA receptors, with the consequent channel opening. 
Following NMDARs activation, calcium enters the post-synaptic neuron and it can mediate the 
                                          Studying the Ras-ERK pathway through single-cell analysis in acute striatal slices 
 13 
activation of different protein kinases, including Calcium-calmodulin Kinase II (CamKII), thus 
contributing to the LTP onset. Interestingly, calcium-calmodulin can also activate Ras-GRF1, a Ras 
exchange factor specifically expressed in neurons of the adult brain, leading to the activation of the 
Ras-ERK pathway. Upon a prolonged activation of the post-synaptic neuron, the ERKs are 
phosphorylated and they translocate into the nucleus where they activate specific transcription  
factors, such as CREB and Elk-1, and immediate early genes, including zif268, which are necessary 
for the consolidation of memory (Sheng and Kim, 2002). 
In addition, the ERKs have many other substrates, including cytoskeletal proteins (MAP-2 and 
Tau), which are necessary for synaptic remodelling, and mTOR, a protein associated with the 
translation machinery (Vaillant et al., 2002; Kelleher et al., 2004).  
   
 
                                       
Fig. 4. The MAPKs activation during long term potentiation (LTP) (From Sheng M. and Kim M. J., 
2002) 
 
In recent years, several studies have extensively documented that a normal-functioning ERK 
cascade is required in different forms of neuronal plasticity, such as learning and memory formation 
and consolidation. In particular, the use of the MEK inhibitors UO126 and SL327 provided the first 
evidence that ERK signalling is required for the brain functions. The initial studies focused on 
NMDA-dependent long-term potentiation (LTP) in the CA1 and in the dentate gyrus using 
hippocamapal slices in vitro and demonstrated that three distinct MEK inhibitors completely block 
late LTP and attenuate early LTP. Consistently, it was shown that the induction of LTP in the 
dentate gyrus results in a rapid and transient increase of activated ERK (Sweatt, 2001). 
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Furthermore, it was demonstrated that ERK activation is a key step that regulates AMPARs activity 
and structural plasticity, thus contributing to increase the synaptic transmission. In particular, MEK 
inhibitors or the expression of Ras dominant negative forms prevent AMPARs insertion in the post-
synaptic neurons and the formation of new dendritic spines (Zhu et al., 2002). 
Subsequent studies in vivo highlighted the evidence that the activation of ERK is necessary for the 
consolidation of long-term memories associated to different types of learning, including fear 
associated learning (Atkins et al., 1998; Schafe et al., 2000; Selcher et al., 1999; Walz et al., 1999), 
conditioned taste aversion (Berman et al., 2000; Swank, 2000), object recognition (Kelly et al., 
2003) and spatial learning (Blum et al., 1999; Selcher et al., 1999; Hebert and Dash, 2002). These 
studies have also shown that ERK is hyperphosphorylated after the learning phase and that MEK 
inhibition results in an impaired consolidation of long-term memory, without affecting short-term 
memory and learning (Miyamoto, 2006; Davis and Laroche, 2006; Thomas and Huganir, 2004). 
It should be noted that all these studies relied on the use of MEK inhibitors that do not allow to 
dissect any functional difference between  ERK1 and ERK2. However, recent studies based on the 
use of knock-out mice  have provided a strong evidence that ERK1 and ERK2 play specific and 
distinct roles in synaptic plasticity. Although the ERK1 KO mice do not show any compensatory 
changes in basal ERK2 expression, they manifest a robust increase of ERK2 phosphorylation 
following exposure to glutamate or dopamine receptor D1 agonist compared with wild type mice. 
This result correlate with the evidence that synaptic plasticity in the striatum is enhanced in ERK1-
KO mice, correlating with an improved memory formation in striatum-dependent learning tasks and 
an enhanced behavioural response to reward properties of morphine and cocaine (Mazzucchelli et 
al., 2002; Ferguson et al., 2006).  
 
Ras-related syndromes 
Mutations within genes of ERKs signalling pathway have been associated to several diseases that 
often includes neurological and cognitive deficits. A group of syndromes are characterized by 
cardiac and craniofacial abnormalities and includes Costello, Noonan, LEOPARD, Legius and 
cardio-facio-cutaneous (CFC) syndromes. A related disorder is also Neurofibromatosis Type 1 
disease, mainly characterized by cutaneous abnormalities (café au lait spots),  and neurofibromas. 
All these disorders show a certainly degree of cognitive impairments (from mild to severe) (Aoki et 
al., 2009; Samuels et al., 2009; Fasano and Brambilla, 2011). 
Costello syndrome is associated to a gain of function mutation of H-Ras and has clinical features 
similar to CFC; in particular, in Costello syndrome 40% of the patients exhibits frontal lobe 
atrophy, 26% of the patients shows cerebellar abnormalities and all these patients are affected by 
significant mental retardation.Instead, CFC results from mutations in K-Ras, B-Raf and MEK and 
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almost 80% of the patients are affected by mental retardation associated with severe CNS 
abnormalities. Noonan syndrome (NS) has been associated to point mutations in distinct genes 
coding for upstream proteins in the ERK cascade, such as SHP2, K-Ras, Sos-1 and Raf. All these 
mutations lead to the upregulation of the ERK pathway and the classical clinical manifestations 
include pulmonic stenosis, short stature, and facial dysmorphia. In this case, mental retardation has 
been reported only in 25% of the patients.  Neurofibromatosis type 1 (NF1) arises from mutation or 
deletion of the NF1 gene encoding neurofibromin, a RasGTPase activating protein that acts as a 
negative regulator of ERK activation. Over half of individuals with NF1 mutations have intellectual 
impairment. In addition, individuals with deletions encompassing the NF1 gene exhibit a more 
severe intellectual impairment. LEOPARD syndrome (lentigines, EKG abnormalities, ocular 
hypertelorism, pulmonic stenosis, abnormal genitalia, retardation of growth, and deafness) arises 
from loss-of-function mutations in PTPN11 and K-RAS that are distinct from those associated with 
NS, though there is clinical overlap between the two disorders (Bentires-Alj et al., 2006). Two 
recent reports of gain-of-function mutations in RAF1 were shown to cause Noonan and LEOPARD 
syndromes, and were associated with increased ERK activation (Pandit et al., 2007; Razzaque et al., 
2007). Recently a new syndrome has been described, termed NF1-like or Legius syndrome, which 
results from loss-of-function mutations in the SPRED1 gene. The SPRED1 gene product normally 
acts to suppress ERK activation, as does NF1 (Brems et al., 2007). Thus, loss-of-function mutations 
in NF1 or SPRED1 result in elevation of ERK pathway activation. These patients are also 
cognitively impaired and macrocephalic and exhibit facial dysmorphism similar to other NCFC 
syndromes (Brems et al., 2012). 
Among the diseases associated to the ERK pathway, also a X-linked syndrome has been identified: 
the Coffin-Lowry Syndrome, resulting from mutations at Xp22.2, that causes a loss of function of 
the kinase RSK-2 (Ribosomal S6 kinase-2), associated to a severe mental retardation (Samuels et 
al., 2009; Stornetta and Zhu, 2010). 
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Fig.5. Mutations of genes in ERK pathway and associated syndromes (From Stornetta and Zhu, 2010) 
 
Ras-GRF1 
Ras-GRF1 is a Ras exchange factor exclusively expressed in the central nervous system, in 
particular in the hippocampus, thalamus, cortex and cerebellum, whereas it is not expressed in the 
peripheral neuronal cells, and in non-neuronal cells. Subcellular fractionation of the mouse brain 
has shown that it is localized in synaptosomes and enriched in post-synaptic densities. In the 
rodents, the expression of Ras-GRF1 is regulated during the development; in fact, this protein has 
not been found in the embryos but its expression increases in the first few days after birth, a timing 
that correlates with the maturation of the synapses (Zippel et al., 1997). 
Ras-GRF1 can be regulated both by calcium and heterotrimeric G proteins  (Shou et al., 1995; 
Zippel et al., 1996; Mattingly et al., 1999) and more recent studies demonstrated that the N-terminal 
region of Ras-GRF1 can interact with HIKE domain of the tyrosine kinase receptor TrkA (Robinson 
et al., 2005).  In addition, Ras-GRF1 can be activated by calcium influx through NMDARs; in fact, 
it has been shown that Ras-GRF1 binds directly the NR2B subunit of NMDA receptor and therefore 
mediates a large fraction of NMDAR-dependent ERK activation in cultured hippocampal neurons 
(Krapivinsky et al., 2003). 
Experiments conducted on Ras-GRF1 knock-out animals contributed to define the role of the Ras-
ERK pathway in the neuronal signalling. In fact, although these animals are viable, fertile and they 
do not have any phenotypic difference compared to wild-type mice besides a small reduction in 
body weight, they show learning and memory impairments. In particular, behavioural studies 
conducted on Ras-GRF1 knock out mice put in evidence that Ras-GRF1 ablation does not affect 
hippocampal learning and spatial memory, but significantly impairs fear conditioning and 
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procedural learning (Brambilla et al., 1997; D’Isa et al., 2011). Furthermore, the use of Ras-GRF1 
knock out mice has also suggested the implication of Ras-ERK pathway in drug-dependent 
behavioural changes (“drug addiction”). For instance, Ras-GRF1 knock our mice do not develop 
tolerance to analgesic and hypolocomotor effects induced by the chronic treatment with 
cannabinoids (Rubino et al., 2004).  More recently, it has been shown that these animals manifest a 
reduced response to cocaine, measured as locomotor sensitization and conditioned place preference 
(Fasano et al., 2009).  
 
Signal transduction in the striatum 
The striatum, composed by the caudate putamen and the nucleus accumbens, is the input nucleus of 
the basal ganglia, a group of interconnected subcortical nuclei sustaining diverse functions as motor 
control, learning, planning, working memory and emotions. 
The basal ganglia also include: 
-the globus pallidus pars externa (GPe) and pars interna (GPi),  
-the subthalamic nucleus (STN),  
-the substantia nigra pars compacta (SNc) and pars reticulata (SNr) 
 
The GABAergic medium spiny neurons (MSNs) are the main neuronal type in the striatum and they 
receive excitatory glutamatergic inputs from the cortex, thalamus and limbic areas and modulatory 
dopaminergic inputs from midbrain neurons located in the SNc and in the ventral tegmental area.  
In addition, MSNs receive inhibitory synapses originating from other MSNs and GABAergic 
interneurons, and many others afferents such as cholinergic and serotoninergic inputs. 
The putamen efferent neurons connect the striatum to the output nuclei of the basal ganglia, such as 
GPi and SNr, via two distinct projection systems: the “direct striatonigral pathway”, that projects 
directly to these nuclei, and the “indirect striatopallidal pathway”, which projects via a circuit 
including the GPe and the STN. The MSNs of the direct pathway express preferentially the D1 
subtype of dopamine receptors (D1Rs) and they produce the neuropeptide cotransmitters dynorphin 
and the substance P, whereas the MSNs of the indirect pathway are enriched in D2 subtype of 
dopamine receptors type 2 (D2Rs) and adenosine A2A receptors and they produce the neuropeptide 
enkephaline. 
According to the general model of basal ganglia transmission, the direct pathway disinhibits the 
thalamo-cortical neurons thus promoting the motor activity, whereas the indirect pathway reduces 
motor activity by inhibiting the thalamo-cortical neurons. In addition, dopamine promotes motor 
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activity by exerting opposite actions on the two pathways; in particular, it activates the striatonigral 
MSNs and, in the same time, inhibits the striatopallidal MSNs. 
 
                                       
 
Fig. 6. The two distinct classes of striatal MSNs. Representation of a striatopallidal MSN (left) and a 
striatonigral MSN (right)(From Cenci, 2007). 
 
 
 
Dopaminergic and glutamatergic signalling in the striatum and their synergism 
Dopaminergic signalling in the striatum is mediated by the two classes of dopamine receptors, 
D1Rs and D2Rs, that are coupled respectively to the Gαolf and Gαi/o, thereby exerting opposite 
effects on the production of cAMP. Once stimulated by burst firing of dopaminergic neurons, the 
D1Rs promote the Gαolf-mediated stimulation of adenyl-cyclase, thus increasing intracellular 
cAMP level and leading to the enhancement of motor activity. The increase in cytosolic cAMP 
levels results in the activation of various intracellular targets, such as cAMP-regulated 
phosphoprotein of 32 kDa (DARPP-32), that mediates the activation of several downstream factors 
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involved in the control of the excitability of the MSNs.  Once activated, DARPP-32 acts as a strong 
inhibitor of the phosphatase PP1 and thus prevents the dephosphorylation of  different downstream 
targets of PKA, thereby amplifying the cAMP-mediated responses. PP-1 acts at the level of 
NMDARs, by dephosphorylating the NR1 subunit, and also activates the striatal-enriched tyrosine 
phosphatase (STEP) that dephosphorylates the regulatory tyrosine of ERK.  
A series of studies have shown that D1Rs-mediated PKA activation promotes surface expression of 
both AMPARs and NMDARs, even though the precise mechanism is still unknown. It has been 
suggested that PKA may be involved in receptor trafficking through DARPP-32-mediated inhibiton 
of PP-1 and through the inhibition of STEP (Braithwaite et al., 2006). Another mechanism 
underlying the surface expression of glutamate receptors may be mediated  by an independent 
pathway involving Src-family tyrosine kinases (Pascoli et al., 2010).  
The D2Rs have higher affinity for dopamine and therefore they are activated by low basal levels of 
dopamine; upon stimulation, the D2Rs mediate a tonic inhibition on adenyl-cyclase and membrane 
potential, thereby opposing the action of D1Rs but also A2A receptors. In addition, released Gβγ 
subunits stimulate phospholipase Cβ, leading to the activation of PKC and calcium release from the 
intracellular stores. Several studies have highlighted the evidence that the activation of D2Rs reduce 
the excitability of striatopallidal neurons by decreasing AMPARs currents of MSNs recorded in 
brain slices and also promoting the trafficking of AMPARs out of the synaptic membrane (Cepeda 
et al.,1993; Hakansson et al., 2006). In addition, D2Rs are able to modulate in a coordinate manner 
the activity of different ion channels, thus reducing the responsiveness of MSNs to glutamatergic 
inputs (Hernandez-Lopez et al., 2000). 
 
The ERK cascade in the striatum 
Different types of ionotropic and metabotropic glutamate receptors are stimulated by glutamate 
released from corticostriatal and corticothalamic neurons. 
As summarized in figure 6, NMDARs activation allows calcium influx that stimulates various 
proteins, such as Ras-GRF1, thereby triggering the ERK cascade. This event is amplified by D1Rs 
stimulation through a cAMP-independent pathway involving the Src-family tyrosine kinases (SFK) 
and through the  DARPP-32-mediated inhibition of PP-1, thus blocking the dephosphorylation of 
NR1 subunit of NMDARs and the activation of STEP (Pascoli et al., 2010; Valjent et al., 2005). In 
this manner, the ERK cascade is likely to act as coincident detector between the dopamine and the 
glutamate pathways.  
A large part of calcium-dependent activation of ERK seems to be mediated by Ras-GRF1 (Fasano 
et al, 2009), but also two other GEFs, CalDAG GEFI and CalDAG GEFII, stimulated by calcium 
and diacyl glycerol, are involved in the triggering of ERK pathway (Toki et al., 2001). 
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Fig. 7. Glutamatergic and dopaminergic signalling pathways in striatonigral MSNs (From Matamales 
and Girault, 2011). Glutamate-induced ERK activation involves calcium influx from NMDARs that 
stimulates RasGRF1, triggering Raf/MEK/ERK cascade. Active ERK, together with Elk1, is able to 
associate with endocytosed AMPARs through the adaptor protein AP2; this complex mediates the nuclear 
import of active ERK and Elk1. ERK activation is strongly potentiated by dopamine-induced D1Rs 
activation through two different mechanisms: i) cAMP-independent pathway involving Src family tyrosine 
kinases (SFK); ii) cAMP/PKA pathway that inhibits protein phosphatase 1 (PP1) through phospho-DARPP-
32. D1Rs stimulation promotes the Gαolf-mediated stimulation of adenyl-cyclase 5 (AC5), thus increasing 
intracellular cAMP level. The inactive PKA heterotetramer is anchored through AKAPs; cAMP binds the 
regulatory subunits (R) of PKA and releases the catalytic subunits (C). C subunits phosphorylate several 
substrates in the cytoplasm and also diffuse  into the nucleus where they mediate the activation of CREB and 
histone H3. 
 
 
ERK effectors in MSNs  
The activation of PKA and ERK mediates gene transcription through the phosphorylation of several 
downstream proteins, including other kinases and transcription factors. Among the effectors of 
ERK, it should be mentioned RSK family composed by RSK1-3 that are able to phosphorylate 
CREB on Ser133. This factor is one of the most studied targets of the ERK pathway and it is also 
the substrate of PKA and many other kinases, including CamKII/IV and PKC (Johannensen and 
Moens, 2007). CREB  binds constitutively the CRE sites located in the promoters of a series of 
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genes in its inactive form; once phosphorylated on Ser133, CREB is activated and binds the co-
activator CREB binding protein (CBP) that interacts with the translational machinery. Another 
important partner of CREB is the transducer of regulated CREB (ToRC), that is activated by cAMP 
and calcium and promotes the nuclear localization of CREB. 
Another target of the ERK cascade is the transcription factor Elk1, a member of the Ets family that 
forms the ternary complex following the association with serum response factor (SRF), a MADS 
box protein that binds DNA at the CC(A/T)6GG consensus sequence, known as a CArG box or 
serum response element (SRE). SRE has been found in the promoters of actin cytoskeleton genes 
and immediate-early genes, including c-fos, Arc and Egr1 (Miano et al., 2007, Besnard et al., 2010). 
In MSNs, Elk-1 is located in part in the cytoplasm and it accumulates into the nucleus following 
ERK-dipendent phosphorylation (Vanhoutte et al., 1999). In addition , ERK and Elk1 are recruited 
from neuritis to cell bodies and nucleus in response to glutamate stimulation and they undergo 
retrograde trafficking with AMPARs (Trifilieff et al., 2009). 
The ERK cascade not only controls transcription by activating a series of transcription factors, but 
also by regulating chromatin remodelling. In the nucleus, DNA is packaged into chromatin, a DNA-
protein complex, that regulates the transcriptional rate of different genes depending on the degree of 
its condensation. In particular, condensed or relaxed chromatin respectively represses or promotes 
transcription.  Distinct post-translational modifications can occur at histones tails, the major  protein 
component of chromatin, thereby contributing to the dynamic process of chromatin remodelling. It 
has been shown that Lys9/Lys14 acetylation and Ser10 phosphorylation of histone H3 are involved 
in  transcriptional regulation; in particular, a rapid but transient phosphorylation on Ser10 of histone 
H3 has been associated with transcriptional activation of immediate-early transcriptional genes 
(IEGs), including c-fos and c-jun, upon mitogenic or stress stimuli (Mahadevan et al., 1991; Chadee 
et al., 1999). In addition, Lys9 methylation promotes gene silencing, whereas Lys9 acetylation 
correlates with transcriptional activation. In hippocampal neurons , H3-Ser10 phosphorylation in 
combination with Lys14 methylation mirrors the increase of c-fos transcription, in response to  the 
stimulation of different receptors such as D1Rs (Crosio et al., 2003). In addition, H3-Ser10 
phosphorylation is increased following cocaine treatment and this event depends on MSK-1 (Brami-
Cherrier et al., 2005) and occurs selectively in the striatonigral pathway (Bertran-Gonzalez et al., 
2008). Importantly, the use of MSK-1 knock out mice treated with cocaine have demonstrated  the 
critical role of MSK-1 in cocaine–induced transcriptional events leading to drug addiction. In 
particular, MSK-1 knock-out mice have shown decreased locomotor sensitization and many nuclear 
responses induced by cocaine, such as histone H3 phosphorylation, are blocked; on the contrary, 
zif268 expression and conditioned place preference are not impaired. (Brami-Cherrier et al, 2005). 
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Conversely, recent evidence supports the idea that H3-Ser10 phosphorylation in striatopallidal 
neurons, triggered by D2Rs blockade, is not mediated by MSK-1, but it might depend on A2Rs-
mediated activation of cAMP/PKA/DARPP-32 signalling pathway (Bertran-Gonzalez et al., 2008). 
 
L-DOPA-induced dyskinesia 
Recent studies have demonstrated that the Ras-ERK pathway in the striatum plays a pivotal role not 
only in the normal striatal functions, but it is also involved in neurological diseases such as L-
DOPA-induced dyskinesia (LID). 
Parkinson’s disease (PD) is a frequent neurodegenerative disorder that affects about 1-2% of the 
population over 60 years. PD is caused by the progressive death of dopaminergic neurons in the 
substantia nigra pars compacta and leads to a deficit in dopamine transmission to the striatum. The 
depletion of dopamine in the posterior putamen, which is the motor region of the striatum, causes 
the four symptoms of PD: bradykinesia/akinesia, rigidity, tremor and postural instability (Fahn, 
2003). 
The pharmacological treatments currently available for PD are based on dopamine replacement, 
through the administration of the dopamine precursor L-DOPA, which is converted into dopamine 
in the Parkinsonian brain providing a partial restoration of dopamine levels. Although L-DOPA 
represents an efficient therapy at the initial phase of the disease, after few years its therapeutic 
effect is shortened to the intake of a single dose. This phenomenon, called “wearing-off effect”, 
imposes an escalation in the dosage of the drug, thus inducing the appearance of abnormal 
involuntary movements or dyskinesia (Obeso et al., 2000). 
It has been estimated that up to 90% of the patients develop dyskinesia within 10 years from the 
beginning of the therapy and, for this reason, LID currently represents one of the major challenges 
in the treatment of PD.  LID is a severe motor complication characterized by a mixture of chorea 
(abrupt movements that seem to flow from one body part to another) and dystonia (slow twisting 
movements) (Cenci, 2007).  Dyskinesia is usually most severe during the two-three hours that 
follow a drug dose, when plasma and brain levels of exogenous L-DOPA reach their peak (Fahn, 
2000). However, dyskinesia can also be present when brain L-DOPA concentration is low. 
Dyskinesia is also frequent at the beginning or at the end of L-DOPA action cycle, when L-DOPA 
levels are rising or falling. 
Currently, three strategies are used to prevent or reduce LID. The first is based on the 
administration of long-acting agonists instead of L-DOPA, in order to avoid the pulsatile dopamine 
receptor stimulation that is induced by the common L-DOPA therapy and it is also the main risk 
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factor for developing LID.  Unfortunately, dopamine agonists have also side effects and they are not 
as effective as L-DOPA in treating PD. 
The second strategy consists in giving non-dopaminergic drugs during L-DOPA treatment, in order 
to reduce dyskinesia. In particular, several drugs, such as serotonin reuptake inhibitors, adrenergic 
antagonists and NMDA receptors antagonist have shown antidyskinetic properties. However, the 
efficacy of these drugs is quite modest; the most effective agent and the only one currently 
marketed for LID treatment, amantadine, is able to reduce dyskinesia in the range of 40-60% in the 
best responding patients.  
A final strategy is the neurosurgical intervention targeting specific nuclei within the basal ganglia 
(Deep Brain Stimulation, DBS), developed in 1987 by Benabid and collaborators as treatment for 
PD. This strategy  is based on  high-frequency stimulation (HFS) of the STN or GPi through 
chronically implanted macroelectrodes. After setting the electrode placement, the stimulation 
voltage is progressively increased while checking both the clinical efficiency and the induction 
threshold for side effects, such as dyskinesia, muscle contractions, or eye deviation (Benabid et al., 
2009). At present, in the overall PD patient population, the GPi is less frequently chosen than the 
STN as a target for DBS surgery because pallidal stimulation is commonly regarded as having a 
weaker antiparkinsonian effect, although it provides a direct and pronounced antidyskinetic effect 
(Toda et al., 2004; Follett, 2004; Guridi et al., 2008). Conversely, STN-HFS does not have an 
antidyskinetic effect per se, but effectively improves tremor, rigidity and bradykinesia allowing for 
L-DOPA dosage to be reduced by an average of 60% (Limousin et al., 1998), thus indirectly 
improving dyskinesia too (Benabid et al., 2000; Toda et al., 2004). However, although many 
successful cases have been reported in literature, it has to be considered that this strategy, in 
addition to being expensive and invasive, can be offered only to restricted groups of patients, 
responding to specific criteria (Benabid et al., 2006). 
 
In recent years the study of the molecular changes occurring in the striatum during the development 
of LID and the role of the specific components of the signalling machinery has revealed potential 
new therapeutic targets.  For this purpose, different experimental PD models have been used; before 
describing the alterations occurring  in the intracellular signalling during LID, it is useful to 
describe briefly the two major animal models that have been used: the 1-methyl 4-phenyl 1,2,3,6-
tetrahydropyridine (MPTP)-treated primate and mice and the 6-hydroxydopamine (6-OHDA) 
lesioned rodents. 
The neurotoxin MPTP was discovered in the 1980s when it was found to produce  striking 
parkinsonian features in humans (Langston et al., 1983). Subsequently it contributed to the 
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improvement of PD research, by providing a symptomatic model of the disease. MPTP is uptaken 
by astrocytes where it is converted to MPDP+ through the action of monoamine oxidase type B 
(MAO-B). MPDP+ is then metabolized to MPP+, which is taken up by DA transporters (DAT) 
through dopamine uptake sites on dopamine nerve terminals and concentrated in mitochondria. 
Here MPP+ inhibits complex I of the mitochondrial respiratory chain, decreasing tissue ATP and 
stimulating the production of reactive oxygen species (ROS) (Nicklas et al., 1985; Przedborski and 
Jackson-Lewis, 1998). The resulting disturbance of mitochondrial function can lead to oxidative 
stress and neuronal death. MPTP is generally administered by intracarotid injection or 
subcutaneously and the behavioural evaluations are usually performed at least 3 months after MPTP 
administration in order to have stable motor deficits. 
The 6-OHDA model consists in an intracerebral infusion, typically unilaterally, of the neurotoxin 6-
OHDA. Specifically, 6-OHDA is directly injected into the medial forebrain bundle (MFB) or the 
dorsal striatum, leading to retrograde dopaminergic cell loss in the SN, the area predominantly 
affected in PD. 
 
Changes in cAMP -mediated signalling in the onset and development of LID  
It is currently known that dopamine depletion determines an hyper-responsiveness of D1Rs to L-
DOPA, that cannot be attributed to  increased levels of D1Rs since a number of studies did not find 
significant changes in the number or affinity of D1Rs (Turjanski et al., 1997; Hurley et al., 2001; 
Aubert et al., 2005).  
Chronic administration of L-DOPA promotes also the release of BDNF from corticostriatal 
neurons, leading to the activation of TrkB receptors and increased expression of D3Rs in 
striatonigral MSNs. Direct interaction with D3Rs is likely to increase the levels of membrane-bound 
D1Rs, thereby exacerbating D1R sensitization and dyskinetic behaviour.  
Consistent evidence now indicates that cAMP-mediated signalling plays a pivotal role in the 
development of dyskinesia. In fact, the enhanced responsiveness of D1Rs results in an increased 
coupling to Golf, thus leading to an increase in cAMP production and PKA activation (Herve et al., 
2001, Santini et al., 2007). Importantly, the abnormal enhancement of cAMP signalling that occurs 
during LID is also linked to an hyperactivation of  downstream effectors, such as GluR1 subunit of 
AMPAR (Santini et al., 2007). PKA-mediated phosphorylation of Ser845 of GluR1 promotes 
glutamatergic transmission by maintaining the AMPARs in an open state and by increasing their 
surface expression; this event correlates with LID since in MPTP-lesioned monkeys, that represent 
an experimental model of PD, LID is increased by administration of AMPARs agonist and reduced 
by AMPARs antagonist (Konitsiotis et al., 2000). 
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Recent evidence has also suggested that the administration of L-DOPA to 6-OHDA lesioned mice 
increases the phosphorylation of DARPP-32. This event leads to the inhibition of PP-1, thereby 
suppressing the dephosphorylation of downstream target proteins. In addition, DARPP-32 knock 
mice chronically treated with L-DOPA show a significant attenuation of LID symptoms. 
Phosphorylation of DARPP-32 in LID is also involved in the activation of GluR1 via inhibition of 
PP-1-mediated dephosphorylation (Santini et al., 2007) and it is implicated in the increase of 
expression of immediate early genes, such as c-fos, arc and zif268 (Svenningsson et al., 2000). 
 
                                 
Fig.8. The signalling pathways activated by L-DOPA and involved in LID (From Feyder et al., 2011). 
Supersensitization of D1Rs in LID may be mediated by different mechanisms. First, chronic L-DOPA 
treatment promote the release of BDNF from corticostriatal neurons, leading to TrkB receptors activation 
and increased expression of D3Rs in the striatonigral MSNs. The interaction between D3Rs and D1Rs may 
lead to increased D1Rs expression on MSNs surface. Another possible mechanism underlying D1Rs 
sensitization in LID is mediated by cAMP/PKA/DARPP-32 pathway.; in fact, increased D1Rs responsivity 
results in PKA and DARPP-32 hyperactivation, leading to an augmented ERK signalling. This aberrant ERK 
activation leads to increased MSK-1, CREB and histone H3 phosphorylation, causing an altered gene 
transcription; in addition, ERK promotes mTORC signalling thereby enhancing protein synthesis. 
 
 
 
Alterations of ERK activity in LID 
A number of experimental evidence indicate that ERK hyperactivation is a major additional 
consequence associated to D1Rs supersensitization and that ERK activity correlates well with the 
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LID symptoms in animal models (Gerfen et al., 2003; Pavon et al., 2006; Santini et al., 2007; 
Westin et al., 2007; Fasano et al., 2010; Santini et al., 2010). 
Increase of ERK activity can be achieved through several mechanisms. First of all, activated 
DARPP-32 may control ERK 1/2 phosphorylation through the inhibition of the protein phosphatase 
STEP which normally negatively controls MEK1/2 (Valjent et al., 2005). This idea is also 
supported by the observation that in 6-OHDA lesioned DARPP-32 knock out mice the 
hyperactivation of ERK does not occur upon L-DOPA treatment (Santini et al., 2007). In addition, 
the relevance of abnormal activation of ERK in LID is also supported by the observation that Ras-
GRF1 ablation can prevent the development of LID and reduce ERK activity. Importantly, the 
combined administration of MEK inhibitors (such as SL237) enhances the antidyskinetic effect 
observed in Ras-GRF1 deficient mice. In addition, striatal inhibition of Ras-GRF1 and ERK 
signalling using viral vectors ameliorates already established dyskinetic symptoms in the non 
human primates (NHP), thus opening the way for a possible therapy of LID based on targeting Ras-
GRF1 (Fasano et al., 2010; Fasano and Brambilla, 2011). 
 
In the nucleus, ERK activates MSK-1, that directly phosphorylates histone H3, thereby regulating 
transcription of several genes c-fos, dynorphin and zif268, which are hyperactivated in  6-OHDA 
lesioned rodents treated with L-DOPA (Santini et al., 2009; Andersson et al., 1999). 
Recent studies conducted on transgenic mice expressing EGFP in the striatonigral (Drd1 mice) or in 
the striatopallidal (Drd2 mice) pathway demonstrated that L-DOPA-induced ERK-MSK1-H3 
activation is restricted to the striatonigral pathway without affecting the striatopallidal MSNs. 
Moreover, ERK-MSK1-H3 upregulation depends on D1R activation since it is prevented by the 
administration of the specific antagonist of D1Rs, but not by blocking D2Rs (Santini et al., 2009). 
Finally, the involvement of ERK in LID may depend not only on the regulation of transcription but 
also on the modulation of local protein synthesis in the cytoplasm. In this regard, ERK1/2 have 
been proposed to activate mTOR complex 1 (mTORC1), a component of mTOR involved in the 
control of protein synthesis and autophagy (Costa-Mattioli et al., 2009). In particular, ERK 
phosphorylates, directly or via RSK, the tuberous sclerosis complex 1 (TSC1) that consequently is 
inhibited, leading to the activation of mTORC1. It has been recently shown that LID is associated 
with an increased phosphorylation of S6 ribosomal protein and two targets of mTORC1, the S6 
kinase and the initiation factor 4E-binding protein (4EBP), in the striatonigral pathway. Collectively 
these events are likely to be involved in the enhancement of protein translation observed in LID 
(Richter and Sonenberg, 2005; Ruvinsky and Meyuhas, 2006; Roux et al.,2007). Importantly, the 
blockade of mTORC1 by the specific inhibitor rapamycin has been found to attenuate LID in 
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dyskinetic mice, thus suggesting that an aberrant enhancement of protein synthesis may be 
implicated in the development of LID (Santini et al., 2009). 
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Materials and methods 
 
Experimental animals. Experiments were conducted in 2 months old mice C57/BL6 purchased 
from Charles River Laboratories, in BAC transgenic mice expressing EGFP under the control of 
muscarinic receptor M4 promoter selectively in the direct pathway (M4-EGFP mice, Dobrossy et al, 
2011) and in Ras-GRF1 knock out mice (Brambilla et al., 1997). 
Animals were housed in a 12h light-dark cycle, in stable conditions of temperature, with food and 
water ad libitum. All experimental procedures were performed in accordance with protocols 
approved by the Institutional Animal Care and Use Committee (IACUC) and communicated to the 
local authorities.  
 
Genotyping. Mouse tails biopsy were digested in 500 µl of tail buffer with 1 mg/ml Proteinase K 
(Roche) overnight at 55°C. Genomic DNA was purified throughout two successive steps, in which 
the samples were mixed with an equal volume of phenol/chloroform solution, vortexed for 30 sec 
and the aqueous phase was recovered centrifuging for 5 min at room temperature. The DNA was 
then precipitated adding 2.5 volumes of absolute ethanol and centrifuging for 5 min. The resulting 
pellet was washed with 70% ethanol, let dry and resuspended in 150 µl of sterile water.  
The hot-start PCR for M4-EGFP mice was performed as follows: 
95°C for 5 min 
94°C for 30 sec 
60°C for 30 sec       for 30 cycles               
72°C for 30 sec 
72°C for 10 min     
 
Forward primer: 5’-CACATGAAGCAGCACGACTT-3’  
Reverse primer: 5’-TGCTCAGGTAGTGGTTGTCG-3’.  
 
The hot-start PCR for Ras-GRF1 KO mice was performed as follows: 
95°C for 5 min 
94°C for 1 min 
68°C for 2 min        for 35 cycles               
72°C for 2 min 
72°C for 10 min    
Ras-GRF1 mutant forward primer: CTGCTAAAGCGCATGCTCCAGACTGCC 
Ras-GRF1 mutant reverse primer: CGTGACTCCTCAGGATGAGGTGCTGTGG 
Ras-GRF1 wild-type forward primer: AACAGATCACCCTGTATTTGAGCGTATCGTCGG 
Ras-GRF1 wild-type reverse primer: CAGTAAGTGATAGCAGACAGTGGGTCAACAGG 
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DNA was then loaded onto 1% agarose gel and separated by electrophoresis at constant voltage in 
order to visualize the transgene. 
 
Preparation of acute striatal slices. Mice were anesthetized, killed by decapitation and the brain 
was rapidly removed in ice-cold carboxygenated sucrose-based dissecting solution. 200 µm-thick 
slices were cut using a vibratome (VT1000S, LeicaMicrosystems) keeping the brain submerged in 
ice-cold carboxigenated sucrose-based dissecting solution. The slices were then transferred to the 
brain slice chamber-BSC1 (Scientific System design Inc., Mississauga, ON, Canada), placing them 
upon a lens paper (up to 4 slices in every chamber). The slices were then incubated for 1h at 32°C 
and constantly perfused with carboxygenated artificial cerebrospinal fluid. After the recovery 
period, the slices were stimulated with the appropriate agonists for 10 min. In the experiments with 
the inhibitors, the slices were pre-treated with U0126 for 1 hour during the recovery period, 
whereas SCH23390, CNQX and AP5 were applied 30 min before the stimulation. 
 
Western blot analysis. Following stimulation, the slices were rapidly frozen in dry ice, 
homogenized in ice-cold SDS lysis buffer and boiled for 5 min. Following dosage with Biorad DC 
protein Assay (Biorad), the desired amount of protein was added to an equal volume of sample 
buffer 1X and boiled for 5 min. The samples were then separated by SDS-PAGE onto 10% 
polyacrylamide gels (acrylamide/bysacrylamide 40:1, Merck) at constant amperage (35 mA/gel) in 
a Biorad electrophoresis apparatus filled with running buffer 1X. The proteins were transferred to 
nitrocellulose membranes (Schechter and Schuell) for 2 h at constant amperage (250 mA) using an 
immersion apparatus (Biorad) filled with transfer buffer 1X. After Ponceau staining (Sigma 
Aldrich), the membranes were washed in TBS 1X and blocked in TBS-Tween 0.1% with 5% BSA 
for 1 h at room temperature. The membranes were then incubated with anti-phospho-p44/p42 MAP 
kinase (1:1000, Cell signaling) overnight at 4°C and anti-GAPDH (1:1000, Sigma Aldrich) for 2 
hours at room temperature. Following three washes in TBS-Tween 0.1%, the membranes were 
incubated with the secondary antibodies: anti-mouse or anti-rabbit IgG, horseradish peroxidase 
linked whole antibody (from sheep, GE Healthcare). 
Following three washes in TBS-Tween 0.1%, the membranes were developed using ECL PLUS kit 
(GE Healthcare) according to the manufacturer’s instructions. Different exposures were taken using 
Amersham Hyperfilm ECL high performance chemiluminescence film (GE Healthcare) with 
automatic developer apparatus (Kodak). 
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The immunoblots were then analyzed using ImageJ software to measure the optical density of the 
bands, using anti-GAPDH as loading control. 
 
Immunofluorescence. Following stimulation, the slices were fixed in 4% paraformaldehylde  for 
15 min at room temperature and rinsed three times for 10 min in  0.1M sodium phosphate buffer pH 
7.4. The slices were then cryoprotected overnight in 30 % sucrose in 0.1M sodium phosphate buffer 
pH 7.4 overnight at 4°C. 18 µm cryosections were cut and washed three times for 10 min with 
Dulbecco’s phosphate buffered saline (D-PBS, Invitrogen). After blocking in D-PBS containing 5% 
normal goat serum and 0.1% Triton X-100 for 1 hour at room temperature, the sections were 
incubated overnight at 4°C with the primary antibodies: anti-phospho-S6 ribosomal protein (Ser 
235/236) 1:200 (Cell signaling Technology), anti-phospho (Ser10)-acetylated (Lys14) histone H3 
1:1000 (Upstate),  anti-NeuN 1:1000 (CHEMICON).  
The sections were then washed three times for 10 min with D-PBS and incubated for 1h at room 
temperature with the secondary antibodies: Alexa Fluor 546 goat anti-mouse (1:200) or goat anti-
mouse Pacific blue (1:200) or Alexa Fluor 488 goat anti-mouse (1:500, Invitrogen) and Alexa Fluor 
488 goat anti-rabbit (1:500, Invitrogen) or Cy3-conjugated goat anti-rabbit (1:200, Jackson 
Immunoresearch). 
Following the incubation with the secondary antibodies the sections were washed three times for 10 
min with D-PBS and the coverslips were mounted using the fluorescent mounting medium (Dako). 
In the experiments conducted on M4-EGFP mice, following the incubation with the secondary 
antibodies the sections were washed three times for 10 min with D-PBS and incubated with anti-
GFP rabbit polyclonal antibody Alexa Fluor 488-conjugated (Invitrogen) for 5 h at 4°C. The 
sections were then washed three times for 10 min with D-PBS and the coverslips were mounted 
using the fluorescent mounting medium (Dako). 
Images were obtained using a laser scanning confocal microscopy (Leica SP2), equipped with the 
corresponding lasers and the appropriate filters sets to avoid the cross-talk between the 
fluorophores. Neuronal quantification was performed with ImageJ software on images taken at 40X 
magnification by counting phospho-S6 or phospho-H3 immunoreactive neurons among NeuN 
positive neurons in each slice, in 2 cryosections per slice. In the experiments with M4-EGFP mice, 
also the number of phospho-S6 or phospho-H3 positive neurons among EGFP-positive cells and 
among EGFP-negative cells was counted. Statistical analysis were performed using GraphPad 
Prism 5.  
 
Immunohistochemistry. Following transcardiac perfusion with with 4% paraformaldehyde (PFA) 
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in PBS, postfixation, cryopreservation, and storage in anti-freeze solution at -20° C, 35 µm-thick 
free-floating sections were rinsed three times with KPBS, incubated for 15 min in quenching 
solution and  rinsed again three times in KPBS-Triton 0.1% (KPBS-T). The sections were then 
incubated overnight at 4 °C with the primary antibody: anti-TH (1:1000, Pel-Freez Biologicals) or 
anti-phospho-p44/42 MAP kinase (1:200, Cell signalling) in 5% normal goat serum in KPBS-T. 
Sections were then rinsed three times in KPBS-T and incubated with the biotinylated anti-rabbit 
secondary antibody 1:200 (Vector Labs) for 2 h. Tissue sections were processed further using 
Avidine Biotin Elite (ABC kit, Vector Labs) following the manufacturer’s instructions. Following 1 
h incubation in ABC solution,  the sections were rinsed three times in KPBS-T and incubated with 1 
ml of 0.05% DAB in KPBS. After  2-3 min, 13 µl of 3% H2O2 were added to the sections for 30-60 
sec. Following three washes, the sections were mounted onto Superfrost slides, let dry overnight 
and dehydrated throughout successive immersions, each one lasting two min and repeated 2 times, 
in 50%, 75%, 95% and 100% ethanol solutions. The sections were coverslipped with d-N-butyl-
phthalate in xylene (DPX) and images were acquired using a Quantification of p-ERK positive 
neurons was performed from dorsolateral striatum, in 4 sections per mouse, bilaterally, using the 
Image J software. All visible positive nuclei or cell bodies within a field were counted and 
expressed as number of cells per square millimeter.  
 
Drugs. Glutamate, BDNF SCH-23390 were purchased from Sigma Aldrich, SKF-38393, UO126, 
CNQX and AP5 were purchased from Tocris; N/OFQ was synthetized in the Department of 
experimental and Clinical Medicine, Section of Pharmacology, University of Ferrara, Italy. 
Stocks of glutamate, BDNF, SCH-23390, SKF-38393 and AP5 were easily dissolved in H20, 
N/OFQ was dissolved in saline and stocks of UO126 and CNQX were dissolved in DMSO 
 
Buffers and solutions 
 
Tail buffer 
50 mM Tris HCl pH 8 
100 mM EDTA pH 8 
100 mM NaCl 
0.5% (w/v) SDS 
Up to volume with sterile water and filter. 
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Phenol Chloroform solution 
25:24:1 (v : v : v) phenol: chloroform: 3-methyl-1-butanol (Sigma Aldrich) 
 
DNA loading buffer 6X 
50 mM bromophenol blue 
1mM EDTA 
50% (w/v) glycerol 
 
TBE 10X pH 8 
980 mM Trizma base 
980 mM Boric Acid 
10 mM EDTA 
Dissolve in deionized water and adjust pH  
 
Agarose gel 
1% agarose dissolved in TBE 1X with 1mg/ml ethidium bromide 
 
Sucrose-based dissecting solution 10X  
87 mM NaCl 
2.5 mM KCl 
7 mM MgCl2 6H2O 
1 mM NaH2PO4 H2O 
75 mM sucrose 
25mM NaHCO3 
10mM D-glucose 
0.5 mM CaCl2 (1M stock) 
2 mM kynurenic acid  
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Artificial cerebrospinal fluid 10X 
124mM NaCl 
5mM KCl 
1.3 mM MgSO4 7H2O 
1.2 mM NaH2PO4 H2O 
25mM NaHCO3 
10mM D-glucose 
2.4mM CaCl2 (1M stock)  
 
Lysis buffer pH 6.8 
125 mM Trizma base 
2.5% SDS 
 
Sample buffer 5X 
10% (w/v) SDS 
250 mM Tris HCl pH 6.8 
50% glycerol 
0.02% bromophenol blue 
111 mM dithiothreitol (DTT) 
up to volume with glycerol 
 
Stacking gel 4.5% 
4.5% acrylamide/bis-acrylamide (40:1, Merck) 
125 mM Tris HCl pH 6.8 
0.1% SDS 
0.05% ammonium persulfate 
0.005% N,N,N’,N’-tetramethylethylenediamine (TEMED) 
 
Running gel 10% 
10% acrylamide/bis-acrylamide (40:1) 
375 mM Tris HCl pH 8.8 
0.1% SDS 
0.05% ammonium persulfate 
0.005% N,N,N’,N’-tetramethylethylenediamine (TEMED) 
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Running buffer 10X 
250 mM Trizma base 
1.92 M glycine 
 
Transfer buffer 1X 
25 mM Trizma base 
190 mM glycine 
20% methanol 
 
TBS 10X pH 7.4 
200 mM Trizma base 
1.5 M NaCl 
 
0.2 M phosphate buffer pH 7.4 
4.32 g Na2HPO4 2H2O 
0.78 g NaH2PO4 H2O 
An equal volume of deionized water was added to obtain 0.1M phosphate buffer. 
 
Anti-freeze solution 
320 ml PBS 1X pH 7.4 
240 ml ethylene glycol 
240 ml glycerol 
 
KPBS 10X 
1.4 M NaCl 
26 mM KCl 
64 mM Na2HPO4 
15 mM KH2PO4 
 
Quenching solution 
3% H2O2 
10% methanol   
in KPBS 1X 
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Results 
Glutamate and SKF38393 induce S6 ribosomal protein and histone H3 phosphorylation in an 
ex-vivo model of striatal slices 
 
In order to investigate the regulation of Ras-ERK signalling in the striatum, we set up an ex-
vivo system in which striatal slices can be acutely prepared from adult mice, incubated in a 
perfusing chamber and then stimulated with appropriate agonists and antagonists. 
In order to validate this experimental model, we first stimulated slices with glutamate, with the D1R 
agonist SKF38393 or with the brain derived neurotrophic factor (BDNF), three stimuli able to 
activate the ERK cascade (Sgambato et al., 1998; Vanhoutte et al., 1999; Kaplan and Miller, 2000; 
Pascoli et al., 2010). 
In the initial phase, we decided to test the ability of glutamate to phosphorylate ERK1/2 using 
Western blot analysis, that gives an initial measure of the global striatal activation of this signalling 
pathway. As shown in figure 9, 200 µm-thick slices stimulated with 100 µM glutamate for 10 min 
show a significant increase of phospho-ERK1/2.  
 
 
 
 
Fig.9. Adult striatal slices show an 
increase in ERK2 phosphorylation 
following the stimulation with  
glutamate 100 µM.  a) Representative 
immunoblots of  striatal slices obtained 
from adult wild-type mice and 
stimulated or not with glutamate 100 
µM for 10 min. Following stimulation, 
the slices were lysed and equal 
amounts of proteins (20 µg) for each 
sample were separated onto SDS-
PAGE electrophoresis. After Western 
blot, the nitrocellulose membranes 
were probed against phospho-ERK1/2 
and GAPDH as loading control. b) The 
histogram represents the mean±SEM 
of phospho-ERK2 induction expressed 
as the ratio normalized to not 
stimulated slices. Unpaired Student’s t 
test has revealed a significant increase 
in ERK2 phosphorylation upon 
glutamate stimulation in comparison to 
the not-stimulated condition (* p<0.05, 
n=39 for stimulated and not stimulated  
groups).  
 
 a 
b 
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Next, in order to develop a system to study ERK activation at a single cell definition, and to have 
the possibility to discriminate between different cell populations in the striatum, for instance using 
the available BAC transgenic mice expressing EGFP, we decided to test several antibodies against 
the phosphorylated form of ERK1/2. Unfortunately, none of the antibodies tested showed a 
significant signal in immunofluorescence (data not shown). Therefore, we decided to test two 
specific phospho-antibodies against two proteins that have been previously shown to be 
downstream of ERK1/2: S6 ribosomal protein (cytoplasmic target) and histone H3 (nuclear target). 
Brains were rapidly dissected from 2 months-old wild-type mice and  200 µM striatal slices were 
cut using a vibratome. Slices were then transferred in the perfusing chamber for 1 hour at 32°C. 
After the recovery period, slices were stimulated for 10 min with  glutamate (100 µM), SKF38393 
(100 µM) or BDNF (100 µM), fixed and cryoprotected overnight at 4°C. 18 µm cryosections were 
then co-labeled with anti-phospho (Ser235/236) S6 ribosomal protein (in green, fig. 10 and fig. 12 
panel a) or anti-phospho (Ser10)-acetyl (Lys14) histone H3 (in green, fig. 11 panel a and fig.12 
panel c) and with the antibody against the specific neuronal marker NeuN (in red, fig. 10, 11, panel 
a and fig. 12, panel a,c). The percentage of activation was calculated by counting phospho-S6 or 
phospho-H3 positive neurons among NeuN positive neurons.  As shown in the graphs (fig. 10, 11, 
panel b and c  and fig. 12, panel b and d), the application of either glutamate, SKF38393 or BDNF 
elicits a strong activation of both S6 ribosomal protein and histone H3. 
 
 
The MEK inhibitor U0126 completely blocks the phosphorylation of S6 ribosomal protein and 
histone H3 
 
We next assessed whether the phosphorylation of S6 ribosomal protein and histone H3 on 
those specific sites was indeed ERK-dependent.  
In order to do this, striatal slices were pre-treated with 5 µM U0126, a specific MEK inhibitor, for 1 
hour before the stimulation with 100 µM glutamate. As shown in the figure 13 and 14, the 
phosphorylation of both S6 ribosomal protein and histone H3 was completely abolished by the 
treatment with 5 µM U0126. 
This result demonstrates that the activation of these two proteins is specifically regulated by the 
ERK cascade.  
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Fig.10. Glutamate and SKF-38393 activate S6 ribosomal protein in a model of adult striatal slices. a) 
Double immunolabeling of phospho S6 ribosomal protein (Ser235/236) (green) and NeuN (red) in striatal 
slices obtained from adult wild-type mice stimulated or not with glutamate 100 µM or SKF-38393 100 µM 
for 10 min. b) The data from the quantification are represented in the graphs as mean±SEM (n=13 and n=14 
for the groups respectively stimulated or not with glutamate, n=7 for the groups stimulated or not with SKF-
38393). Phospho-S6 levels were significantly increased in striatal neurons stimulated with glutamate 
(stimulated vs not stimulated, **** p<0.0001, unpaired Student’s t-test) and SKF38393 (stimulated vs not 
stimulated *** p<0.001, unpaired Student’s t-test).  
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Fig.11. Glutamate and SKF-38393 activate histone H3 in a model of adult striatal slices. a) Double 
immunolabeling of phospho (Ser10)-acetyl (Lys14) histone H3 (in green) and NeuN (in red) in striatal slices 
obtained from adult wild-type mice stimulated or not with glutamate 100 µM or SKF-38393 100 µM for 10 
min. b) The data from the quantification are represented in the graphs as mean±SEM (n=7 and n=9 for the 
groups respectively stimulated or not with glutamate, n=11 for the groups stimulated or not with SKF-
38393). The unpaired Student’s t-test indicated a significant difference between the groups (stimulated vs not 
stimulated, **** p<0.0001, ** p<0.01).  
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Fig.12. BDNF induces S6 and histone H3 phosphorylation in adult striatal slices. Striatal 
slices obtained from wild type mice were incubated for 1h at 32°C and then stimulated with 
BDNF 100 µM for 10 min. The slices were then processed for immunofluorescence. a) 
Double immunolabeling of phospho-S6 (green) and NeuN (red). The data from the 
quantification are represented in the graph (panel b) as mean±SEM (n=10). c) Double 
immunolabeling of phospho-H3 (green) and NeuN (red). The data from the quantification are 
represented in the graph (panel d) as mean±SEM (n=8 for not stimulated group; n=7 for 
BDNF stimulated group. Statistical analysis were performed using unpaired Student’s t test 
(stimulated vs not stimulated, ** p<0.01, *** p<0.001) 
 
a b 
c d 
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Fig. 13. S6 ribosomal protein phosphorylation is prevented by MEK inhibitor U0126 in striatal slices. 
a) Striatal slices were pre-treated with 5µM U0126 or vehicle for 1 h before the stimulation with glutamate 
100 µM for 10 min. The slices were then immunolabeled with anti-phospho S6 ribosomal protein 
(Ser235/236) (green) and anti-NeuN (red) antibodies. b) The data from the quantification are represented in 
the graph as mean±SEM (n=14 for the groups treated with the vehicle, n=10 and n=8 for the groups treated 
with U0126 and respectively stimulated or not with glutamate ). Statistical analysis were performed using 
two-way ANOVA followed by Bonferroni’s post-hoc test (glutamate vs not stimulated , **** p<0.0001).  
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Fig.14. Histone H3 phosphorylation is prevented by MEK inhibitor U0126 in striatal slices. a) Adult 
striatal slices were pre-treated  with U0126 5µM or vehicle for 1 hour before the stimulation with glutamate 
100 µM for 10 min. The slices were processed for immunofluorescence against phospho- histone H3 (green) 
and NeuN (red). b) The data from the quantification are represented in the graph as mean±SEM (n=4 and 
n=3 for the groups treated with vehicle and respectively stimulated or not with glutamate, n=6 and n=5 for 
the groups treated with U0126 and respectively stimulated or not with glutamate). Statistical analysis were 
performed using two-way ANOVA and post-hoc comparisons between groups using Bonferroni’s post-hoc 
test (glutamate vs not stimulated , **** p<0.0001).  
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Co-stimulation with glutamate and SKF38393 causes an additive effect on the activation of S6 
ribosomal protein in the striatonigral MSNs, but not in the striatopallidal MSNs  
 
An important open question is the integration between glutamatergic and dopaminergic 
signals within the striatum. Previous experiments conducted on organotypic slices analysed by 
western blot demonstrated that the co-stimulation with glutamate and SKF38393 caused a clear 
additive effect on the phosphorylation of ERK2 in comparison with that observed upon single 
stimulations (Fasano et al., 2009).  
To further elucidate this point, we took advantage of our ex-vivo system applied on M4-EGFP 
transgenic mice that express EGFP specifically in the striatonigral pathway, to compare the changes 
in S6 activation between the two major neuronal population in the striatum (Fasano et al, 2010). 
Firstly, we wanted to confirm that in this EGFP expressing transgenic the percentage of neurons 
expressing or not EGFP were similar, as expected from the known ratio of MSN belonging to the 
direct and indirect pathway. Our results, obtained from 21 M4-EGFP mice and co-labeled against 
NeuN and EGFP (fig. 15)  demonstrate that the percentage of striatonigral MSNs (47%) is similar 
to the percentage of striatopallidal MSNs (52%), thus validating M4-EGFP mice as a model to 
compare the striatal signalling in the two pathways.  
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However, before using the M4-EGFP animals, we also determined the lowest concentration of both 
glutamate and SKF38393 able to elicit S6 and histone H3 phosphorylation after a 10 min 
stimulation. The treatment with different doses of glutamate or SKF-38393 indicates that 20 µM of 
glutamate and SKF-38393 is sufficient to induce a maximal S6 (fig. 16,18) and H3 phosphorylation 
(fig.17,19), whereas slices challenged with lower doses of glutamate and SKF-38393 (5 µM, 2 µM, 
and 1 µM) failed to show a significant activation of both S6 and histone H3. 
Therefore, we investigated the phosphorylation of both S6 and histone H3 in EGFP-positive cells 
and EGFP-negative cells in striatal slices obtained from M4-EGFP mice and we stimulated them 
with  either glutamate 20 µM,  SKF38393 20 µM or co-stimulated them for 10 min. We found that 
glutamate activates S6 ribosomal protein ( in red, fig. 20, panel a ) preferentially in the 
striatopallidal neurons ( in blue and EGFP-negative cells). Unexpectedly, we also found that SKF-
38393 activates S6 ribosomal protein not only in the direct pathway but also in the indirect 
a b 
c 
Fig.15. Characterization 
of M4-EGFP mice. 
Striatal slices obtained 
from 21 M4-EGFP mice 
were immunolabeled 
against EGFP and NeuN 
(panel b) and the 
percentage of EGFP-
positive and EGFP-
negative cells was 
calculated, as shown in the 
table (panel a) and 
averaged, as represented in 
the graph (panel c).  
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pathway. In addition, S6 phosphorylation is enhanced by the combined treatment with glutamate 
and SKF38393; interestingly, this additive effect seems to be restricted to the striatonigral MSNs (in 
green), whereas in the striatopallidal MSNs the phosphorylation of S6 ribosomal protein upon co-
stimulation is not significantly different to that observed upon single stimulations. 
To further elucidate the SKF38393-induced activation of S6 in the indirect pathway, we pre-treated 
the slices with SCH-23390 50 µM, the selective antagonist of D1Rs,  for 30 min before the 
stimulation with SKF-38393 20 µM. Interestingly, upon D1Rs blockade, S6 phosphorylation is 
completely prevented both in the striatonigral and striatopallidal MSNs, as shown in fig. 21.  
This result suggests that the SKF-38393-dependent S6 activation in the indirect pathway might be 
mediated by D1Rs, either directly or indirectly. 
Our data also clearly indicate that the basal phosphorylation of S6, completely abolished by MEK 
inhibition with U0126 in both neuronal populations (fig. 22), is about two times higher in the 
indirect pathway in comparison with the direct pathway. This asymmetry is probably attributable to 
the increased excitability of the striatopallidal MSNs with respect to the striatonigral MSNs 
(Cepeda et al., 2008; Day et al., 2008).  
 
We next examined the activation of histone H3 following stimulation with glutamate, SKF38393 or 
co-stimulation. Differently from what observed for S6 activation, the co-application of glutamate 
and SKF38393 does not further increase the level of histone H3 phosphorylation in each pathway in 
comparison with the single stimulations, suggesting that at the doses used of glutamate and 
SKF38393 H3 is maximally activated (fig. 23). 
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Fig.16. Glutamate induces S6 
phosphorylation in a dose dependent 
manner in adult striatal slices. Striatal 
slices obtained from wild type mice were 
incubated for 1h at 32°C and then 
stimulated with different doses of 
glutamate (100, 50, 20, 10, 5, 2, 1 µM) for 
10 min. The slices were then processed for 
immunofluorescence. a) Double 
immunolabeling of phospho-S6 (green) and 
NeuN (red). b) The data from the 
quantification are represented in the graph 
as mean±SEM (n=23 for not stimulated, 
n=13 for glu 100 µM, n=9 for glu 50 µM, 
n=7 for glu 20 µM, n=8 for glu 10 µM, 
2µM and 1µM and n=6 for glu 5µM). 
Statistical analysis were performed using 
one-way ANOVA and post-hoc 
comparisons between groups using 
Bonferroni test (stimulated vs not 
stimulated, *** p<0.001) 
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Fig.17. Glutamate induces histone H3 
phosphorylation in a dose dependent 
manner in adult striatal slices. Striatal 
slices obtained from wild type mice were 
incubated for 1h at 32°C and then stimulated 
with different doses of glutamate (100, 50, 
20, 10, 5, 2, 1 µM) for 10 min. The slices 
were then processed for 
immunofluorescence. a) Double 
immunolabeling of phospho-H3 (green) and 
NeuN (red). b) The data from the 
quantification are represented in the graph as  
mean±SEM (n=26 for not stimulated, n=13 
for glu 100 µM, n=8 for glu 50 µM, n=7 for 
glu 20 µM, 2 µM and 1µM, n=9 for glu 10 
µM and n=12 for glu 5 µM). Statistical 
analysis were performed using one-way 
ANOVA  and post-hoc comparisons between 
groups using Bonferroni test (stimulated vs 
not stimulated, **** p<0.0001) 
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Fig.18. SKF38383 induces S6 ribosomal 
protein phosphorylation in a dose dependent 
manner in adult striatal slices. Striatal slices 
obtained from wild type mice were incubated 
for 1h at 32°C and then stimulated with 
different doses of SKF38393 (100, 50, 20, 10, 
5, 2, 1 µM) for 10 min. The slices were then 
processed for immunofluorescence. a) Double 
immunolabeling of phospho-S6 (green) and 
NeuN (red). b) The data from the quantification 
are represented in the graph as mean±SEM 
(n=27 for not stimulated, n=9 for SKF 100 µM 
and 20 µM, n=15 for SKF 50 µM, n=7 for SKF 
10 µM and  
1 µM, n=6 for SKF 5 µM  and n=8 for SKF 2 
µM). Statistical analysis were performed using 
one-way ANOVA and post-hoc comparisons 
between groups using Bonferroni test 
(stimulated vs not stimulated,**** p<0.0001) 
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Fig.19. SKF38383 induces histone H3 
phosphorylation in a dose dependent 
manner in adult striatal slices. Striatal 
slices obtained from wild type mice were 
incubated for 1h at 32°C and then 
stimulated with different doses of 
SKF38393 (100, 50, 20, 10, 5, 2, 1 µM) for 
10 min. The slices were then processed for 
immunofluorescence. a) Double 
immunolabeling of phospho-H3 (green) 
and NeuN (red). b) The data from the 
quantification are represented in the graph 
as mean±sem (n=25 for not stimulated, 
n=12 for SKF 100 µM, n=8 for SKF 50 µM 
and 20 µM, n=9 for SKF 10 µM, n=6 for 
SKF 5 µM  and n=7 for SKF 2 µM and 1 
µM). Statistical analysis were performed 
using one-way ANOVA and post-hoc 
comparisons between groups using 
Bonferroni test (stimulated vs not 
stimulated, *** p<0.001, **** p<0.0001) 
 
 
 b  c 
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Fig.20. The co-application of glutamate and SKF38383 has an additive effect on S6 activation in  
the direct pathway. Striatal slices obtained from M4-EGFP mice were stimulated with glutamate 20 
µM, SKF38393 20 µM or their combination for 10 min. a) Immunofluorescence against phospho-S6 
ribosomal protein (red), NeuN (blue) and EGFP (green). b) S6 positive cells among EGFP positive 
cells (direct pathway) and EGFP negative cells (indirect pathway) were counted. The data are 
expressed as mean±SEM (n=10 for not stimulated, n=9 for glutamate, n=11 for SKF38393 and for 
glutamate+ SKF-38393). One-way ANOVA and post-hoc comparisons between groups using 
Bonferroni test were performed (stimulated vs not stimulated, ** p<0.01, **** p<0.0001). c) The 
graph represents the number of  S6 positive neurons among NeuN positive neurons. One way ANOVA 
followed by Bonferroni post-hoc test revealed a significant  effect of treatment (stimulated vs not 
stimulated ** p<0.01, *** p <0.001, **** p<0.0001,  skf+glu vs glutamate and  skf+glu vs SKF-
38393,  •• p<0.01).  
a 
b c 
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 Fig.21. The blockade of D1Rs completely prevents S6 activation in  both direct and indirect 
pathways. Striatal slices obtained from M4-EGFP mice were pretreated or not with SCH23390 for 30 
min and then stimulated with SKF38393 20 µM for 10 min. a) Immunofluorescence against phospho-S6 
ribosomal protein (red), NeuN (blue) and GFP (green). b) The graph represents the number of S6 positive 
neurons in the direct and in the indirect pathway in the different conditions. The data are expressed as 
mean±SEM (n=8 for for SKF38393 and n=7 for the other conditions. One-way ANOVA and post-hoc 
Bonferroni test showed a significant difference between stimulated and not stimulated groups (**** 
p<0.0001). c) The graph represents the number of  S6 positive neurons among NeuN positive neurons. 
One way ANOVA followed by Bonferroni post-hoc test revealed a significant  effect of treatment 
(stimulated vs not stimulated, **** p<0.0001).  
 
 
 b  c 
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Fig.22. The basal S6 activation is 
completely abolished by the treatment 
with U0126 in both direct and indirect 
pathways. Striatal slices obtained from 
M4-EGFP mice were treated with U0126 5 
µM or with the vehicle for 1h. a) 
Immunofluorescence against phospho-S6 
ribosomal protein (red), NeuN (blue) and 
GFP (green). b) The graph represents the 
quantification of S6 positive neurons in the 
direct and in the indirect pathways. The 
data are expressed as mean±SEM (n=9 for 
vehicle, n=14 for U0126). Statistical 
analysis was performed using two-way 
ANOVA and post-hoc comparisons 
between groups using Bonferroni test 
(vehicle vs U0126, **** p<0.0001). 
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Fig.23. The co-application of glutamate and SKF-38383 does not increase the level of histone H3 
phosphorylation in adult striatal slices. Striatal slices obtained from M4-EGFP mice were stimulated with 
glutamate 20 µM, SKF-38393 20 µM or their combination for 10 min. a) Immunofluorescence against 
phospho-H3 (red), NeuN (blue) and GFP (green). b) The graph represents the quantification of H3 positive 
neurons in the striatonigral and in the striatopallidal pathways in the different conditions. The data are 
expressed as mean±SEM (n=8 for not stimulated, n=9 for glutamate, n=8 for SKF38393 and n=7 for 
glutamate+ SKF-38393). Statistical analysis was performed using one-way ANOVA and post-hoc 
comparisons between groups using Bonferroni test (stimulated vs not stimulated, * p<0.05, ** p<0.01, **** 
p<0.0001). c) The graph represents the number of  S6 positive neurons among NeuN positive neurons. One-
way ANOVA and Bonferroni post-hoc test revealed a significant effect of treatments (stimulated vs not 
stimulated, *** p<0.001, **** p<0.0001).  
 
 
 
 a 
 b  c 
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SKF38393-mediated S6 activation is completely abolished by the treatment with the NMDARs 
antagonist and glutamate–mediated  S6 phosphorylation is decreased following the 
application of the D1Rs antagonist 
 
Another important point is the potential crosstalk in the MSN circuitry between D1Rs and 
NMDARs; an early evidence showed that cocaine-induced ERK activation in vivo in the striatum 
requires the concomitant stimulation of D1Rs and NMDARs (Valjent et al., 2005). In addition, 
previous experiments performed in our laboratory have suggested that a crosstalk between 
NMDARs and D1Rs, possibly via Ras-GRF1, is necessary to activate ERK in organotypic slices 
(Fasano et al., 2009). 
To elucidate in detail the crosstalk between D1Rs and glutamate receptors in both striatonigral and 
striatopallidal MSNs, we took advantage of our ex-vivo system by treating striatal slices from M4-
EGFP mice with glutamate and SKF38393 in the presence of specific antagonists of NMDARs and 
D1Rs.  Firstly, we found that S6 phosphorylation is completely prevented by the specific 
antagonists of either AMPARs and NMDARs (fig. 24). We next found that SKF38393-dependent 
S6 activation is totally abolished either in the direct and indirect pathway not only by the treatment 
with the corresponding antagonist SCH23390 but also when SKF38393 is applied in combination 
with the NMDAR antagonist AP5. Conversely, glutamate-mediated S6 activation is totally 
prevented by the treatment with AP5 but it is only partially blocked (48% of inhibition) when 
glutamate is applied in combination with SCH23390 (fig. 25). In addition, in the direct pathway S6 
activation seems to be more inhibited (55 % of inhibition) by SCH23390 with respect to the indirect 
pathway (41% of inhibition). 
These results suggest that a crosstalk between  NMDARs and D1Rs is required to trigger ERK 
cascade either in the striatonigral and striatopallidal pathways. 
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Fig.24. The blockade of 
AMPARs or NMDARs 
completely prevents glutamate-
dependent-S6 activation in adult 
striatal slices.  Striatal slices 
obtained from wild type mice were 
pre-treated with AP5 50 µM or 
with CNQX 10 µM for 30 min 
before the stimulation with 
glutamate 20 µM.  
a) Immunofluorescence against 
phospho-S6 ribosomal protein 
(red) and NeuN (blue). b) The 
graph represents the quantification 
of S6 positive neurons among 
NeuN positive cells. The data are 
expressed as mean±SEM (n=10 for 
not stimulated, n=9 for glutamate, 
n=11 for SKF38393 and for 
glutamate+ SKF38393). Statistical 
analysis was performed using one-
way ANOVA; Bonferroni post-hoc 
test revealed a significant 
difference between the group 
treated with glutamate and each of 
the other groups (**** p<0.0001). 
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a 
b 
c 
Fig. 25. The application of either 
SCH23390 and AP5 results in an 
inhibition of both glutamate- and 
SKF38393-mediated S6 activation 
in adult striatal slices. a) The 
striatal slices obtained from M4-
EGFP mice were treated with the 
different agonists and antagonists 
and immunolabeled against S6 
ribosomal protein  (red), NeuN (blue) 
and EGFP (green). b) The number of 
S6 positive cells in the direct and in 
the indirect pathway was calculated. 
One-way ANOVA and Bonferroni 
post-hoc test showed a significant 
effect of treatments (not stimulated 
vs glutamate or vs SKF38393, 
glutamate vs glutamate+SCH23390, 
SKF38393 vs SKF38393+AP5, *** 
p< 0.001, **** p< 0.0001). c) The 
graph represents the quantification of 
S6 positive cells among NeuN 
positive cells. Statistical analysis was 
performed using one-way ANOVA 
followed by Bonferroni post-hoc test 
(not stimulated vs glutamate or vs 
SKF38393, glutamate vs 
glutamate+SCH23390, SKF38393 vs 
SKF38393+AP5, **** p< 0.0001). 
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D1Rs-mediated ERK activation is prevented by the neuropeptide nociceptin/orphanin FQ 
(N/OFQ) 
 
In the last part of this project, we have decided to use the ex-vivo technique we developed to 
investigate the role of Ras-ERK signalling in pathological conditions in the striatum, including L-
DOPA induced diskynesia (LID) (Berthet and Bezard, 2009; Jenner, 2008). It is well known that 
this neurological condition is associated with hyperesponsiveness of D1 receptors on striatonigral 
MSNs leading to an increased activity of the Ras-ERK pathway  
Recently, several studies have been conducted to elucidate the molecular mechanisms underlying 
LID. For instance, the nociceptin opioid (NOP) receptor has been suggested as a new potential 
therapeutic target (Marti et al., 2012).  The endogenous agonist of NOP receptor is nociceptin 
(N/OFQ) that is able to trigger a series of intracellular events mediated by G-proteins, including the 
inhibition of adenylyl cyclase and Ca++ channels, and the activation of phospholipase C (PLC), K+ 
channels and MAPKs. In the central nervous system, the main effect of N/OFQ is the inhibition of 
the release of neurotransmitters, including acetylcholine, catecholamines, GABA and glutamate. 
Recent studies have provided a link between N/OFQ and Parkinson’s Disease; in particular, an 
increase of N/OFQ expression was found in parkinsonian patients. Consistently, NOP receptor 
antagonists reversed experimental parkinsonism. In addition, recent evidences have shown that 
N/OFQ counteracts striatal D1 signalling postsynaptically , pointing to a possible beneficial effect 
of NOP receptor agonists in LID.  In vivo studies conducted by Morari’s group and collaborators 
have suggested that N/OFQ reduces dyskinesia in 6-OHDA lesioned rats and also in MPTP-treated 
macaques without impairing the antiparkinsonian effect of L-DOPA (Marti et al., 2012). 
Thus, we investigated whether the antidyskinetic property of N/OFQ could be ascribed to the 
inhibition of D1Rs-mediated signalling. In particular, we used our ex-vivo system to monitor the 
effect of N/OFQ alone or given with SKF-38393 on S6 phophorylation in striatal slices obtained 
from naïve mice. As shown in figure 26, the application of N/OFQ 1 µM is ineffective alone but 
totally prevents the D1Rs-mediated  ERK signalling activation. 
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Fig. 26. N/OFQ inhibits D1 receptor-mediated activation of ERK signalling in mouse striatal slices. 
a) Representative photomicrographs showing ERK-dependent S6 phosphorylation (pS6 Ser235/236) 
(green) and NeuN (red) immunofluorescence in mouse striatal slices in response to SKF38393 (100 µM), 
N/OFQ (1 µM), or their combination. b) Phospho-S6 levels were significantly increased in striatal neurons 
stimulated with SKF38393 (Student’s t test, Control vs SKF38393, t(10)6.452, *p=0.0006). N/OFQ, 
ineffective by itself, prevented the effect of SKF38393 (Student’s t test, Control vs SKF38393N/OFQ, 
t(12)0.947, p=0.363). One-way ANOVA revealed a significant effect of treatment F(5,31)27.235, p> 
0.0001. Bonferroni’s post hoc, SKF38393 vs SKF38393N/OFQ, #p<0.0001. Data are expressed as 
number ± SEM of pS6 positive cells with respect to NeuN positive cells. 
a 
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Ras-GRF1 ablation prevents histone H3 hyperactivation but not S6 phosphorylation, in 
dyskinetic  mice 
 
Previous work from my laboratory  has demonstrated that the absence of Ras-GRF1 
attenuates LID in 6-OHDA lesioned mice and this effect correlates with a significant decrease of 
ERK1/2 phosphorylation in the dorsolateral lesioned striatum (Fasano et al, 2010). In addition, S6 
ribosomal protein and histone H3 have been found to be hyperactivated in dyskinetic mice 
specifically in the striatonigral pathway (Santini et al., 2009). 
Therefore, we set out to investigate the effect of Ras-GRF1 ablation in LID by monitoring the 
changes in S6 and histone H3 phosphorylation. In collaboration with Milica Cerovic (Cardiff 
University), Ras-GRF1 KO mice and wt littermates were stereotactically injected with one 
microliter of 6-hydroxydopamine (6-OHDA)-HCl (3 µg/µL) into the right ascending medial 
forebrain bundle. Mice were then evaluated in the open field 2 weeks after lesion to estimate the 
success rate of lesioning. Starting from day 18, mice were treated twice a day, for 9 consecutive 
days with an escalating L-dopa dosing regimen (1.5, 3, and 6 mg/kg) plus benserazide (12 mg/kg) 
to induce LID. We next confirmed the entity of the neurotoxic damage induced by 6-OHDA by 
immunohistochemistry using antibodies against tyrosine hydroxylase (TH), the enzyme responsible 
for catalyzing the conversion of L-tyrosine into L-DOPA. As shown in  fig. 27 (panel a, b), both 
wild-type and RasGRF1 KO mice show a positive TH staining in the intact side, whereas the 
lesioned side shows a profound loss of dopaminergic fibers. Consistently with previous results, we 
also found an hyperactivation of ERK1/2 in the dorsolateral lesioned striatum of wt mice, whereas 
lower levels of ERK1/2 phosphorylation were observed in Ras-GRF1 KO mice (fig.27, panel c, d). 
Interestingly, immunofluorescence analysis (fig. 28) has demonstrated that Ras-GRF1 ablation 
while reduces histone H3 phosphorylation in Ras-GRF1 KO dyskinetic mice (fig. 28, panel c, d), 
does not alter the level of  S6 phosphorylation in comparison to wild type mice (fig. 28, panel a, b), 
suggesting that pS6 in dyskinetic animals may be independent from Ras-GRF1 activity, while it is 
likely to be still ERK dependent.  
Altogether, these in vivo data confirm the validity of the analysis of the Ras-ERK pathway using 
pS6 and pH3 antibodies also in pathological conditions of the the striatum, such as LID. 
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Fig. 27. Dyskinetic Ras-GRF1 KO mice show a reduction in ERK phosphorylation. a,b) 
Representative images of TH positive staining in the intact striatum (left part of the slice) in 
wild-type (a) and Ras-GRF1 KO (b) mice. Following 6-OHDA lesion a profound loss of 
dopamine fibers in the striatum was observed (right part of the slice). c) Representative 
photomicrographs of phospho-ERK1/2 immunoreactive cells in the dorsolateral part of the 
striatum after 9 days of L-dopa treatment. An aberrant phospho-ERK activation was observed 
in dyskinetic WT animals while a reduction was seen in Ras-GRF1 KO animals. c) 
Quantification of p-ERK1/2 positive cells (mean±sem) in the striatum of Ras-GRF1 mutants 
and control animals. Two–way ANOVA revealed a significant reduction in the number of 
pERK positive cells in lesioned striatum of Ras-GRF1 mutants (n=8) in comparison to 
littermate controls (n=8) (Tukey’s HSD test, *p<.001 genotype effect).  
 
a 
c 
b 
d 
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Fig. 28. Dyskinetic Ras-GRF1 KO mice show a reduction in histone H3, but not in S6 activation. 
a,c) Immunofluorescence of phospho-S6 or phospho-H3 (red), and NeuN (blu) of MSNs of dyskinetic 
Ras-GRF1 mutants and control animals. b,d) The graphs provide quantitative data of the percentage of 
phospho-S6 and phospho-H3 positive cells over the total NeuN-positive neurons. Two-way ANOVA 
revealed a significant reduction in the phosphorylation level of H3 in dyskinetic Ras-GRF1 mutants 
(Tukey’s HSD test , *p<.001 genotype effect) whereas S6 activation is not affected by  Ras-GRF1 
ablation.  
 
 
a b 
c d 
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Conclusions and future perspectives  
 
The striatum, the input nucleus of the basal ganglia circuit, integrates excitatory glutamatergic 
signals from the cortex, thalamus and limbic areas with modulatory dopaminergic signals from 
midbrain neurons located in the SNc and in the ventral tegmental area.  
Thus, signal integration is necessary for normal striatal functions and for the development of 
various forms of behavioural plasticity, including learning of procedural actions and motor skills, 
habit formation and reward mechanisms. In addition, the abnormal potentiation of dopamine- and 
glutamate-dependent signalling, including ERK activation, is implicated in neurological diseases 
such as L-DOPA induced dyskinesia and drug addiction (Fasano and Brambilla, 2011, Hervé et al., 
2001; Cenci et al., 2007; Santini et al., 2007). In particular, psychostimulants and L-DOPA are able 
to promote cAMP-dependent signalling in the striatum trigger ERK1/2 and MSK-1 signalling 
specifically in the striatonigral pathway, through phosphorylation of DARPP-32 at Thr34 (Santini et 
al., 2007; Valjent et al., 2000); this activation of ERK1/2 and MSK1, which depends on the 
concerted activation of D1Rs and glutamate receptors, mediates also the concomitant increase in the 
state of phosphorylation of histone H3 and S6 ribosomal protein (Brami-Cherrier et al, 2005; 
Santini et al, 2007). Conversely, in the striatopallidal pathway, cAMP signalling is controlled by the 
opposite actions of A2ARs, which increase cAMP production through Gαolf, and D2Rs, which 
reduce cAMP production through Gαi/o. Therefore, haloperidol and other D2R antagonists promote 
cAMP/PKA/DARPP-32 signalling, thus increasing the state of phosphorylation of ERK, S6 and 
histone H3 (Bertran-Gonzalez et al., 2008, 2009; Valjent et al., 2011). This effect has been 
attributed to the removal of the inhibitory tone exerted by D2Rs on adenylyl cyclase, which leads to 
the accumulation of cAMP and activation of PKA. The ability of D2R antagonists to promote 
cAMP/PKA signaling depends on A2ARs which maintain basal adenylyl cyclase activity via 
activation of Gαolf (Bertran-Gonzalez et al., 2009).  
In this work, I showed the development of a new experimental approach in acute striatal slices 
obtained from the mature brain that has allowed me to characterize the regulation of the Ras-ERK 
pathway in the striatum with a single-cell definition.  
The first aspect to be highlighted is that this ex-vivo system provides some advantages with respect 
to the other traditional techniques that have been used so far to study signal transduction. For 
instance, my approach represents a more physiological setting in comparison to the dissociated 
neuronal cultures (either embryonic or early postnatal ones), in which the cytoarchitecture of the 
brain structures is completely lost and the cell composition is likely to be altered. In addition, 
differently from the common use of organotypic cultures obtained from post-natal rodents, this 
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system uses adult slices that, following the incubation in a perfusion chamber, can be challenged 
with specific agonists and antagonists and the induction of signaling events, including the ERK 
cascade, can be monitored using specific antibodies against phosphorylated  or unphosphorylated 
proteins. 
In the initial phase of the project, I tested the ability of glutamate to elicit ERK activation using 
Western blot analysis and I confirmed the induction of ERK following 10 min stimulation with 
glutamate 100 µM. However, since Western blot analysis examines an average of signaling events 
in a mixed neuronal population without discriminating between different cell types I decided to 
develop a system to target specific cell populations in the striatum, also by using transgenic mouse 
lines expressing EGFP in restricted cell types, including MSNs from the direct and in the indirect 
pathways.  
In particular, I monitored the phosphorylation of two proteins downstream ERK, S6 ribosomal 
protein and histone H3, respectively a cytoplasmic and a nuclear marker, by immunofluorescence 
analysis, demonstrating that glutamate, the D1 agonist SKF-38393 or BDNF are able to induce a 
robust S6 phosphorylation, assessed at Ser235/236 sites. Similarly, I found that the Lys14-
acetylated form of histone H3, an important target of MSK1 in striatal neurons (Brami-Cherrier et 
al., 2005, Santini et al., 2007), is strongly phosphorylated following the application of glutamate, 
SKF38393 or BDNF.  
These observations, together with the demonstration that upon MEK blockade the glutamate-
dependent activation of either S6 and H3 is completely abolished, indicate that it is possible to 
study at a single-cell level both cytoplasmic and nuclear events induced by ERK activation and that 
these phosphorylation sites on S6 ribosomal protein and histone H3 are reliable indicators of the 
Ras-ERK pathway. Regarding S6 phosphorylation, my findings are partially in agreement with a 
previous study conducted on mammalian cells challenged with several stimuli, including serum and 
growth factors; in fact, these experiments have shown that S6 phosphorylation at the dual site 
Ser235/236 occurs either via p70 S6 kinase 1 (S6K1) and via the p90 ribosomal S6 kinases (RSKs), 
which are activated by ERK independently from mTORC1 (Roux et al., 2007). Consistently, I 
found that S6 phosphorylation at Ser235/236 is totally dependent on ERK activation, strongly 
suggesting that both S6K1 and RSKs require to be fully activated by ERK1/2 in order to 
phosphorylate these two sites. 
Having validated this experimental setting, we next investigated the integration between 
dopaminergic  and glutamatergic signaling underlying striatal plasticity. Recently, the interactions 
between NMDARs and dopamine receptors has been extensively studied, given their essential 
physiological role but also their involvement in pathological conditions; for instance, it has been 
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documented that the integration of these two signalling pathways, finely balanced in the intact 
brain, controls a variety of functions according to the area in which they occur, including motor 
control in the dorsal striatum (Cepeda and Levine, 1998) and working memory and cognition in the 
frontal cortex (Castner et al., 2007); however, the disruption of this homeostasis may contribute to 
pathological states, including addiction. The classical paradigm of NMDARs interactions with 
dopamine receptors is that these take place through the crosstalk between their signalling 
transduction cascades; for instance, in the striatum, upon stimulation D1Rs are able to enhance 
NMDARs responses by cAMP-PKA-DARPP-32 pathway that leads to the phosphorylation of the 
NR1 subunit of NMDARs (Snyder et al., 1998) and activation of voltage-gated channels (Cepeda et 
al., 1998), but also exerts an inhibitory action on striatal-enriched tyrosine phosphatase (STEP) and 
protein phosphatase-1 (PP-1) (Valjent et al., 2005). In contrast, when the D1 receptor is blocked, 
activation of D2 receptors reduces the PKA-mediated phosphorylation of both DARPP-32 and NR1 
subunits (Edwards et al., 2002) and inhibits NMDAR-mediated calcium influx (Higley and 
Sabatini, 2010).  
Besides the indirect crosstalk between NMDARs and dopamine receptors, other studies have found 
physical interactions between these receptors; for instance, the interaction of the C-terminal tails of 
D1Rs with NR1 NMDAR subunit enables an increased membrane insertion of D1Rs and it is also 
implicated in the attenuation of NMDAR-dependent excitotoxicity through a PI-3 kinase-dependent 
pathway (Pei et al., 2004). In addition, the C-terminal tails of D1Rs have also been found to interact 
with NR2A NMDAR subunit in hippocampus, and this event results in the inhibition of NMDARs-
gated currents, via a decrease in the number of cell surface receptors (Lee et al., 2002).  
It is now known that ERK cascade is a common downstream target of glutamate and dopamine 
pathways in different brain regions, since its triggering requires both calcium influx from 
AMPARs/NMDARs and D1Rs activation (Bertran-Gonzales et al., 2008; Kaphzan et al., 2006; 
Valjent et al., 2005). In addition, both NMDARs/AMPARs and D1Rs are potently activated during 
rewarding experiences and exposure to addictive drugs, and the integration between the signalling 
pathways harboring from the two classes of receptors modulates the enduring changes in synaptic 
plasticity underlying addictive behaviour. For instance, in vivo studies have demonstrated that mice 
treated with cocaine show a robust activation of ERK1/2, dependent on the concomitant stimulation 
of NMDARs/AMPARs and D1Rs; in addition, ERK activation is involved in the long lasting 
behavioural changes induced by cocaine, including psychomotor sensitization and conditioned 
place preference (Valjent et al., 2006; Fasano et al., 2009). More recently, it has been shown that 
D1R-mediated tyrosine phosphorylation of NR2 subunit of NMDARs is necessary to trigger 
cocaine-induced ERK activation (Pascoli et al., 2010). Furthermore, previous experiments 
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conducted in our laboratory have clearly demonstrated an additive effect of SKF38393- and 
glutamate-dependent signalling on ERK1/2 activation in organotypic slices, an effect completely 
lost in Ras-GRF1 knock out mice, suggesting that Ras-GRF1 acts as integrator of dopaminergic and 
glutamatergic signalling in striatum (Fasano et al., 2009).  
These observations, together with the availability of M4-EGFP mice expressing EGFP in the 
striatonigral pathway, have prompted us to investigate the integration of dopaminergic and 
glutamatergic  signalling specifically in the direct and in the indirect pathway in adult striatal slices. 
However, before using M4-EGFP mice, we first characterized these animals calculating the 
proportions of EGFP-expressing MSNs with respect to MSNs that do not express EGFP, 
considering that it is highly believed that the cellular composition belonging to the direct and the 
indirect pathway is quite similar. The result demonstrated that the percentage of EGFP-positive 
cells is similar to the percentage of EGFP-negative cells (48% of striatonigral MSNs and 52% of 
striatopallidal MSNs), suggesting that M4-EGFP mice may represent a good model to study and 
compare the signaling pathways in the two populations  of MSNs. 
Having validated M4-EGFP mice, we next determined the lowest concentration of both glutamate 
and SKF38393 able to efficiently activate S6 and histone H3 after a stimulation of 10 min. The 
treatment with different doses of glutamate and SKF38393 has demonstrated that both agonists 
affect in a dose-dependent manner the level of  S6 and histone H3 phosphorylation and 20 µM of 
either glutamate and SFK38393 is able to induce the maximal activation of  S6 and histone H3 after 
10 min stimulation. 
On the basis of these preliminary observations, we wanted to further explore the interplay between 
the glutamatergic and the dopaminergic signaling in the two striatal pathways, using M4-EGFP 
mice. In particular, our results confirm that an additive integration between glutamate and 
SKF38393 converges on S6 phosphorylation.  Interestingly, this effect seems to be restricted to the 
striatonigral pathway. In addition, we found that the basal level of S6 activation, that is MEK-
dependent, is two fold higher in the indirect pathway in comparison to the direct pathway. This last 
observation seems to be in accordance with previous electrophysiological observations suggesting a 
generally higher excitability of the striatopallidal MSNs (Cepeda et al., 2008; Day et al., 2008).  
Furthermore, we also found that the application of SKF38393 activates S6 ribosomal protein also in 
the indirect pathway, even though at a lower level in comparison to what observed in the 
striatonigral MSNs. This finding, quite unexpected since SKF38393 is supposed to be a D1R-like 
specific agonist, has prompted us to further investigate the effect of  D1Rs blockade on SKF38393-
induced S6 activation; our data clearly demonstrate that S6 phosphorylation observed in the indirect 
pathway depends directly on D1Rs stimulation since the D1Rs antagonist SCH233390 completely 
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abolishes SKF38393-induced S6 activation in both pathways. Thus, the exact mechanism, either 
direct or indirect, by which SKF38393 is able to induce S6 activation in the striatopallidal neurons 
still remains to be elucidated. However, in this regard, it has to be noted that, although several 
neuroanatomical and functional studies support the selective distribution of D1/5Rs and D2/3/4Rs 
respectively in the striatonigral and in the striatopallidal pathway, other studies have disclosed a 
partial overlap between the expression of the two receptor classes (Aizman et al., 2000, Bertran-
Gonzales et al., 2008). The fact that the degree of overlap has been continuously questioned is a 
clear indication of this controversy but a recent study estimated that only 5% of MSNs co-expresses 
the D1s and D2Rs in the dorsal striatum and in the NAc core, whereas co-expressing neurons are 
more abundant in the NAc shell (about 17%) (Bertran-Gonzales et al., 2008). These findings, 
although still under debate, might partially explain our observations since SKF38393-induced S6 
phosphorylation in the indirect pathway might be mediated  by D1Rs localized in the subset of 
striatopallidal MSNs expressing both types of dopamine receptors. Another possibility to be 
considered is that SKF38393-induced S6 activation in the indirect pathway might be mediated 
indirectly by D1Rs that, for instance, might trigger signaling pathways that finally modulate other 
receptors, including A2ARs, thereby leading to S6 phosphorylation in the indirect pathway. The 
final possibility is that some EGFP negative cells in the M4-EGFP model are indeed part of the 
indirect pathway despite they do not express the fluorescence marker (see comment further below). 
This possibility will be explored in the near future by using a BAC transgenic mouse specifically 
expressing EGFP in the indirect pathway, i.e. the A2A-EGFP line (Fasano et al., 2010). 
We next wanted to investigate the effect of the co-stimulation of glutamate receptors and D1Rs on 
histone H3 phosphorylation but, in contrast to what observed for S6, we have not found an additive 
integration between glutamate and SKF38393. A possible explanation of this result is that histone 
H3 is already maximally phosphorylated at the doses used of glutamate and SKF38393, as we also 
observed in the dose-response curves. 
Our results also confirm and extend previous evidence from our laboratory that suggested, by 
Western blot analysis, a reciprocal dependence of both glutamate and SKF38393 on NMDARs and 
D1Rs activation in organotypic slices extracts (Fasano et al., 2009). This finding was unique to the 
striatum since in hippocampus only dopaminergic activity requires NMDAR activation to trigger 
ERK cascade (Kaphzan et al., 2007). Accordingly to what published by Fasano et al. in 2009, we 
found that D1Rs-mediated signalling depends on glutamatergic activity since SKF38393-dependent 
S6 activation is totally abolished either in the direct and indirect pathway not only by the treatment 
with the D1Rs antagonist SCH23390 but also when SKF38393 is applied in combination with the 
NMDAR antagonist AP5. Conversely, glutamatergic activity does not completely depend on 
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dopaminergic signalling since glutamate-mediated S6 phosphorylation is only partially inhibited 
(48% of inhibition) when glutamate is applied in combination with SCH23390. In addition, when I 
compared the direct and the indirect pathways, my results highlighted a difference in the level of 
glutamate-induced S6 activation in the slices pre-treated with SCH23390. In particular, in the direct 
pathway, S6 activation seems to be more inhibited (55 % of inhibition) by SCH23390 with respect 
to the indirect pathway (41% of inhibition). Regarding all these findings, it should be noted once 
again that, whereas the data referred to the direct pathway are certainly reliable, we are planning to 
perform further experiments in A2A-EGFP mice, expressing EGFP in the indirect pathway, to 
confirm the results concerning the indirect pathway.  
In fact, although we estimated that the number of the EGFP-expressing cells is quite similar to the 
number of EGFP-negative cells in the whole striatum, we also observed that the fluorescence is not 
always distributed homogeneously within the different striatal slices, possibly resulting in an 
underestimation of the EGFP positive cells. Therefore, the data relative to the striatopallidal 
pathway may appear overestimated by counting the EGFP-negative cells in the specific fields that 
we considered.  
As future perspective, another step forward may be represented by the genetic manipulation of Ras-
ERK components in EGFP mice, for instance by injecting viral vectors with cell-specific promoters 
in the direct or in the indirect pathways.  
In the last part of the project, we also investigated the role of Ras-ERK signalling in L-DOPA 
induced dyskinesia (LID), a severe and disabling pathology characterized by involuntary 
choredystonic movements that develop as consequence of chronic L-DOPA treatment in 
parkinsonian patients. Several lines of evidence have suggested that LID largely results from the 
pulsatile stimulation of dopamine receptors, triggering a complex cascade of molecular changes 
including ERK activation that concur to modify neuronal firing patterns in the basal ganglia-
thalamocortical networks. Unfortunately, at present only two therapeutic options are used for the 
treatment of severe LID. The first strategy is  the neurosurgical intervention targeting the deep basal 
nuclei (deep brain stimulation, DBS) but, in addition to being expensive and invasive, can only be 
offered to selected parkinsonian patients responding to specific criteria (Lang et al., 2006); the 
second strategy is a pharmacological therapy using NMDA receptor antagonist amantadine; 
however, the main disadvantage of this type of treatment is given by its modest antidyskinetic 
efficacy since amantadine is able to reduce dyskinesia in the range of 40-60% in the best responding 
patients. 
However, in recent years the study of the molecular changes occurring in the striatum during the 
development of LID and the role of the specific components of the signalling machinery has 
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revealed potential new therapeutic targets. For instance, the recent discovered NOP receptor has 
been suggested as a possible target for treating PD and motor disorders. In particular, NOP receptor 
antagonists have been found to reverse experimental parkinsonism thereby suggesting a possible 
application in PD treatment (Marti et al., 2005; Marti et al., 2008; Volta et al., 2010). In addition, 
NOP receptor antagonists might affect the dyskinesiogenic activity of L-DOPA since they elevate 
striatal DA (Marti et al., 2004) and raphe serotonin (Tao et al., 2007; Nazzaro et al., 2009) levels.  
On the other hand, NOP receptor agonists (N/OFQ) impair the firing activity of ascending DA  and 
serotonin  neurons, and inhibit DA (Flau et al., 2002; Olianas et al., 2008) and serotonin (Sbrenna et 
al., 2002) released presynaptically. Therefore, these observations, together with the recent finding 
that N/OFQ counteracts striatal D1 signalling postsynaptically , have suggested a possible anti-
dyskinetic effect of N/OFQ.  
In this direction, Morari and collaborators have recently performed experiments either in 6-OHDA 
lesioned rats and in MPTP-treated macaques to evaluate whether NOP receptors agonists and 
antagonists affected the expression of dyskinetic movements. They demonstrated that N/OFQ is 
able to reduce dyskinesia in both these animal models without impairing the antiparkinsonian effect 
of L-DOPA. Therefore, on the basis of these observations, we wondered whether the antidyskinetic 
property of N/OFQ might correlate with a negative modulation of D1Rs-mediated signalling. To 
support this idea I decided to use the ex-vivo system I developed on striatal slices obtained from 
naive mice; my results clearly indicate that the application of N/OFQ completely prevents S6 
activation induced by D1Rs stimulation, thereby suggesting that N/OFQ is able to block D1Rs-
mediated ERK signalling pathway.  
Another perspective for pharmacological treatments of LID is given by the demonstration that LID 
is causally linked to ERK hyperactivation and thus it can be prevented in 6-OHDA mice by the 
treatment with SL237, a MEK inhibitor (Santini et al., 2007). From this point of view, the striatal 
signalling machinery controlled by ERK may represent an appealing drug target but, since ERK 
cascade is involved in a number of important biological processes including cell proliferation, 
differentiation and neuronal plasticity, a complete blockade of this pathway may produce negative 
side effects, including neuronal cell loss. To overcome this problem, Fasano et al. (2010, 2011) 
have suggested that Ras-GRF1, a brain-specific Ras exchange factor, may represent an alternative 
target for pharmacological treatment of LID. In fact, they demonstrated that LID is significantly 
reduced both in Ras-GRF1 KO mice and in mice injected in the dorsal striatum with lentiviral 
vectors causing Ras-GRF1 knockdown (Fasano et al., 2010).  
In this work, I wanted to investigate the effect of Ras-GRF1 ablation in LID by monitoring the 
changes in ERK1/2, S6 and histone H3 phosphorylation in dyskinetic Ras-GRF1 KO mice. Our 
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data confirmed previous evidence (Fasano et al., 2010; Santini et al., 2009), demonstrating that 
ERK, S6 and histone H3 are hyperactivated in the dorsolateral striatum of dyskinetic mice. 
In addition, I showed that the lack of Ras-GRF1 prevents histone H3, but not S6 hyperactivation 
following chronic L-DOPA treatment. Altogether these findings suggest that the chronic treatment 
with L-DOPA produces some adaptive processes that may bypass Ras-GRF1 and possibly ERK 
requirement; for instance, in neuronal cells, ERK signalling is promoted not only via calcium-
dependent activation of Ras-GRF1 but also by other calcium-sensitive Ras-GEFs, including the 
striatal-enriched members of Ras-GRP/CalDAG GEFs family (Ebinu et al., 1998). In addition, 
other lines of evidence have demonstrated  that LID is also associated with a persistent 
enhancement of  mTORC1 signalling, leading to an increased S6 phosphorylation, assessed both at 
Ser 235/236 sites and Ser 240/244 sites (Santini et al., 2009) and this event may be related to an 
enhanced local protein synthesis underlying LID. Thus, it is possible that mTOR pathway may 
converge to activate S6 in dyskinetic Ras-GRF1 KO mice bypassing ERK. In order to test our 
hypothesis, further experiments will need to be performed, for instance by treating dyskinetic wild 
type and Ras-GRF1 KO mice or striatal slices obtained from these animals with MEK inhibitor, to 
investigate the effect of ERK blockade on L-DOPA induced S6 hyperactivation in this pathological 
condition. 
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In the present studywe investigatedwhether the neuropeptide nociceptin/orphanin FQ (N/OFQ), previously implicated in the pathogen-
esis of Parkinson’s disease, also affects L-DOPA-induced dyskinesia. In striatal slices of naive rodents, N/OFQ (0.1–1M) prevented the
increase of ERK phosphorylation and the loss of depotentiation of synaptic plasticity induced by the D1 receptor agonist SKF38393 in
spiny neurons. In vivo, exogenous N/OFQ (0.03–1 nmol, i.c.v.) or a synthetic N/OFQ receptor agonist given systemically (0.01–1 mg/Kg)
attenuated dyskinesias expression in 6-hydroxydopamine hemilesioned rats primed with L-DOPA, without causing primary hypoloco-
motive effects. Conversely, N/OFQ receptor antagonists worsened dyskinesia expression. In vivo microdialysis revealed that N/OFQ
prevented dyskinesias simultaneously with its neurochemical correlates such as the surge of nigral GABA and glutamate, and the
reduction of thalamic GABA. Regional microinjections revealed that N/OFQ attenuated dyskinesias more potently and effectively when
microinjected in striatum than substantia nigra (SN) reticulata, whereas N/OFQ receptor antagonists were ineffective in striatum but
worsened dyskinesias when given in SN. Quantitative autoradiography showed an increase in N/OFQ receptor binding in striatum and a
reduction in SN of both unprimed and dyskinetic 6-hydroxydopamine rats, consistent with opposite adaptive changes of N/OFQ trans-
mission. Finally, the N/OFQ receptor synthetic agonist also reduced dyskinesia expression in 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine-treated dyskinetic macaques without affecting the global parkinsonian score. We conclude that N/OFQ receptor
agonists may represent a novel strategy to counteract L-DOPA-induced dyskinesias. Their action is possibly mediated by upregulated
striatal N/OFQ receptors opposing the D1 receptor-mediated overactivation of the striatonigral direct pathway.
Introduction
Nociceptin/orphanin FQ (N/OFQ) (Meunier et al., 1995; Reins-
cheid et al., 1995) and its receptor (NOP) represent a neuropep-
tide system bearing structural and functional analogies with
classical opioid systems but unique pharmacological profile
(Calo` et al., 2000). NOP receptor expression and binding are
widespread throughout the rodent and primate brain, support-
ing the role of the N/OFQ-NOP receptor system in the modula-
tion of central functions such as sensory nociceptive processing,
learning and memory, reward, mood, feeding, stress, and move-
ment (Mogil and Pasternak, 2001; Lambert, 2008).
Preclinical and clinical studies revealed a link betweenN/OFQ
and Parkinson’s disease (PD) (Marti et al., 2005, 2010). Indeed,
an increase of N/OFQ expression (Marti et al., 2005, 2010; Gouty
et al., 2010) and release (Marti et al., 2005) in the substantia nigra
(SN) of parkinsonian animals was found, together with an eleva-
tion of N/OFQ levels in the CSF of parkinsonian patients (Marti
et al., 2010). Consistent with a pathogenic role of endogenous
N/OFQ, NOP receptor antagonists reversed parkinsonian-like
motor deficits (Marti et al., 2005, 2008; Viaro et al., 2008; Volta et
al., 2010), also synergizing with L-3,4-dihydroxyphenylalanine
(L-DOPA) (Marti et al., 2007; Visanji et al., 2008; Viaro et al.,
2010). Contrary to substantia nigra reticulata (SNr), a reduction
in N/OFQ expression was found in the dopamine (DA)-depleted
striatum (Marti et al., 2010), suggesting a different adaptive re-
sponse of striatal N/OFQ transmission in PD. The striatal
N/OFQ-NOP receptor system has so far received little attention,
possibly due to the low expression of N/OFQ and NOP receptor
in the rodent striatum (Neal et al., 1999a,b).Nonetheless, N/OFQ
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impairs the firing activity of ascendingDA (Marti et al., 2004) and
serotonin (Tao et al., 2007; Nazzaro et al., 2009) neurons, and
inhibits DA (Flau et al., 2002; Olianas et al., 2008) and serotonin
(Sbrenna et al., 2000) release presynaptically. N/OFQ also post-
synaptically counteracts the D1 receptor-stimulated cAMP accu-
mulation in striatal neurons (Olianas et al., 2008), overall
suggesting that endogenous N/OFQ might control striatal func-
tion. This controlmight bemore relevant in the primate caudate/
putamen due to the much greater expression of NOP receptors
(Berthele et al., 2003; Bridge et al., 2003). We therefore investi-
gated whether NOP receptor agonists and antagonists affect the
expression of L-DOPA-induced dyskinesias (LID) in rats (Cenci
et al., 1998) and nonhuman primates (Be´zard et al., 2003). In-
deed, LID are a major motor complication of L-DOPA pharma-
cotherapy thought to originate from aberrant striatal plasticity
(Calabresi et al., 2010). LID are involuntary choreodystonic
movements (Nutt and Gancher, 1994) that develop as a conse-
quence ofDAdenervation and nonphysiological DA release from
both residual DA and serotonin striatal terminals (Carta et al.,
2007; Navailles et al., 2010). This leads to “pulsatile” DA receptor
stimulation and upregulation of D1 signaling (Andersson et al.,
1999; Aubert et al., 2005), increased activity along the Ras/MEK/
ERK kinase pathway (Valjent et al., 2005; Feyder et al., 2011) and
loss of neuronal depotentiation after long-term potentiation
(LTP) induction in striatonigral spiny neurons (Picconi et al.,
2003).
Materials andMethods
In vitro experiments
Immunohistochemistry
Anesthetized 2-month-old C57BL/6 mice were decapitated and the
brains rapidly removed. Slices (200mthick)were cut using a vibratome
keeping the brain submerged in ice-cold carboxygenated sucrose-based
dissecting solution containing the following (inmM): 87 NaCl, 2.5 KCl, 7
MgCl2, 1 NaH2PO4, 75 sucrose, 25 NaHCO3, 10 D-glucose, 0.5 CaCl2,
and 2 kynurenic acid. The slices were transferred into BSC1 chambers
(Scientific System Design) and constantly perfused with carboxygenated
artificial CSF solution containing the following (inmM): 124NaCl, 5KCl,
1.3 MgSO4, 1.2 NaH2PO4, 25 NaHCO3, 10 D-glucose, and 2.4 CaCl2 at a
constant rate of 2 ml/min at 32°C for 1 h. Slices were then stimulated for
10 min with 100 M SKF38393, 1 MN/OFQ, or their combination, and
fixed in 4%paraformaldehyde in 0.1 M sodiumphosphate buffer, pH 7.4,
at room temperature for 15 min. Slices were then rinsed three times for
20 min in 0.1 M sodium phosphate buffer, pH 7.4, at room temperature
and cryoprotected in 30% sucrose overnight at 4°C.
Eighteenmicrometer cryosectionswere cut andwashed three times for
10 min with Dulbecco’s PBS (D-PBS). After blocking in D-PBS contain-
ing 5% normal goat serum and 0.1% Triton X-100 for 1 h at room
temperature, sections were incubated overnight at 4°C with the primary
antibodies: anti-phospho-S6 ribosomal protein (Thr235/236) (1:200;
Cell signaling Technology) and anti-NeuN (1:1000; Chemicon). Sections
were then washed three times for 10 min with D-PBS and incubated for
1 h at room temperature with the secondary antibodies: Alexa Fluor 546
goat anti-mouse (1:200) and Alexa Fluor 488 goat anti-rabbit (1:500)
(Invitrogen).
Following the incubation with the secondary antibodies, the sections
were washed three times for 10 min with D-PBS and the coverslips were
mounted using the fluorescent mounting medium (Dako).
Single- and double-labeled images were obtained using a laser scanning
confocal microscopy (Leica SP2), equipped with the corresponding lasers
and the appropriate filter sets to avoid cross talk between the fluorophores.
Neuronal quantification was performed with ImageJ software on images
taken at 40magnification by counting phospho-S6-immunoreactive neu-
rons among NeuN positive neurons in each slice.
Electrophysiology
Corticostriatal coronal slices (270 m thick) were cut from 1- to
2-month-old male Wistar rats (n  12; Harlan) using a vibratome, as
previously described (Calabresi et al., 1998; Picconi et al., 2003). A single
Figure 1. N/OFQ inhibited D1 receptor-mediated activation of ERK signaling in mouse striatal slices. A, Representative photomicrographs showing ERK-dependent ribosomal protein S6
phosphorylation (pS6 Thr235/236) (green) andNeuN (red) immunofluorescence inmouse striatal slices in response to SKF38393 (100M), N/OFQ (1M), or their combination.B, Phospho-S6 levels
were significantly increased in striatal neurons stimulatedwith SKF38393 (Student’s t test, Control vs SKF38393, t(10)6.452, *p 0.0006). N/OFQ, ineffective by itself, prevented the effect of
SKF38393 (Student’s t test, Control vs SKF38393N/OFQ, t(12) 0.947, p 0.363). One-way ANOVA revealed a significant effect of treatment F(5,31) 27.235, p 0.0001. Bonferroni’s post hoc,
SKF38393 vs SKF38393N/OFQ, #p 0.0001. Data are expressed as number SEM of pS6 positive cells with respect to NeuN positive cells. *p 0.05 different from control. #p 0.05 different
from SKF38393 alone.
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slice was then transferred to a recording chamber and submerged in a
continuously flowing (2.5–3 ml/min) carboxygenated (95% O2-5%
CO2) Krebs solution (in mM): 126 NaCl, 2.5 KCl, 1.2 MgCl2, 1.2
NaH2PO4, 2.4 CaCl2, 10 glucose, and 25 NaHCO3 kept at 34°C. Drugs
were bath applied by switching the solution to one containing known
concentrations of drugs. Total replacement of the medium in the cham-
ber occurred within 1 min. Intracellular recordings of striatal medium
spiny neurons (MSNs) were obtained with sharp microelectrodes pulled
fromborosilicate glass pipettes backfilled with 2MKCl (30–60M). An
Axoclamp 2B amplifier (Molecular Devices) was connected in parallel to
an oscilloscope to monitor the signal in “bridge” mode and to a PC for
acquisition of the traces using a pClamp9 software (Molecular Devices).
Only neurons electrophysiologically identified asMSNs were considered
for experiment (Calabresi et al., 1992).
A glutamatergic EPSP was evoked every 10 s by means of a bipolar
electrode connected to a stimulator unit (Grass Telefactor). The stimu-
lating electrode was located in the cortical areas close to the recording
electrode or in the white matter between the cortex and the striatum to
activate corticostriatal fibers. The recording electrodes were invariably
placed within the striatum. The experiments were conducted in aMg2-
free Krebs’ solution to unmask the NMDA glutamate (Glu) receptor
component of the EPSP. After 10–15 min the acquisition of EPSPs of
stable amplitude, a high-frequency stimulation protocol (HFS), consist-
ing of three trains of stimuli at 100 Hz (20 s intertrain interval), was
delivered to the slice to induce LTP of the EPSP (Calabresi et al., 1992).
Twentyminutes after theHFS protocol a low-frequency stimulation pro-
tocol (LFS), consisting of repeated stimuli applied at 2Hz for 10min, was
applied to induce depotentiation of the EPSP amplitude to pre-HFS
conditions (Picconi et al., 2003). Quantitative data are expressed as a
percentage of the EPSP amplitudes in respect to the relative control am-
plitude values, the latter representing the mean of responses recorded
during a stable period. EPSP amplitudesweremeasured 20min afterHFS
or LFS and compared with pre-HFS baseline. Off-line analysis was per-
formed using Clampfit (Molecular Devices) and GraphPad Prism 5
software.
Autoradiography
Twenty micrometer coronal sections were obtained from the frozen
brains of sham-operated, untreated 6-hydroxydopamine (OHDA) le-
sioned and dyskinetic 6-OHDA lesioned (killed 48 h after last L-DOPA
injection)male SpragueDawley rats (see below). Sections were cut at two
different brain levels from bregma: anteroposterior (AP)0.30 to0.92
and 3.60 to 5.80 (Paxinos and Watson, 1986) using a cryostat
(1315°C). Sets of five slides (three slides for total binding and two slides
for nonspecific binding) were used for each group. Iodination of
[Arg14Lys 15Tyr18(di)iodo]N/OFQ-NH2 was performed according to
the Chloramine Tmethod (Hunter and Greenwood, 1962). Briefly, 5 g
of peptide was incubated in 0.05 M phosphate buffer, pH 7.4, for 30 s in
the presence of 0.5 mCi (18.5 MBq) of Na125I and 220 nmol of Chlora-
mine T in a total volume of 85l. The mono-iodinated peptide was then
immediately purified by HPLC on a C18 Jupiter 300 column (250 4,6
mm; Phenomenex) with 0.1% trifluoroacetic acid and acetonitrile as
Figure 2. N/OFQ restored synaptic depotentiation of MSNs in the presence of a D1 receptor agonist. A, Time course of the HFS-induced LTP followed by the LFS-induced depotentiation of MSN
EPSPs in control conditions (n 3, open circles) and in the presence of 0.1M N/OFQ (n 3, filled circles). B, EPSP traces recorded in representative MSNs before HFS (left), and 20min post-HFS
(middle) or LFS (right) in control conditionsand in thepresenceof 0.1MN/OFQ.C, TimecourseofHFS followedbyLFS in thepresenceof 3MD1 receptor agonist SKF38393applied for 20min (white
bar). SKF38393 alone prevented depotentiation in MSNs (control, n 3, open circles) whereas N/OFQ reversed this effect (n 5, filled circles). The NOP receptor antagonist UFP-101 (0.1M)
counteracted theeffect ofN/OFQ (n4,diamonds).D, EPSP traces acquiredbeforeHFSandafterHFSor LFS in thepresenceof SKF38393applied10minafterHFS (top),N/OFQSKF38393 (middle),
and N/OFQ SKF38393 in the presence of UFP-101 (bottom). ***p 0.001 different from control.
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mobile phases. The specific activity of the iodinated peptides corre-
sponds to 2000 cpm/fmol or 1212 Ci/mmol.
The bindingmethod used in this studywas adapted from (Bridge et al.,
2003). Tissue sections were thawed at room temperature and preincu-
bated for 30min in a solution containing: 50mMTris-HCl, pH 7.4; 5mM
MgCl2; and 0.2% bovine serum albumin (BSA). They were then incu-
bated at room temperature for 90 min in the same buffer solution, to
which 5 mg/ml Bacitracin and 150 pM 125I[Tyr14]N/OFQ were added.
Nonspecific binding was determined by adding 1 M cold ligand to the
mixture. Slides were then rinsed in the preincubation solution without
BSA (four rinses, 1 min each), then in distilled water at 4°C (15 s, to
remove the excess of salts) and air dried. Kodak Scientific Biomax MS
films were juxtaposed onto the slides for 3 d at room temperature. Films
were developed in D-19 (Kodak developer) and fixed in Kodak fixer.
Image analysis was performed using a computerized image analysis sys-
tem (MCID; InterFocus GmbH). Specific binding was determined by
subtracting nonspecific binding from total binding taken from adjacent
sections. Calibration was performed on a standard curve generated using
polymer [C14]-microscale standards (GE Healthcare), thereby enabling
conversion of relative optical intensity units, directly measured from
autoradiograms, to binding site density expressed in fmol/mg.
In vivo experiments in rats
Male Sprague Dawley rats (150 g; Harlan) were kept under regular light-
ing conditions (12 h light/dark cycle) and given food and water ad libi-
tum. The experimental protocols performed in rodents were in
accordance with the European Communities Council Directive of No-
vember 24, 1986 (86/609/EEC), and were approved by the ItalianMinis-
try of Health (license #194/2008-B) and the Ethical Committee of the
University of Ferrara. Adequate measures were taken to minimize the
number of animals used and animal pain and discomfort.
Experimental design
Experiments in rats. A total of 126 6-OHDA hemilesioned dyskinetic, 10
6-OHDA hemilesioned naive and 14 sham-operated rats were used.
Pharmacological treatments were randomized and usually administered
every 3 d. A maintenance dose of L-DOPA was administered the day
before treatment, and animals were scored. In experiment using NOP
agonists (see Fig. 3), 20 dyskinetic animals implanted with an intracere-
broventricular cannula received either saline or three doses of N/OFQ,
ON and OFF L-DOPA (n  10 each condition). Another group of 20
animals was treated with saline or three different doses of Ro 65–6570
(i.p.), ON and OFF L-DOPA (n  10 each condition). In microdialysis
experiments (see Fig. 5), six dyskinetic animals were implanted with a
cannula (i.c.v.) and two microdialysis probes in SNr and the ventrome-
dial thalamus (VMTh). Microdialysis was performed for 4 d and treat-
ments (saline, L-DOPA, N/OFQ, and L-DOPA N/OFQ) were given in
a randomized fashion. In experiments using NOP antagonists (see Fig.
6), 10 dyskinetic animals implanted with an intracerebroventricular can-
nula received L-DOPA in combination with saline or UFP-101 (i.c.v.),
whereas another group of 10 animals received L-DOPA in combination
with saline or J-113397 (i.p.). In separate experiments, saline, UFP-101
and J-113397 were also given OFF L-DOPA to measure the impact of
NOP receptor antagonists alone on rotarod performance. Control group
Figure3. NOP receptor agonists attenuated LID. Effect of N/OFQ (0.03–1nmol, i.c.v.) andRo 65–6570 (0.01–1mg/kg, i.p.) onALOAIMs inducedby L-DOPA (6mg/kgplus benserazide 15mg/kg,
i.p.). N/OFQ (A) or Ro 65–6570 (D), given 5 and 30 min before L-DOPA, respectively, attenuated the severity of dyskinesias in a dose-related fashion. N/OFQ and Ro 65–6570 improved rotarod
performance ON L-DOPA (B, E) but worsened it OFF L-DOPA (C, F ). Data are expressed as percentage of the L-DOPA effect measured in the same animal in the last training session, and represent the
mean SEM of 10 determinations. Statistical analysis was performed by conventional (A, D) or RM (B, C, E, F ) one-way ANOVA followed by the Newman–Keuls test for multiple comparisons. A,
Significant effect of treatment (F(11,153) 24.78, p 0.0001). B, Significant effect of treatment (F(3,114) 77.29, p 0.0001), time (F(2,114) 35.08, p 0.0001), and time treatment
interaction (F(6,114)5.42,p0.0001).C, Significant effect of treatment (F(3,114)400.64,p0.0001), butnot time (F(2,114)1.21,p0.30) or time treatment interaction (F(6,114)0.64,
p0.70).D, Significant effect of treatment (F(11,147)11.27,p0.0001).E, Significant effect of treatment (F(3,114)68.86,p0.0001) and time (F(2,114)18.24,p0.0001) butnot time
treatment interaction (F(6,114) 1.10, p 0.36). F, Significant effect of treatment (F(3,114) 387.52, p 0.0001), time (F(2,114) 20.66, p 0.0001), and time treatment interaction (F(6,114)
 5.39, p 0.0001). *p 0.05, **p 0.01, significantly different from saline.
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was injected with saline in both areas. In exper-
iments using regional microinjections (see Fig.
7) 20 dyskinetic rats had a cannula implanted
either in the SNr or dorsolateral striatum
(DLS) (n 10 each group) and received saline
or three doses of N/OFQ in combination with
L-DOPA. Another group of 10 animals was im-
planted both in the SNr and DLS, and received
a single dose ofN/OFQ inDLS, SNr, or both. In
combination experiments (see Fig. 8), 20 dys-
kinetic animals implanted with a cannula in
DLS or SNr (n  10 each) received saline,
N/OFQ (0.1 nmol), UFP-101 (10 nmol), or
N/OFQ  UFP-101, in combination with
L-DOPA. In autoradiography experiment (see
Fig. 9) brain slices were obtained from 8 sham-
operated, 10 6-OHDA hemilesioned, and 10
dyskinetic rats.
Experiments in nonhuman primates. Five
macaques rendered stably parkinsonian with
1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) and dyskinetic with L-DOPA (see be-
low)(see Fig. 10).
Unilateral lesion with 6-OHDA
Unilateral lesion ofDAneuronswas induced in
isoflurane-anesthetized Sprague Dawley male
rats by stereotaxically injecting 8 g of
6-OHDA(dissolved in 4l of saline containing
0.02% ascorbic acid) into the medial forebrain
bundle (Marti et al., 2005), according to the
following coordinates from bregma: AP 4.4
mm, mediolateral (ML)1.2 mm, and dorso-
ventral (DV) 7.8 mm below dura (Paxinos
and Watson, 1986). Sham-operated animals
were injected with 4 l of saline (containing
0.02% ascorbic acid). Two weeks after
6-OHDA injection, denervation was evaluated
with a test dose of amphetamine (5 mg/kg,
i.p.). Rats showing ipsilateral turning 7
turns/min were enrolled in the study (Marti et
al., 2002a, 2007).
L-DOPA treatment and Abnormal Involuntary Movement
Scale rating
Two weeks after amphetamine testing, DA-depleted rats were made dys-
kinetic by a 21 d course of L-DOPA treatment (6mg/kg benserazide 15
mg/kg, i.p., once daily). Quantification of abnormal involuntary move-
ments (Abnormal Involuntary Movement Scale; AIMs), a correlate of
dyskinesia (Cenci et al., 1998), was performed as extensively described in
previous papers (Lundblad et al., 2002; Mun˜oz et al., 2008; Berthet et al.,
2009;Mela et al., 2010). Briefly, rats were observed individually for 1min
every 20 min during the 3 h that followed L-DOPA injection. Dyskinetic
movements were classified based on their topographic distribution into
three subtypes: (1) axial AIMs, i.e., twisted posture or choreiform twist-
ing of the neck and upper body toward the side contralateral to the lesion;
(2) forelimb AIMs, i.e., jerky or dystonic movements of the contralateral
forelimb and/or purposeless grabbing movement of the contralateral
paw; and (3) orolingual AIMs, i.e., orofacial muscle twitching, empty
masticatory movements and contralateral tongue protrusion. Each AIM
subtype was rated on a frequency scale from 0 to 4 (1, occasional; 2,
frequent; 3, continuous but interrupted by sensory distraction; and 4,
continuous, severe, and not interrupted by sensory distraction) on each
monitoring period (Cenci et al., 1998). In addition, the amplitude of
these AIMswas scored based on a scale from 0 to 4 as described by (Cenci
and Lundblad, 2007). Axial, forelimb, and orolingual (ALO) AIMs were
calculated as the sum of the product of amplitude and frequency scores
from all monitoring periods (Cenci and Lundblad, 2007), and presented
either separately or together (global score). AIMs scoring was performed
five times during L-DOPA treatment; dyskinetic rats showing total AIMs
score 100 in the last session were enrolled in the study. The theoretical
maximal total AIMs score for each animal is 432 (48 each of the nine 20
minute sessions).
Tyrosine immunohistochemistry analysis revealed that dyskinetic rats
were fully DA denervated since the ratio of optical density in the ipsilat-
eral versus contralateral side was 99.1  0.2% in sham-operated and
0.1 0.01% in dyskinetic rats (n 6 both).
Rotarod experiments
The rotarod test was used to quantify the degree of motor impairment
both ON and OFF L-DOPA. Dyskinetic rats were tested before (control
session) and 20, 60, and 120 min after acute drug treatment (L-DOPA,
NOP ligands or their combination). These windows were selected based
on the AIMs time course (data not shown), showing a peak after 60–80
min and extinction after 180 min from L-DOPA administration. The
speed of rotating cylinder was stepwise increased (180 s each step) from 5
rpm until animals fell off the rod (Marti et al., 2004). Dyskinesias nega-
tively correlated with rotarod performance (r0.75, Spearman’s non-
parametric correlation test, p  0.001), with a maximal reduction of
	85% at peak (data not shown).
Drug microinjections in dyskinetic rats
Under isoflurane anesthesia, a stainless steel infusion cannula (15 mm
long, 24 gauge) was stereotaxically lowered over the lateral ventricle [in-
tracerebroventricular: AP  0.9 mm; ML  1.4 mm; ventrodorsal
(VD)2.0 mm; DLS: AP0.7 mm; ML3.5 mm; VD3.2
mm; and/or SNr: AP  5.5 mm; ML  2.2 mm; VD  7.3 mm]
ipsilateral to the lesioned side. A stainless steel stylet was inserted into the
Figure 4. In vivo specificity of NOP receptor agonists. A, B, Ro 65–6570 (0.01–1mg/kg, i.p.) inhibited stepping activity in the
drag test in NOP/mice, being ineffective in NOP/mice. Each experiment consisted of three different sessions: a control
session followedby twoother sessions performed15min (A) and90min (B) after saline or drug administration. Data are expressed
as percentages of motor performance in the control session and are means SEM 6–7 determinations per group. C, D, NOP
receptor antagonists prevent the antidyskinetic effect of NOP receptor agonists. UFP-101 (10 nmol, i.c.v.) was administered
simultaneously with N/OFQ (0.1 nmol, i.c.v.; C) or 5 min before Ro 65–6570 (0.1 mg/kg, i.p.; D). J-113397 (3 mg/kg, i.p.) was
administered 15 min before NOP agonists. Data are expressed as percentages of L-DOPA effect, and are means SEM of 10–12
determinations per group. Statistical analysiswas performedby one-wayANOVA followedby theNewman–Keuls test formultiple
comparisons. A, Significant effect of treatment in NOP/mice (F(3,23) 17.61, p 0.0001). B, Significant effect of treatment
in NOP/mice (F(3,23) 19.89, p 0.0001). *p 0.05, **p 0.01, different from saline. °°p 0.01, different from N/OFQ
or Ro 65–6570 alone.
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cannula to avoid its occlusion. Animals were
allowed 6 d to recover, during which they were
handled to familiarize with the operator and
injection procedures. On the day of experi-
ment, the rat was gently restrained by the op-
erator, the stylet was removed and 0.5 l of
saline (control rats) or saline containing NOP
receptor peptide ligands (N/OFQ and UFP-
101) was injectedwithout the use of anesthesia.
Alternatively, systemic (i.p.) administration of
saline, Ro 65–6570 or J-113397, was per-
formed. In combination studies, NOP ligands
were given 5 min (N/OFQ and UFP-101), 15
min (J-113397), or 30 min (Ro 65–6570) be-
fore L-DOPA.
Microdialysis
Twomicrodialysisprobes (1mmdialyzingmem-
brane,AN69;Hospal)were implanted in theDA-
lesioned SNr (AP5.5,ML2.2, VD8.3) and
ipsilateral VMTh (AP2.3,ML1.4, VD7.4)
of isoflurane-anesthetized dyskinetic rats, as pre-
viously described (Marti et al., 2007, 2008). In the
same surgery session, animals were also im-
planted with an intracerebroventricular cannula
(coordinated as above). Twenty-four hours after
surgery, probes were perfused with a modified
Ringer’s solution (1.2 mMCaCl2, 2.7 mMMgCl2,
148mMNaCl, and 0.85mMMgCl2) at a 3l/min
flow rate and, after 6 h rinsing, samples were col-
lected every 15 min. L-DOPA (6 mg/kg plus
benserazide 15mg/kg)was administered system-
ically (i.p.), whereas N/OFQ 0.1 nmol was in-
jected (i.c.v., 5 min before L-DOPA). In control
rats, saline was injected (i.c.v.) and, 5 min later,
administered intraperitoneally. AIMs monitor-
ing was performed every 15 (for 1 min). At the
end of the experiments, animals were killed and
the correct placement of the probes was verified
histologically.
Endogenous Glu and GABA analysis
Glu and GABAweremeasured by HPLC cou-
pled with fluorometric detection following
o-phthaldialdehyde/mercaptoethanol deri-
vatization (Marti et al., 2007). Glu and GABA
were separated in a 5-C18 Chromsep analytical
column (Chrompack) perfused at 0.48 ml/min
with amobile phase containing 0.1 M sodium ac-
etate, 10% methanol and 2.2% tetrahydrofuran,
pH 6.5). Glu and GABA were detected by a FP-
2020Plus spectrophotometer (Jasco)with the ex-
citation and the emissionwavelengths set at 370
and 450 nm, respectively. The limits of detec-
tion for Glu and GABA were	1 and	0.5 nM,
and their retention timeswere	3.5 and	 18.0
min, respectively.
In vivo experiments in mice
To investigate the in vivo selectivity of Ro 65–
6570, motor activity was evaluated in NOP/
and NOP/ naive mice (25–30 g; 12–15
weeks old) (Nishi et al., 1997) by means of the
drag test. This test measures the ability of the
animal to balance its body posture with fore-
limbs in response to an externally imposed dy-
namic stimulus (backward dragging) (Marti et
al., 2005). The animalwas gently lifted from the
tail allowing the forepaws to rest on the table,
Figure5. N/OFQattenuatedtheelevationofnigralaminoacidsandthereductionof thalamicGABAassociatedwithLID.Dyskinetic rats
wereimplantedwithonemicrodialysisprobeinthelesionedSNrandanother in ipsilateralVMTh.Twenty-fourhours later, ratswereacutely
challengedwithsaline,L-DOPA(6mg/kgplus15mg/kgbenserazide, i.p.),N/OFQ(0.1nmol, i.c.v.),ortheircombination(N/OFQgiven5min
before). In control rats, salinewas injected (i.c.v.) and, 5min later, administered (i.p.). ALOAIMs in arbitrary units (A)weremonitored (for
1min every 15min) simultaneously with GABA and Glu levels in SNr (B, C) and VMTh (D, E) up to 180min from L-DOPA administration.
Microdialysis data were expressed as percentage of basal pretreatment levels (calculated as themean of the two samples preceding the
treatment).DataaremeansSEMof six animals.BasaldialysateGABAandGlu levelswere13.41.0and190.69.7nM, respectively,
in SNr, and 16.7 0.9 and 204.8 8.7 nM, respectively, in VMTh. Statistical analysiswas performed on area-under-the-curve values by
two-wayANOVAfollowedbyNewman–Keuls test formultiple comparisons.A,MaineffectofN/OFQ(F(1,1)80.75,p0.0001), L-DOPA
(F(1,1)472.44,p0.0001), and their interaction (F(1,20)78.63,p0.0001).B,Main effect ofN/OFQ (F(1,1)56.64,p0.0001),
L-DOPA (F((1,1) 158.69, p 0.0001), and their interaction (F(1,20) 21.64, p 0.0001). C,Main effect of N/OFQ (F(1,1) 24.30, p
0.0001), L-DOPA(F(1,1)88.86,p0.0001),andtheir interaction(F(1,20)32.30,p0.0001).D,MaineffectofN/OFQ(F(1,1)40.09,
p0.0001), L-DOPA (F(1,1)17.42,p0.0001), and their interaction (F(1,20)12.01, p0.0001).E,Main effect of N/OFQ (F(1,1)
33.25, p 0.0001), L-DOPA (F(1,1) 169.20, p 0.0001), and their interaction (F(1,20) 46.30, p 0.0001). *p 0.05, **p 0.01
significantly different from saline. ##p 0.01, significantly different from L-DOPA.
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and dragged backwards at a constant speed (	20 cm/s) for a fixed dis-
tance (100 cm). The number of steps made with each paw was recorded
by two distinct observers.
In vivo experiments in nonhuman primates
Experiments were conducted according to previously published proce-
dures and methods (Be´zard et al., 2003; Aubert et al., 2005; Fasano et al.,
2010). Five cynomolgus monkeys (Macaca fascicularis; SAH/Xierxin)
were housed in individual primate cages under controlled conditions of
humidity (50 5%), temperature (24 1°C), and light (12 h light/dark
cycles, time lights on 8:00 A.M.) with food and water ad libitum. Exper-
iments were performed in accordance with European Communities
Council Directive of November 24, 1986 (86/609/EEC) for care of labo-
ratory animals in an Association for Assessment and Accreditation of
Laboratory Animal Care -accredited facility following acceptance of
study design by the Institute of Lab Animal Science (Chinese Academy
of Science, Beijing, China) Institutional Animal Care and Use Commit-
tee. Veterinarians skilled in the healthcare and maintenance of nonhu-
man primates supervised animal care.
Animals were treated daily (9:00 A.M.) withMPTP hydrochloride (0.2
mg/kg, i.v.) dissolved in saline (Bezard et al., 2001a). Following stabiliza-
tion of the MPTP-induced syndrome (2 months), animals received a
tailored dose (16–19 mg/kg) of an L-DOPA/carbidopa combination
(100/25 mg) designed to optimally reverse the parkinsonian features of
each animal, twice daily for 3 months. Animals developed severe and
reproducible dyskinesias, presenting choreic-athetoid (characterized by
constant writhing and jerking motions), dystonic, and sometimes ballis-
ticmovements (large-amplitude flinging and flailingmovements). These
animals were not terminated after completion of experiments, but we
demonstrated in several occasions that animals intoxicated with this reg-
imen display a dramatic reduction of DAergic nigrostriatal markers
(95%) comparedwith control animals (Bezard et al., 2001b; Guigoni et
al., 2005; Fernagut et al., 2010).
Behavioral experiments
Macaque’s behavior was first recorded in the OFF state for 0.5 h in an
observation cage (dimensions: 1.1  1.5  1.1 m). Drugs were then
administered, and behavior was recorded for at least a further 4 h in the
observation cage. The parkinsonian condition (and its reversal) was as-
sessed on a validated parkinsonian monkey rating scale by post hoc anal-
ysis of video recordings by observers blinded to treatment. The
parkinsonian disability score is a combination of the range ofmovement,
bradykinesia, posture, and tremor scores according to the following for-
mula: range of movement  bradykinesia  postural abnormality 
tremor (Be´zard et al., 2003; Aubert et al., 2005; Fasano et al., 2010). The
severity of dyskinesia is rated using the Dyskinesia Disability Scale: 0,
dyskinesia absent; 1, mild, fleeting, and rare dyskinetic postures and
movements; 2, moderate, more prominent abnormal movements, but
not interfering significantly with normal behavior; 3, marked, frequent
and, at times, continuous dyskinesia intruding on the normal repertoire
of activity; or, 4, severe, virtually continuous dyskinetic activity replacing
normal behavior and disabling to the animal. Locomotor activity is con-
Figure 6. NOP receptor antagonists worsened LID. Effect of UFP-101 (10 nmol, i.c.v.) and J-113397 (3 mg/kg, i.p.) on ALO AIMs induced by L-DOPA (6 mg/kg plus benserazide 15 mg/kg, i.p.).
UFP-101 (A) and J-113397 (D), given5and15minbefore L-DOPA, respectively,worsened limbAIMswithout affectingaxial andorolingual AIMs.UFP-101also slightlyworsened rotarodperformance
ON L-DOPA (B) while J-113397 left it unaffected (E). Both compounds improved rotarod performance OFF L-DOPA (C, F ). Data are expressed as percentage of the L-DOPA effectmeasured in the same
animal in the last training session, and represent themean SEM 10 determinations. Statistical analysis was performed by conventional (A,D) or RM (B, C, E, F ) one-way ANOVA followed by the
Newman–Keuls test for multiple comparisons. A, Significant effect of treatment (F(5,60) 5.99, p 0.0001). B, Significant effect of treatment (F(1,54) 7.02, p 0.0106) and time (F(2,54)
12.95, p 0.0001) but not time treatment interaction (F(2,54) 2.83, p 0.0678). C, Significant effect of treatment (F(1,60) 115.65, p 0.0001), time (F(2,60) 17.11, p 0.0001), and
time treatment interaction (F(2,60) 3.29, p 0.0441). D, Significant effect of treatment (F(5,84) 3.056, p 0.0001). E. Significant effect of time (F(2,54) 5.41, p 0.0072) but not
treatment (F(1,54) 0.79, p 0.37) or time treatment interaction (F(2,54) 0.37, p 0.69). F, Significant effect of treatment (F(1,54) 175.12, p 0.0001) but not time (F(2,54) 1.09, p
0.3448) or time treatment interaction (F(2,54) 1.95, p 0.15). *p 0.05, **p 0.01, significantly different from saline.
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comitantly monitored with infrared activity monitors, providing a mo-
bility count every 5min (Be´zard et al., 2003; Aubert et al., 2005; Fasano et
al., 2010).
Data presentation and statistical analysis
Behavior (Figs. 3, 4, 6) and autoradiography (Fig. 9) data were analyzed
using conventional or repeated measure (RM) one-way ANOVA as ap-
propriate, followed by theNewman–Keuls test formultiple comparisons.
Conventional two-way ANOVAwith a 2 2 factorial design was used to
analyze drug interactions (Figs. 5, 7, 8). Nonparametric one-way RM
ANOVA followed by the Dunn’s test for multiple comparisons was used
to treat behavioral scores in nonhuman primates (Fig. 10). p values
0.05 were considered to be statistically significant.
Materials
D-Amphetamine sulfate, benserazide hydrochloride, L-DOPA methyl-
ester hydrochloride,MPTPhydrochloride, 6-OHDAhydrobromide, and
SKF38393were purchased from Sigma. N/OFQ,UFP-101, J-113397, and
Ro 65–6570 were synthesized in our laboratory. All drugs were readily
dissolved in saline.
Results
Effects of N/OFQ on D1 receptor-induced ERK
phosphorylation and loss of synaptic depotentiation
Upregulation of striatal D1 signaling in LID is associated with an
increased activity along the Ras/MEK/ERK kinase pathway
(Valjent et al., 2005; Feyder et al., 2011) and a loss of neuron
capability to depotentiate striatal synaptic response after LTP
induction (Picconi et al., 2003). To investigate the effect of NOP
receptor activation on these D1 receptor-dependent biochemical
correlates of LID, we explored whether N/OFQ could prevent
ERK phosphorylation and restore a physiological depotentiation
of synaptic plasticity in striatal slices of naive animals stimulated
with the D1 receptor agonist SKF38393.
To quantify ERK phosphorylation, we used a recently estab-
lished ex vivo system, in which brain slices prepared from adult
mice can be stimulated with appropriate agonists and antago-
nists. For ERK signaling activation we monitored the ribosomal
protein S6 phosphorylation at the Thr235/236 site (Orellana et
al., 2012). D1 receptor activation by 100 M SKF38393 applica-
tion dramatically elevated ERK signaling by 	10-fold (Fig.
1A,B). N/OFQ 1 M was ineffective alone but prevented the D1
agonist effect (Fig. 1A,B).
Cortically evoked EPSPs were measured in electrophysiologi-
cally identified striatal MSNs (Fig. 2). In a first group of control
slices, after acquiring EPSPs of stable amplitudes for 10min, LTP
of synaptic transmission was induced by HFS protocol (EPSP
amplitude post-HFS, 162.7 6.7%). A subsequent application of
LFS protocol in these recordedMSNs produced a depotentiation
of the synaptic response to pre-HFS conditions (EPSP amplitude
post-LFS, 93.9 7.9%; Fig. 2A,B). Bath application of 3 M D1
receptor agonist SKF38393 prevented depotentiation of MSN
synaptic plasticity (EPSP amplitude post-LFS, 160.8 4.3%; Fig.
2C,D). Bath application of 0.1 M N/OFQ did not affect LTP or
Figure 7. N/OFQ attenuated LID when injected in SNr and DLS. Effect of N/OFQ (0.03–1
nmol, i.c.v.) injected in SNr (A), DLS (B), or both (at 0.1 nmol; C) on ALOAIMs induced by L-DOPA
(6 mg/kg plus benserazide 15 mg/kg, i.p.). N/OFQ given 5 min before L-DOPA attenuated the
severity of dyskinesias in a dose-related fashion, being more potent when injected in DLS than
SNr. Coinjection of N/OFQ in SNr and DLS produced an additive antidyskinetic effect (C). Saline
was simultaneously injected in SNr and DLS. Data are expressed as percentage of the L-DOPA
4
effectmeasured in the same animal in the last training session, and represent themean SEM
of 10 determinations. Statistical analysis was performed by one-way (A, B) or two-way (C)
ANOVA followed by the Newman–Keuls test for multiple comparisons. A, Significant effect of
treatment (F(11,71)9.58,p0.0001).B, Significant effect of treatment (F(11,71)38.8,p
0.0001). C, Main effect of N/OFQ (F(3,60) 528.64, p 0.0001), brain area (F(2,60) 33.94,
p 0.0001), and their interaction (F(6,60) 23.76, p 0.0001). **p 0.01, *p 0.05,
significantly different from saline. °°p 0.01, significantly different from SNr injection. ##p
0.01, significantly different from DLS injection.
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depotentiation in MSNs (EPSP amplitude post-HFS, 152.6 
6.5%; EPSP amplitude post-LFS 106.7 6.0%; Fig. 2A,B). How-
ever, when 3 M SKF38393 was bath applied for 20 min in the
presence of 0.1 M N/OFQ, depotentiation of MSN synaptic
transmission was fully restored (EPSP amplitude, post-LFS
97.3 5.9%, SKF38393 vs SKF38393 N/OFQ, p 0.001; Fig.
2C,D). To verify the selectivity of N/OFQ action, we bath applied
3 M SKF38393 and 0.1 M N/OFQ with 1 M NOP receptor
antagonist UFP-101. In these conditions, LFS protocol did not
produce depotentiation, confirming that N/OFQ action was ac-
complished through the NOP receptor.
Effect of NOP receptor agonists on dyskinesias and rotarod
performance in rats
Data obtained in vitro predict that NOP receptor agonists might
selectively target LID pathways and attenuate LID. We therefore
administered exogenous N/OFQ and the NOP receptor synthetic
agonist Ro 65–6570 (Ro¨ver et al., 2000) to dyskinetic rats chal-
lenged with L-DOPA. N/OFQ (i.c.v.) dose-dependently attenu-
ated LID appearance (Fig. 3A) and rescued rotarod performance
(Fig. 3B) in the 0.03–1 nmol range. The rescue effect at 1 nmol
was, however, less pronounced than at lower doses, consistent
with the finding that N/OFQ caused primary hypolocomotive
effect OFF L-DOPA at this dose (Fig. 3C). To prove the antidyski-
netic potential of NOP receptor agonists, the small molecule Ro
65–6570 was used at doses selective for NOP receptor stimula-
tion (0.01–1 mg/kg, i.p.). Indeed, in this dose range Ro 65–6570
reduced stepping activity in NOP/mice but was ineffective in
NOP/ mice (Fig. 4A,B). Ro 65–6570, given 30 min before
L-DOPA, attenuated AIMs appearance at 0.01 mg/kg (Fig. 3D),
and maximally at 1 mg/kg. This antidyskinetic effect was accom-
panied by restoration of rotarod performance (Fig. 3E). Con-
versely, Ro 65–6570 markedly impaired rotarod performance
OFF L-DOPA at 1mg/kg (Fig. 3F). To confirm the pharmacolog-
ical specificity of the antidyskinetic action of NOP agonists, UFP-
101 and J-113397 prevented the antidyskinetic effect of N/OFQ
and Ro 65–6570 (Fig. 4C,D).
Effects of intracerebroventricular injections of N/OFQ on
LID and neurochemical correlates in SNr and VMTh
Microdialysis was used to investigate whether the antidyskinetic
action of N/OFQ was accompanied by changes of the nigral out-
put. AIMs expression (Fig. 5A) was associated with a 	2-fold
elevation of GABA and Glu in SNr (Fig. 5B,C) as well as a	40%
reduction of GABA and a	60% elevation of Glu in VMTh (Fig.
5D,E). Injection of 0.1 nmol N/OFQ (i.c.v.) attenuated (	60%)
LID severity (Fig. 5A) and simultaneously blunted the surge in
nigral amino acids (Fig. 5B,C). In addition, N/OFQ prevented
theGABA inhibition and attenuated theGlu surge in VMTh (Fig.
5D,E).
Effect of NOP receptor antagonists on dyskinesias and
rotarod performance in rats
To investigate whether not only exogenous but also endogenous
N/OFQ affected LID, peptidic (UFP-101) (Calo et al., 2002) and
nonpeptidic (J-113397) (Kawamoto et al., 1999) NOP receptor
antagonists were used at maximal antiparkinsonian doses (Marti
et al., 2005) against a prodyskinetic dose of L-DOPA. UFP-101
(10 nmol, i.c.v.; Fig. 6A) or J-113397 (3 mg/kg, i.p.; Fig. 6D)
worsened limbwithout affecting axial and orolingual AIMs.Con-
sistently, neither antagonist attenuated the impairment of ro-
tarod performance associated with LID (ON L-DOPA; Fig.
6B,E). Conversely, UFP-101 (Fig. 6C) and J-113397 (Fig. 6F)
facilitated rotarod performance OFF L-DOPA.
Effect of regional injections of N/OFQ in the SNr and DLS of
dyskinetic rats
To investigate the brain areas involved in the antidyskinetic and
prodyskinetic effects of NOP receptor ligands, N/OFQ and UFP-
101 were microinjected in SNr and/or DLS. Intranigral N/OFQ
slightly reduced limb AIMs at 0.1 nmol providing a greater and
Figure 8. UFP-101worsened LIDwhen given in SNr but not DLS, preventing N/OFQ action in
both regions. Effect of injections of N/OFQ (0.1 nmol, i.c.v.), UFP-101 (10 nmol, i.c.v.), or their
combinations in SNr (A) or DLS (B) on ALO AIMs induced by L-DOPA (6 mg/kg plus benserazide
15 mg/kg, i.p.). UFP-101 was administered 5 min before L-DOPA, simultaneously with N/OFQ.
Data are expressed as percentage of the L-DOPA effect measured in the same animal in the last
training session, and represent themean SEM of 10 determinations. Statistical analysis was
performed by two-way ANOVA followed by the Newman–Keuls test for multiple comparisons.
A, LimbAIMs,main effect of N/OFQ (F(1,1) 12.95, p 0.0012), UFP-101 (F(1,1) 16.00, p
0.0004), and their interaction (F(1,28) 29.18, p 0.0001); axial AIMs, main effect of N/OFQ
(F(1,1) 13.63, p 0.0012), UFP-101 (F(1,1) 45.11, p 0.0001), and their interaction
(F(1,28) 12.38, p 0.0015); orolingual AIMs, main effect of N/OFQ (F(1,1) 26.90, p
0.0001), UFP-101 (F(1,1) 24.54, p 0.0001), and their interaction (F(1,28) 22.93, p
0.0001). B, Limb AIMs, main effect of N/OFQ (F(1,1) 192.51, p 0.0001), UFP-101 (F(1,1)
12.64, p 0.0014), and their interaction (F(1,28) 9.42, p 0.0047); axial AIMs, main effect
of N/OFQ (F(1,1) 64.43, p 0.0001) but not UFP-101 (F(1,1) 0.01, p 0.89) or their
interaction (F(1,28) 3.65, p 0.07); orolingual AIMs, main effect of UFP-101 (F(1,1) 8.99,
p 0.0056) but not N/OFQ (F(1,1) 0.02, p 0.98) or their interaction (F(1,28) 0.10, p
0.74). **p 0.01, significantly different from saline.
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more generalized effect at 1 nmol (Fig. 7A). Conversely, intrastri-
atal N/OFQ caused a marked reduction of limb and axial AIMs
yet at 0.03 nmol (Fig. 7B). Combined intranigral and intrastriatal
injections of 0.1 nmol N/OFQ (Fig. 7C) caused greater AIMs
attenuation than each injection alone. Contrary to N/OFQ, UFP-
101 (10 nmol) worsened limb and axial AIMs when injected in
SNr (Fig. 8A) but not striatum (Fig. 8B). In both cases, however,
UFP-101 prevented the antidyskinetic effect of locally injected
N/OFQ.
NOP receptor binding associated with parkinsonism
and dyskinesias
To investigate whether LID is associated with changes of NOP
receptor binding, quantitative autoradiographywas used (Fig. 9).
In sham-operated rats, binding appeared highest inmotor cortex
(M1 andM2), intermediate in striatum and SN, and lowest in the
subthalamic nucleus of (Fig. 9A,E) (Table 1). 6-OHDA lesioning
(Fig. 9B,F) caused an increase of ipsilateral binding throughout
the striatum and a reduction in both SN subdivisions (Fig.
9D,H). Similar patterns were observed in the brain of dyskinetic
rats (Fig. 9C,D,G–H).
NOP receptor agonists in dyskinetic nonhuman primates
To confirm the antidyskinetic potential of NOP receptor ago-
nists, Ro 65–6570 was systemically injected in MPTP-lesioned
dyskinetic macaques (Fig. 10A). Ro 65–6570 significantly re-
duced dyskinetic movements at 0.01 mg/kg (i.m.) but not lower
dose (Fig. 9B). Ro 65–6570 was effective against dystonia, al-
though a trend for inhibition of chorea was clearly observed (Fig.
10B). Time-course analysis (Fig. 10C,D) revealed that Ro 65–
6570 attenuated the peak and shortened the duration of dyski-
netic movements. Ro 65–6570 did not affect the therapeutic
effects of L-DOPA on movement range, bradykinesia, and
tremor, and even improved posture at the higher dose (Table 2).
Discussion
Opposite adaptive changes of N/OFQ transmission have been
observed in the basal ganglia of the parkinsonian rodent brain:
elevation of N/OFQ expression (and release) accompanied by
reduction of NOP receptor binding in SNr, and reduction of
N/OFQ expression accompanied by elevation of NOP receptor
binding in striatum. These changes underlie the different behav-
Figure9. LIDwas associatedwith an elevation ofNOP receptor binding in the striatumanda reduction in the SN. Representative total binding of 125I[Tyr 14]N/OFQ toNOP receptors in cortical and
subcortical areas of sham-operated (A, E), hemiparkinsonian (B, F), and dyskinetic (C,G) rats. Twentymicrometer coronal sections were cut at two different brain levels from bregma: AP0.30 to
0.92 and3.60 to5.80. Specific binding values, given in Table 1, were obtained by subtraction of nonspecific from total binding. Binding changes are expressed as percentage of the
contralateral hemisphere (D,H) and aremeans SEM of 6 –10 animals. Statistical analysis was performed by one-way ANOVA followed by Newman–Keuls test for multiple comparisons.
**p 0.01, significantly different from sham-operated rats.
Table 1. Autoradiographical binding of 125I
Tyr 14N/OFQ to the NOP receptor in
cortical and subcortical areas of sham-operated, untreated 6-OHDA lesioned
(hemiparkinsonian), and dyskinetic rats
Sham operated Hemiparkinsonian Dyskinetic
Level AP0.30 to0.92 mm
M1
Ipsi 71.6 6.7 89.8 14.9 94.6 6.1
C/L 77.2 7.6 83.8 14.1 90.6 6.2
M2
Ipsi 80.8 8.6 90.9 14.9 100.3 6.8
C/L 81.1 6.1 90.0 13.7 97.5 6.9
CPuDL
Ipsi 22.7 4.8 30.6 6.2 31.5 3.5
C/L 23.0 4.9 20.9 4.5 21.5 3.0
CPuVL
Ipsi 24.8 4.7 30.1 3.9 34.3 3.1
C/L 25.9 4.7 22.5 3.8 25.9 2.8
CPuDM
Ipsi 24.8 4.9 28.6 3.0 30.4 3.4
C/L 26.1 4.7 19.2 1.5 21.6 3.1
CPuCe
Ipsi 27.0 6.4 27.7 4.2 30.6 3.7
C/L 27.7 6.5 20.7 3.4 23.1 3.6
CPuVM
Ipsi 29.7 3.0 39.5 6.3 36.9 3.1
C/L 29.5 3.1 30.0 5.3 27.1 3.0
Level AP3.60 to5.80 mm
M1
Ipsi 72.4 6.8 89.7 13.9 96.6 7.2
C/L 75.4 8.6 84.8 12.1 94.6 7.3
M2
Ipsi 78.4 5.0 85.7 14.0 90.1 7.5
C/L 76.4 8.6 84.8 13.0 91.0 7.8
STN
Ipsi 17.4 1.7 32.3 6.1 35.4 7.0
C/L 18.5 4.1 30.9 6.0 38.5 7.4
SNr
Ipsi 25.5 1.3 16.0 4.6 16.6 4.4
C/L 25.1 2.7 28.1 4.9 26.8 4.7
SNc
Ipsi 22.9 0.6 17.7 3.9 19.9 3.4
C/L 24.6 1.8 34.7 3.2 32.1 4.8
Twenty micrometer coronal sections were cut at two different brain levels from bregma: AP0.30 to0.92 and
3.60 to5.80. Absolute binding values are given as fmol/mg tissue. Ce, Cerebellar; CPu, caudate-putamen; DL,
dorsolateral; DM, dorsomedial; VL, ventrolateral; VM, ventromedial.
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ioral responses toNOP receptor ligands in
PD models. Indeed, we have previously
reported that NOP receptor antagonists
exert a symptomatic antiparkinsonian ef-
fect (Marti et al., 2005, 2008; Viaro et al.,
2008, 2010; Visanji et al., 2008; Volta et al.,
2010), and that such effect is mediated by
blockade of SNr NOP receptors (Marti et
al., 2005, 2010). We now report that NOP
receptor agonists provide an antidyski-
netic effect, which is faithfully replicated
by intrastriatal N/OFQ injections, sug-
gesting the involvement of striatal NOP
receptors. LIDs are associated with hyper-
esponsiveness of upregulated D1 recep-
tors on striatonigral MSNs (Aubert et al.,
2005; Berthet et al., 2009) leading to an
increased activity along the Ras/MEK/
ERK kinase pathway (Valjent et al., 2005;
Feyder et al., 2011) and a loss of neuron
capability to depotentiate striatal synaptic
response after LTP induction (Picconi et
al., 2003). In vitro and in vivo data revealed
that NOP receptor activation opposes D1
signaling in striatum. Indeed, N/OFQ
prevented the D1 receptor-mediated in-
crease in ERKphosphorylation and loss of
striatal depotentiation of striatal plasticity
in striatal MSNs, without being per se ef-
fective. These data add to the previous
finding that N/OFQ inhibited the D1 re-
ceptor stimulated cAMP accumulation in
striatal slices (Olianas et al., 2008) and suggest the existence of a
negative interaction between the NOP and D1 receptor on the
membranes of striatal MSNs. The NOP receptor is expressed not
only presynaptically on nigrostriatal DA terminals (Norton et al.,
2002) but also postsynaptically on striatal GABAergicMSNs neu-
rons (Olianas et al., 2008). The postsynaptic action of N/OFQ
might be favored under dyskinetic conditions, since in the stria-
tum of L-DOPA primed and unprimed 6-OHDA hemilesioned
rats, NOP receptor binding is upregulated, probably to compen-
sate for the reduction of N/OFQ expression following DA dener-
vation (Marti et al., 2010). Thus, NOP receptor agonists would
reinstate an inhibitory control mediated by endogenous N/OFQ
over striatal D1 signaling, which has been lost following DA de-
nervation.
Indirect evidence that the negative NOP receptor modulation
of D1 signaling is relevant for in vivo conditions was provided by
microdialysis experiments showing that centrally administered
N/OFQ attenuated LID simultaneously with the surge of GABA
levels in SNr. In fact, the same responses were observed in dyski-
netic rats by pairing systemic L-DOPAwith intrastriatal perfusion
of a D1 receptor antagonist (Mela et al., 2012). This endorses the
view that the antidyskinetic effect of N/OFQ is possibly mediated
by upregulated postsynaptic NOP receptors opposing the over-
activation of the direct striatonigral pathway induced by L-DOPA
via D1 receptors. Consistently, microdialysis also revealed that
LIDwas associatedwith inhibition of thalamicGABA release, and
that the antidyskinetic action of N/OFQ was accompanied by
blockade of this response. Indeed, inhibition of thalamic GABA
might reflect overinhibition of nigrothalamic neurons by direct
striatonigral pathway activation, as previously demonstrated for
the anti-akinetic effect of L-DOPA in hemiparkinsonian rats
(Marti et al., 2007). This lends neurochemical support to the
notion that overinhibition of nigrothalamic GABA neurons by
striatonigral direct pathway activation underlies both the motor
promoting and prodyskinetic actions of L-DOPA.
Remarkably, the antidyskinetic action of N/OFQ was not ac-
companied bymotor inhibition. Indeed, it is well known that one
of the main consequences of central NOP receptor stimulation is
motor impairment (Reinscheid et al., 1995; Devine et al., 1996;
Jenck et al., 1997; Marti et al., 2004, 2009). However, the anti-
dyskinetic effect of N/OFQ and Ro 65–6570 was observed at
doses approximately 30- to 100-fold lower than those causing
hypolocomotion, suggesting it was not related to motor impair-
Figure 10. Ro 65–6570 attenuated LID in MPTP-treatedmacaques. Five stably parkinsonianmacaques weremade dyskinetic
by chronic L-DOPA treatment, and then challengedwith L-DOPA combinedwith Ro65–6570 (0.001 and0.01mg/kg, i.m.) or saline
(A). Dyskinetic conditions were assessed on a Dyskinesia Disability Scale (see Materials and Methods) evaluating choreiform and
dystonic components (A, B). The time courses of these motor responses are shown in C and D. Data are expressed as absolute
dyskinesia scores in each animal (A), medians with lower and upper quartiles (B), or means SEM (C,D). Statistical analysis was
performed by one-way nonparametric RM ANOVA (Friedman test) followed by the Dunn’s test for multiple comparisons. *p
0.05, significantly different from saline.
Table 2. Motor behavior of MPTP-treatedmacaques before (OFF score) and after
(ON score) L-DOPA and Ro 65–6570 administration
OFF score
ON score
Saline
Ro 65–6570
0.001 mg/kg
Ro 65–6570
0.01 mg/kg
Chorea 0.0 0.0 23.8 3.3 16.8 3.5 15.4 4.1
Dystonia 0.0 0.0 23.8 3.3 15.8 3.6 16.0 4.4*
Total dyskinesia 0.0 0.0 47.6 6.6 32.8 7.1 31.4 8.4*
Movement 2.4 2.4 39.4 1.9 39.4 1.5 40.0 1.7
Bradykinesia 36.0 0.0 9.4 1.7 8.6 2.2 8.6 3.0
Posture 19.2 2.9 7.2 1.5 3.6 1.6 1.8 1.1*
Tremor 2.4 2.4 0.6 0.6 1.0 0.5 3.2 1.4
Total parkinsonian disability 103.2 6.1 25.8 4.7 21.8 4.9 21.4 6.2
Five stably parkinsonian macaques were made dyskinetic by chronic L-DOPA treatment. Macaques were then chal-
lengedwith L-DOPA combinedwith Ro 65–6570 (0.001 and 0.01mg/kg, i.m.) or saline. Parkinsonian conditionwas
assessedonaparkinsoniannonhumanprimate rating scale scoringmovement range, bradykinesia, posture, tremor,
and total parkinsonian disability (see Materials and Methods). Dyskinetic condition was assessed on a Dyskinesia
Disability Scale evaluating choreiform, dystonic, and total dyskinesiamovements (seeMaterials andMethods). Data
are meansmeans from five animals. Statistical analysis was performed by nonparametric one-way RM ANOVA
followed by Dunn’s test for multiple comparisons. *p 0.05, versus saline.
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ment. Thus, NOP receptor agonists might behave as functional
DA antagonists that can be dosed in a way to improve LID with-
out affecting movement in the OFF state.
N/OFQ also attenuated dyskinesia when injected into SNr.
Indeed, SNr is involved in LID (Meissner et al., 2006; Westin et
al., 2006; Lindgren et al., 2010). In particular, conversion of
L-DOPA to DA in SNr (Sarre et al., 1998) generates abnormal
nigral DA levels (Lindgren et al., 2010) thereby triggering dyski-
netic movements through activation of both D1 and D2 nigral
receptors (Mela et al., 2012). However, different from striatum,
the hypolocomotive and antidyskinetic doses of N/OFQ given
intranigrally largely overlapped, suggesting that attenuation of
LID is due to unspecific motor inhibition. Indeed, exogenous
N/OFQmicroinjected in the SNr of naive rats inhibitsmovement
(Marti et al., 2004, 2009), possibly through elevation of the excit-
atory Glu (Marti et al., 2002b) and attenuation of the inhibitory
GABA inputs (Marti et al., 2007;Mabrouk et al., 2010) impinging
over nigrothalamic neurons. Alternatively, we could speculate
that dyskinesia pathways in SNr are less sensitive to N/OFQ, or
even that N/OFQ itself is less active in the DA-depleted SNr.
Indeed, the enhancement of the N/OFQ tone in SNr along with
the reduction of the NOP receptor binding (present study) and
expression following DA depletion (Marti et al., 2005, 2010) pre-
dict a higher NOP receptor saturation by endogenous N/OFQ,
which favors the motor promoting and antiparkinsonian action
of NOP receptor antagonists (Marti et al., 2007, 2008; Volta et al.,
2011).
Previous studies have demonstrated the potential therapeutic
benefit of a combination of subthreshold doses of an NOP recep-
tor antagonist with L-DOPA in parkinsonian rodents (Marti et
al., 2007; Viaro et al., 2010).We now report that anNOP receptor
antagonist given in SNr worsens dyskinesia severity when com-
bined with dyskinesiogenic doses of L-DOPA. This corroborates
the view that NOP receptor blockade in SNr potentiates the an-
tiparkinsonian action of L-DOPA at the cost of inducing dyski-
nesia, as also observed in marmosets (Visanji et al., 2008).
Although the prodyskinetic effect induced by intracerebroven-
tricularUFP-101 and systemic J-113397wasmild, limited to limb
dyskinesia and observed at maximal antagonist doses, this find-
ing warns of the potential motor side effects of overdosing NOP
antagonists as an adjunct to L-DOPA therapy.
The antidyskinetic effect of Ro 65–6570 was also replicated in
the gold-standard model of LID, the dyskinetic macaque. The
effect of Ro 65–6570 was milder than in rats, but occurred in the
same dose range. Axial symptoms such as gait and balance dis-
turbances are very common and disabling in PD patients (Jank-
ovic, 2008). The finding that an NOP agonist improved posture
in L-DOPA-treated dyskineticmacaquesmight contrast with pre-
vious findings that an NOP antagonist improved balance in
MPTP-treated L-DOPA-unprimedmacaques (Viaro et al., 2008).
The apparent contradiction that an NOP agonist and an antago-
nist have the same impact on axial symptomsmight be explained
on the basis of an action at NOP receptors (possibly located in
different brain areas/circuits) that are differently saturated by
endogenous N/OFQ.Moreover, we should recall that the models
and timing of administration were different in the two studies.
Indeed, the overall behavioral patterns were different since the
NOP antagonist also improved bradykinesia, tremor, hypokine-
sia, and rigidity, whereas the NOP agonist did not.
Concluding remarks
A major side effect of long-term therapy with L-DOPA is the
development of dyskinesias (Nutt and Gancher, 1994; Bezard et
al., 2001a; Obeso et al., 2004; Calabresi et al., 2010), which repre-
sent a clinical challenge due to the poor therapeutic armamentar-
ium available to neurologists, essentially limited to amantadine
(Verhagen Metman et al., 1998). Here we report that exogenous
N/OFQ and the small molecule NOP receptor agonist Ro 65–
6570 inhibited LID expression in dyskinetic rats and macaques
without attenuating the antiparkinsonian effect of L-DOPA. We
also provide evidence that N/OFQ inhibited biochemical, elec-
trophysiological, and neurochemical correlates of striatal D1 re-
ceptor activation in the naive or dyskinetic striatum, which
suggests that NOP receptor agonists exert a selective antidyski-
netic effect by activating striatal NOP receptors that oppose D1
signaling. However, further mechanistic studies in 6-OHDA le-
sioned dyskinetic and nondyskinetic rats need to be performed to
confirm this hypothesis. The possibility that NOP receptor ago-
nists exert an antidyskinetic effect through striatal NOP receptor
does not contradict our previous finding that NOP receptor an-
tagonists exert antiparkinsonian effects through blockade of
NOP receptors in SNr. Indeed, an NOP receptor antagonist is
expected to act primarily where the N/OFQ tone is elevated (i.e.,
in SNr), whereas anNOP receptor agonistwhereN/OFQ is lowor
absent (i.e., in striatum).
In conclusion, NOP receptor agonists have been proven effec-
tive for treating pain (Ko et al., 2009), anxiety (Jenck et al., 1997),
and drug dependence (Zaveri, 2011). The concordance of the
antidyskinetic effects in rats and nonhuman primates suggests
that NOP receptor agonists may also prove effective in attenuat-
ing LID and rescuing motor activity in dyskinetic PD patients.
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 Chapter 8 
 The Extracellular Signal-Regulated Kinase (ERK) Cascade 
in Neuronal Cell Signaling 
 Daniel  Orellana ,  Ilaria  Morella ,  Marzia  Indrigo ,  Alessandro  Papale , 
and  Riccardo  Brambilla  
 Abstract 
 The Ras-controlled extracellular signal-regulated kinase (ERK) pathway mediates a large number of cellular 
events, from proliferation to survival, from synaptic plasticity to memory formation. In order to study the 
role of the two major ERK isoforms in the brain, ERK1 and ERK2, we have generated GFP fusion proteins 
of both protein kinases. In addition, we have produced two swapped constructs in which the N-term tail 
of ERK1, the domain responsible for its unique properties, has either been removed from ERK1 or 
attached to ERK2. We demonstrated that all four GFP proteins are properly expressed in vitro in mouse 
embryo  fi broblasts. However, only ERK1 and ERK2 > 1 overexpression resulted in a signi fi cant growth 
retardation. In addition, we have expressed all four GFP fusion constructs in vivo, in the adult brain, using 
lentiviral vector-assisted transgenesis and found that they are predominantly neuronal. Finally, we have 
devised an ex-vivo system, in which brain slices prepared from adult mice can be stimulated with glutamate 
and the activation of both cytoplasmic and nuclear substrates of ERK can be detected. Since phosphoryla-
tion of both the ribosomal protein S6 and of the histone H3 is completely prevented by a chemical inhibi-
tion of the ERK pathway, this ex-vivo system can be exploited in the future to investigate the regulation of 
the ERK cascade using slices from LV-injected or conventional transgenic animals. 
 Key words:  Ras-ERK signaling ,  Cell proliferation ,  Lentiviral vectors ,  Glutamate ,  MEK inhibitors , 
 Brain slices ,  Immuno fl uorescence 
 
 Cell communication is a major process controlling life of both 
unicellular and multicellular organisms. Within cells, a broad range 
of different signaling pathways is involved in these communications. 
Among them, special attention has been pointed to the mitogen-
activated protein (MAP) kinase system, a major signal transduction 
pathway mediating the transfer of extracellular stimuli to the 
 1.  Introduction
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nucleus. The MAPK system is highly conserved throughout eukaryotic 
evolution, from yeast to humans. The core component of this 
pathway is made up of a three-tier protein kinase system which is 
upstream regulated, at the cell membrane, by members of the Ras 
superfamily of small GTPases. The MAPK family of cellular path-
ways in mammalian cells is divided into four distinct subfamilies 
named following the last protein kinase of the signal transduction 
cascade: ERK (extracellular signal-regulated kinase), JNK (c-Jun 
 N-terminal kinase), p38 SAPK (stress-activated protein kinase), 
and ERK5/BMK1 (big MAP kinase1) subfamily  ( 1– 4 ) . 
 Once activated, ERK signaling may be involved, depending on 
the cell type and on the physiological context, in a wide range of 
processes, ranging from embryogenesis, cell differentiation, cell 
survival, cell proliferation, and cancer. In the brain, this cascade 
provides a link between ionotropic, metabotropic, and neurotrophin 
receptors to cytosolic (regulation of ion channels and of protein 
translation) and nuclear events, leading to gene transcription, 
de novo protein synthesis and changes either in synaptic remodeling 
and plasticity, memory formation, or neuronal survival, depending 
on the context. Once activated by neurotransmitter receptors 
through GTP/GDP exchange factors, the small GTPases belonging 
to the Ras class (p21 H-, K- and N-Ras gene products) stimulate 
sequentially the cascade of protein kinases consisting of serine/
threonine kinases of the Raf subfamily (mainly c-Raf and B-Raf, the 
MAPK Kinase Kinase tier), the threonine/tyrosine dual-speci fi city 
kinases MEK1/2 (MAPK Kinase), and  fi nally ERK1/2 proteins 
(the MAPK component)  ( 5 ) . More speci fi cally, activation of 
MEK1/2 leads to a selective interaction with ERK proteins through 
speci fi c docking domains which result in phosphorylation of the 
conserved recognition motif of threonine and tyrosine (TEY 
domain), within the activation loop of ERK1/2  ( 6 ) . ERK1 and 
ERK2, also known as p44/p42MAPK, respectively, are homolo-
gous isoforms produced by two genes, erk1 (MAPK3) and erk2 
(MAPK1). Both of them have nearly 85% amino acid identity with 
much greater identity in the core regions and are expressed in 
essentially all cells, even if ERK2 is the predominant isoform in 
brain and hematopoietic cells  ( 7 ) . Once activated, ERK1 and 
ERK2, the two major MAPK in the brain, are able to translocate 
into the nucleus. There, they can activate, either directly or indi-
rectly (via the kinases of the RSK families), transcription factors, 
including the CREB-like class of transcriptional regulators, or to 
regulate chromatin remodeling (via the kinases of the MSK family) 
by for instance phosphorylating histone H3  ( 8– 10 ) . The ability of 
ERK in regulating gene expression and chromatin organization is 
believed to be a crucial step not only in the processes of neural 
adaptations underlying normal cognitive processes but also in the 
onset of several neuropsychiatric disorders  ( 11– 15 ) . In addition, 
this signaling pathway also controls protein translation in the 
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cytosol and in the dendrites by activating the mTor pathway that 
regulates a number of factors including the S6 kinase which directly 
phosphorylate the S6 ribosomal protein  ( 16 ) . 
 ERK1 and ERK2 are activated by the same stimuli and are 
believed to bear similar substrate recognition properties and sub-
cellular localization  ( 17 ) . Because of their great similarity, the two 
isoforms have been considered for a long time as largely inter-
changeable, with mostly overlapping functions, and are tradition-
ally designated as a single ERK1/2 entity; this concept is also 
derived from the use, in several studies of the ERK pathway, of 
MEK inhibitors (such as U0126 or SL327) that do not discrimi-
nate between MEK1 and MEK2  ( 18– 20 ) . Although some studies 
still claim that ERK isoforms contribute to ERK signaling accord-
ing to the ratio of their expression levels and not to their speci fi c 
properties, recent evidence has highlighted critical functional dif-
ferences between these two isoforms. A strong support in this 
direction derives from the results obtained using ERK1 or ERK2 
knockout (KO) mice. ERK2 KO mice die early in development, 
showing that ERK1 cannot compensate for ERK2 in the embryo 
 ( 21– 26 ) . On the contrary,  erk1 gene ablation is fully compatible 
with the adult life  ( 27– 29 ) . Experiments at the molecular level in a 
variety of cell types showed that in ERK1-de fi cient cells (taken 
from ERK1 KO mice) the stimulus-dependent activation of ERK2 
was enhanced, without any compensatory increase in ERK2 pro-
tein levels  ( 27,  29 ) . Other studies have used RNA interference 
techniques to silence the activity of ERK1, obtaining its knock-
down in cells: as a result, cell growth was facilitated  ( 7,  30 ) . 
Interestingly, the phenotype caused by ERK1 knockdown, i.e., an 
enhancement of ERK2 activity, strongly parallel that observed 
when a constitutive active form of MEK1 is overexpressed via len-
tiviral vectors into mouse embryo  fi broblasts (MEF) cells. On the 
contrary, the ERK2 knockdown phenotype is similar to what 
observed with a dominant negative form of MEK1  ( 30 ) . 
Importantly, ERK2 activity enhancement in the nervous system of 
ERK1 mutant mice has been linked to improvement of certain 
forms of learning and memory  ( 29,  31 ) . The model put forward to 
explain these functional differences between ERK1 and ERK2 is 
that while ERK2 appears to be the main MAPK isoform transduc-
ing the signal to the nucleus, ERK1 seems to act like a partial ago-
nist, antagonizing the binding of ERK2 with interacting partners. 
Importantly, the structural basis of these differences has recently 
been located to the unique N-terminal moiety of ERK1, which 
causes a signi fi cant delay in the nuclear/cystoplamic shuttling. 
Indeed, a  fi nal con fi rmation that the N-terminal portion of ERK1 
is responsible for the observed phenotype comes from the swap of 
this domain between the two ERK isoforms: ERK1 without its 
N-term behaves in proliferating cells like ERK2 while ERK2 fused 
to the ERK1 N-term causes a ERK1-like phenotype  ( 17 ) . 
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 In order to study in vivo in the brain the functional differences 
between ERK1 and ERK2, we generated GFP fusion proteins not 
only of ERK1 and ERK2 but also of their swapped counterparts: 
ERK1 > 2 (ERK1 deprived of its N-term) and ERK2 > 1 (ERK2 
with the ERK1 N-term attached) (Fig.  1 ). These constructs have 
been introduced in a lentiviral vector (LV) and high-titer viral 
preparations have been obtained. LV is a powerful and ef fi cient 
tool to modify gene expression in primary cells without the need to 
use a selection marker, which is a major complication for in vitro 
study of cell proliferation. Supporting the competition model 
described above, here we show that the overexpression of ERK1 
and of ERK2 > 1 fusion proteins into MEF causes a reduction in 
the cell growth (Fig.  2 ). On the contrary, overexpression of ERK2 
and of ERK1 > 2 fusion proteins results in a growth advantage. 
Importantly, once validated their activity in vitro, these LV con-
structs can now be used to study the function of ERK1 and ERK2 
kinases in the brain. Stereotactic injections at the dorsal striatum of 
the mouse brain of such LV lead to a strong visualization of all four 
GFP fusion proteins. These proteins can be observed within 
4 weeks from the surgical procedure. Superimposition of the 
 fl uorescence signals of GFP expressing cells (in green) with either 
a neuron-speci fi c marker (NeuN, in red, Fig.  3a ) or with a glial-
speci fi c staining (GFAP, in red, Fig.  3b ) demonstrates a preferen-
tial neuronal localization of all four LV-expressed ERK–GFP fusion 
constructs. In order to study biochemically the function of these 
 Fig. 1.  Lentiviral vectors for ERK1, ERK2, and their swapped GFP fusion proteins. Schematic representation of the different 
ERK constructs in which the N-term moiety (1-39aa) of ERK1, conferring unique properties, is either present or absent. The 
ERK constructs were subcloned in a LV vector (pCCLsin.PPT.hPGK.eGFP.PRE) for in vivo expression studies. 
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GFP fusion proteins, we have also set up an ex-vivo system in which 
brain slices can be freshly prepared from adult mice, incubated in a 
perfusing chamber and stimulated with appropriate agonist and 
antagonists. As shown in Figs.  4 and  5 , striatal slices can be chal-
lenged with glutamate and induction of ERK signaling can be 
monitored at the single cell level using phospho-speci fi c antibodies 
either against ribosomal protein S6 (pS6) or histone H3 (pH3). 
Quanti fi cation of double pS6 or pH3 (in red) and anti-NeuN 
staining (in green) allow us to monitor changes in ERK activity. 
Importantly, pretreating the slices with U0126, a speci fi c MEK1/2 
inhibitor, completely blocks S6 and H3 phosphorylation. Having 
validated this ex-vivo system, brain slices can in the future be pre-
pared from LV-injected mice and/or from other transgenic ani-
mals and the activity of the ERK pathway can be easily assessed 
with a tight spatio-temporal resolution. 
 Fig. 2.  Effects of ERK constructs in MEF proliferation. ( a ) Images of MEF cells infected with the LV expressing different GFP 
fusion proteins (MOI = 5). MEF cells were infected with LV vectors expressing ERK1, ERK2, and their swapped counterparts 
ERK1 > 2 and ERK2 > 1. Four days after infection, the GFP protein was found expressed ubiquitously in the cell. Bar = 50  μ m. 
In the low left insert a representative Western blot is shown. A whole-cell extract was immunoblotted for ERK and GADPH 
(loading control). The GFP fusion proteins of ERK1, ERK2, and their swapped counterparts were easily detected by immu-
noblotting. ( b ) Proliferation assay on MEF transduced with LV for ERK1, ERK2, and their swapped versions. Proliferation was 
assessed by counting every day the cells using a Coulter Counter. 1.25 × 10 5 cells/well were seeded in six-well plate and 
maintained in culture medium. The following day (day 0), cells were transduced at MOI = 5 with lentiviral vectors express-
ing ERK1, ERK2, and their swapped counterparts or GFP as a control. At the end of the experiment (day 6), a signi fi cant 
growth retardation was observed in cells infected with LV for ERK1 and ERK2 > 1. Results are the mean of  n = 6. 
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 Fig. 3.  In vivo expression of the LV constructs in the mouse brain. Images from the mouse striatum infected with LV for the 
different ERK constructs. Sections of the mouse brain were studied by immuno fl uorescence at 4 weeks following dorsal 
striatum injections. Immuno fl uorescence for either ( a ) NeuN (a neuron-speci fi c marker, in  red ) or, ( b ) GFAP (a glial-speci fi c 
marker, in  red ) demonstrated a preferential neuronal expression mediated by the lentiviral vectors. Smaller neurons show 
obvious colocalization of GFP and the primarily nuclear NeuN expression. Some neurons do not include the nucleus in the 
confocal optical plane of section and thus do not appear NeuN-positive in these images, although they would show 
 co-localization in subsequent focal planes. Bar = 20  μ m. 
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Fig. 3. (continued)
 Fig. 4.  S6 ribosomal protein phosphorylation is prevented by MEK inhibitor UO126 in a model of mature striatal slices. 
( a ) Double immunolabeling of phospho S6 ribosomal protein (Ser235/236) ( red ) and NeuN ( green ) in adult striatal slices 
stimulated or not with glutamate 100  μ M for 10 min in the presence of the vehicle or 20  μ M UO126. ( b ) The data from the 
quanti fi cation are represented in the graph as mean ± SEM ( n = 7 and  n = 8 for the groups treated with vehicle and respec-
tively stimulated or not with glutamate,  n = 9 for the groups treated with UO126). Statistical analysis was performed using 
two-way  ANOVA and post-hoc comparisons between groups using Bonferroni test (**** p < 0.0001). Scale bars: 30  μ m. 
 
 Fig. 5.  Histone H3 phosphorylation is prevented by MEK inhibitor UO126 in a model of mature striatal slices. ( a ) Double 
immunolabeling of phospho-histone H3 ( red ) and NeuN ( green ) in adult striatal slices stimulated or not with glutamate 
100  μ M for 10 min in the presence of the vehicle or 20  μ M UO126. ( b ) The data from the quanti fi cation are represented in 
the graph as mean ± SEM ( n = 4 and  n = 3 for the groups treated with vehicle and respectively stimulated or not with glu-
tamate,  n = 6 and  n = 5 for the groups treated with UO126 vehicle and respectively stimulated or not with glutamate). 
Statistical analysis was performed using two-way  ANOVA and post-hoc comparisons between groups using Bonferroni test 
(**** p < 0.0001). Scale bars: 30  μ m. 
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  1.  Dulbecco’s Modi fi ed Eagle Medium with GlutaMax (DMEM 
GlutaMax,  GIBCO ). 
  2.  Iscove’s Modi fi ed Dulbecco Medium (IMDM,  SIGMA ). 
  3.  Fetal Bovine Serum (FBS,  EUROCLONE ). 
  4.  100× Glutamine (200 mM Glutamine) ( GIBCO ). 
  5.  100× Pen/Strept (10,000 U/ml Penicillin, 10,000  μ g/ml 
Streptomycin,  GIBCO ). 
  6.  Sodium butyrate ( SIGMA ). 
  7.  Dulbecco’s Phosphate Saline Buffer (PBS,  EUROCLONE ). 
  8.  Trypsin solution (0.05% Trypsin/ethylenediaminetetraacetic 
acid) ( GIBCO ). 
  9.  Tris–EDTA (TE) buffer 1× [10 mM Tris ( SIGMA ) pH 8.0; 
1 mM EDTA,  SIGMA ]. 
  10.  Collagenase ( SIGMA ). 
  11.  100 mm, 150 mm and six-well plates ( CORNING ). 
  12.  2× HBS pH 7.09: 281 mM NaCl, 100 mM HEPES ( SIGMA ), 
1.5 mM Na 2 HPO 4 ( SIGMA ),  fi lter sterilized and stored at 
−20°C. 
  13.  2.5 M CaCl 2 solution ( SIGMA)  fi ltered (0.22  μ m) and stored at 
−20°C. 
  14.  Sterile water ( DIACO ). 
  15.  Syringe-driven  fi lter units (0.22  μ m) MILLEX GP 
( MILLIPORE ). 
  16.  Dimethylsulfoxide (DMSO,  SIGMA ). 
  1.  Fixing solution: 2% Paraformaldehyde ( SIGMA ) in PBS. 
  2.  Cell Coulter Z1 ( BECKMAN ). 
  3.  Saline solution (0.9% NaCl solution in sterile water,  DIACO ). 
  1.  Stacking Gel: 125 mM Tris/HCl pH 6.8; 4.5% Acrylamide-bis 
(37.5:1) ( MERCK ); 0.1% SDS ( SIGMA ); 0.2% Ammonium persul-
phate ( SIGMA ); 0.2%  N , N , N  ¢ , N  ¢ -Tetramethylethylenediamine 
(TEMED,  BIORAD ). 
  2.  Running Gel: 375 mM Tris/HCl pH 8.8; 12% Acrylamide-bis 
(37.5:1); 0.1% SDS; 0.1% Ammonium persulphate; 0.1% 
TEMED. 
  3.  Running Buffer pH 8.8: 25 mM Tris; 190 mM Glycine ( SIGMA ); 
0.1% SDS. 
 2.  Materials
 2.1.  Cell Culture, 
Transfection, 
and Viral Vector 
Production
 2.2.  Proliferation Curve
 2.3.  Sodium Dodecyl 
Sulfate–
PolyAcrylamide Gel 
Electrophoresis 
(SDS–PAGE)
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  4.  Sample Buffer 5×: 250 mM Tris/HCl pH 6.8; 10% SDS; 50% 
Glycerol; 0.02% Bromophenol Blue ( SIGMA ); 110 mM 
Dithiothreitol (DTT,  SIGMA ). 
  5.  Lysis Buffer: 125 mM Tris/HCl pH 6.8, 2.5% SDS. 
  1.  Transfer Buffer: 25 mM Tris; 190 mM Glycine, 20% Methanol 
( MERCK ). 
  2.  Protran Nitrocellulose membrane ( WHATMAN ). 
  3.  Tris Buffered Saline buffer (TBS): 20 mM Tris/HCl pH 7.4; 
150 mM NaCl, ( SIGMA) ) with 0.1% Tween ( SIGMA ) 
(TBS-TW). 
  4.  Blocking buffer: 5% Bovine Serum Albumin, ( SIGMA ) in 
TBS-TW. 
  5.  Antibody buffer: 3% BSA in TBS-TW. 
  6.  Antibodies: p44-42 MAPK #SC-153 ( SANTA CRUZ BIOTECHNOL-
OGY ), GAPDH #SC-25778 ( SANTA CRUZ BIOTECHNOLOGY ). 
  1.  C57/BL6 male mice 26g (Charles River). All experimental 
procedures must be performed in accordance with National 
and Institutional Guidelines for the use of laboratory animals. 
  2.  Anesthetic solution: 100 mg/kg Ketamine (KETAVET, 
INTERVET), 10 mg/kg Xilazina (Rompun, BAYER) in phys-
iologic solution. 
  3.  Microscope (L-0940SD, INAMI). 
  4.  Stereotaxic Frame (Kopf Instruments). 
  1.  Phosphate Buffer (PB): pH 7.4 (Na2HPO4 81 mM, NaH2PO4
 
18.84 mM). 
  2.  Perfusion solution: Paraformaldehyde (PFA) 4% in PB. 
  3.  Sucrose 30% in PB. 
  4.  Anti-Freeze: Na 2 HPO 4 · 2H 2 O 30.62 mM, NaH 2 PO 4 · H 2 O 
11.38 mM, 33.33% ethylene glycol, 33.33% glycerol. 
  5.  Microtome (MICROM HM 430). 
  1.  C57/BL6 mice 2–3 months old (Charles River) (see Note 1). 
All experimental procedures must be performed in accordance 
with National and Institutional Guidelines for the use of labo-
ratory animals. 
  2.  Arti fi cial cerebrospinal  fl uid (ACSF): 124 mM NaCl, 5 mM 
KCl, 1.3 mM MgSO 4 · 7H 2 O, 1.2 mM NaH 2 PO 4 · H 2 O, 
25 mM NaHCO 3 , 10 mM  D -glucose 2.4 mM CaCl 2 (1 M 
stock) in dH 2 O. This solution should be prepared fresh on the 
day of the experiment and saturated with carbogen (95% O 2 , 
5% CO 2 ) for 10 min before use. 
 2.4.  Western Blot
 2.5.  In Vivo Injection
 2.6.  Perfusion 
and Preparation 
of Free-Floating Slices
 2.7.  Preparation 
of Acute Striatal Slices
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  3.  Sucrose-based dissecting solution: 87 mM NaCl, 2.5 mM KCl, 
7 mM MgCl 2 1 mM NaH 2 PO 4 ,  75 mM sucrose, 25 mM 
NaHCO 3 , 10 mM  D -glucose, 0.5 mM CaCl 2 (1 M stock), and 
2 mM kynurenic acid in dH 2 O. This solution should be pre-
pared fresh on the day of the experiment and saturated with 
carbogen for 10 min before use. 
  4.  L -glutamic acid 100  μ M (>99%, Sigma-Aldrich). 
  5.  UO126 20  μ M (Tocris Bioscience) diluted in DMSO. 
  6.  Fixative solution: 4% paraformaldehyde in 0.1 M sodium phos-
phate buffer pH 7.4. This solution should be prepared fresh on 
the day of the experiment. This solution is harmful, and it must 
be used in ventilated hood wearing gloves. 
  7.  Cryoprotectant solution: 30% sucrose in 0.1 M sodium phos-
phate buffer pH 7.4. This solution should be prepared fresh on 
the day of the experiment. 
  8.  Dissection tools for removing the brains (scissors, forceps, and 
spatula). 
  9.  Cyanoacrylate glue. 
  10.  Vibratome (VT1000S, Leica Microsystems). 
  11.  Brain slice chamber-BSC1 (Scienti fi c System design Inc., 
Mississauga, ON, Canada). 
  12.  Proportional temperature controller (Scienti fi c System design 
Inc., Mississauga, ON, Canada). 
  13.  Two peristaltic pumps (Minipuls 3, Gilson) with R8 medium 
 fl ow pump heads (see Note 2). 
  14.  Silicone peristaltic tubing and connectors (Gilson). 
  1.  Cryostat. 
  2.  Embedding medium for frozen sectioning. 
  3.  Superfrost slides. 
  1.  Dulbecco’s Phosphate Saline Buffer (PBS,  EUROCLONE ). 
  2.  Blocking solution:
 (a)  NeuN antibody: 5% NGS (normal goat serum), 0.1% 
Triton100 in PBS. 
 (b)  GFAP antibody: 10% NGS, 0.1% Triton100, BSA 1 mg/
ml in PBS. 
  3.  Primary Antibodies: anti-phospho-S6 ribosomal protein 
(Thr235/236) (Cell signaling Technology) 1:100, anti-phospho 
(Ser10)-acetyl (Lys14)-histone H3 (1:1000) (Upstate), Alexa 
Fluor 488 conjugate antiGFP (1:500) (A21311, Invitrogen), 
NeuN (1:500) (MAB-377, CHEMICON), rabbit anti-GFAP 
(1:500) (DAKO). 
 2.8.  Slices Sectioning
 2.9.  Immuno-
 fl uorescence
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  4.  Secondary Antibodies: Alexa Fluor 546 goat anti-mouse 
(1:200) (A11003, Invitrogen), Alexa Fluor 555 goat anti-
mouse (1:1000) (A21422, Molecular Probes), Alexa Fluor 546 
goat anti-rabbit (1:200) (A-11035, Molecular Probes), Alexa 
Fluor 488 goat anti-mouse (1:200) (A11001, Invitrogen). 
  5.  PapPen (Sigma). 
  6.  Fluorescence Mounting Medium (S3023, Dako). 
  7.  Microscope Slide Superfrost Plus (Thermo Scienti fi c) and 
coverslips. 
  8.  Leica confocal microscope. 
 
 MEF cultures are prepared from wild-type E13.5 embryos obtained 
from commercially available C57 B/6 mice (Charles River) (see 
Note 3).
  1.  Dissection is carried out in PBS. 
  2.  Remove the internal organs and the head, reduce the remain-
ing tissues in small pieces and transfer in a 50 ml tube. 
  3.  Centrifuge at 3,000 rcf for 5 min. 
  4.  Wash in PBS and incubate for 1 h at 37°C in a solution of 
0.25% collagenase and 20% FBS in PBS. 
  5.  Dissociate tissues using a syringe. 
  6.  Centrifuge at 3,000 rcf for 5 min at room temperature. 
  7.  Resuspend the cells in DMEM GlutaMax containing 10% FBS, 
1× Pen/Strept. 
  8.  Count the cells and seed 5 × 10 6 cells on 15 mm plates. 
  9.  Freeze the cells at con fl uence in 95% serum and 5% DMSO. 
 We use all third-generation LV, modi fi cations of the originally 
described backbone (see Note 4).
  1.  Seed and incubate 9 × 10 6 HEK 293T cells [ATCC, CRL-
11268] in 150 mm dishes, approximately 24 h before transfec-
tion. The medium used is DMEM GlutaMax containing 10% 
FBS, 1× Pen/Strept. Use low passage cells (not more than 
P12–15) and do not ever let cells grow to con fl uence. 
  2.  Change medium 2 h before transfection: IMDM supplemented 
with 10% FBS, 1× Pen/Strept, 1× glutamine (22 ml  fi nal 
volume). 
  3.  Prepare the plasmid DNA mix by adding together: 9  μ g ENV 
plasmid (VSV-G), 12.5  μ g packaging plasmid (pMDLg/pRRE 
 3.  Methods
 3.1.  Mouse Embryonic 
Fibroblasts 
Preparation
 3.2.  Lentiviral Vectors 
Production
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or CMV R8.74), 6.25  μ g of pRSV-REV, and 32  μ g of gene 
transfer plasmid. The plasmid mix solution is made up to a  fi nal 
volume of 1,125  μ l with 0.1× TE Buffer (1: 10 mM Tris pH 
8.0; 1 mM EDTA pH 8.0 in water). Finally, 125  μ l of 2.5 M 
CaCl 2 is added. 
  4.  Leave the mix 15 min at room temperature. 
  5.  The precipitate is formed by dropwise addition of 1,250  μ l of 
2× HBS (281 mM NaCl, 100 mM HEPES, 1.5 mM Na 2 PO 4 , 
pH 7.06–7.12) solution to the 1,250  μ l DNA–TE–CaCl 2 mix-
ture from step 3 while vortexing at full speed. The precipitate 
should be added to HEK 293T-cell immediately following the 
addition of the 2 HBS. High magni fi cation microscopy of the 
cells should reveal a very small granular precipitate of CaPO 4 -
precipitate plasmid DNA, initially above the cell monolayer 
and after incubation in 37°C incubator overnight, on the bot-
tom of the plate in the large spaces between the cells. 
  6.  The CaPO 4 -precipitate plasmid DNA should be allowed to 
stay on the cells for 14–16 h, after which the media should be 
replaced with fresh medium (IMDM with 10% FBS, 1× Pen/
Strept, 1× glutamine and 1 M sodium butyrate). 
  7.  Collect the cell supernatants at 36 h after changing the medium, 
 fi lter (0.22  μ m) and centrifuge at 20,000 rpm, at 20°C for 2 h 
(Beckman Ultracentrifuge, SW32Ti rotor). 
  8.  Discard the supernatant and resuspend the pellet in sterile PBS 
1×. 
  9.  Aliquot and store at −80°C. 
  1.  Seed and incubate 5 × 10 4 HEK 293T cells in 35 mm dishes, 
12–14 h before the infection. 
  2.  Make serial dilution of the LV in the growing medium (DMEM 
GlutaMAX, 10% FBS, 1× Pen/Strept) and transduce the cells 
with the desired dilutions in a  fi nal volume of 1 ml. 
  3.  After 5 days, collect the cells, wash in PBS with 1% FBS, and 
resuspend in 2% paraformaldehyde in PBS 1×. 
  4.  The titer (transforming units, TU) is determined by using 
FACS calibur (BD  BIOSCIENCE ) and counting the percentage of 
GFP-positive cells in each dilution. When the percentage is 
between 2.5 and 25%, the titer can be determined using the 
following formula: 
 
=
× × 4
Titer(T.U. / ml)
Percentage of GFP positive cells Cells plated the first day(5 10 )
.
Dilution
 
 3.3.  Titration 
of the Lentiviral 
Vectors
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 Cells are initially plated in the exponential phase and followed for 
5 days, till they reached a subcon fl uent stage (see Note 5).
  1.  The day before the infection seed 1.25 × 10 5 MEF cells/well in 
six-well plates. It is better to use low passage cells, in this case 
P4–5 cells were used. Prepare one plate for each day of count-
ing for each condition. 
  2.  The day after (day 0) count one plate for each condition. The 
count is performed following the next protocol:
 (a)  Detach the cells with the trypsin solution for 5 min at 
37°C. 
 (b)  Collect the cells and wash carefully the wells with PBS 1× 
with 1% serum to be sure to take all the cells. 
 (c)  Centrifuge at 1,500 rcf for 5 min at RT. 
 (d)  Resuspend the cells in 1 ml of  fi xing solution. 
 (e)  Dilute 200  μ l of cell suspension in 10 ml of saline and 
determine the cell number with the coulter counter. 
  3.  Tranduce (MOI=5 in 1 ml of fresh medium) cells in the 
remaining plates. 
  4.  Every day count one plate for each condition and change 
medium in the others. 
  5.  At day 2 after infection, cells are controlled for GFP expression 
in order to check the ef fi ciency of the process. 
  1.  Anesthetize the mouse. 
  2.  Secured the animal in a steroetaxic frame equipped with a 
mouse adaptor. 
  3.  Unilateral LV injection is performed into two different sites of 
the motor dorsal striatum:
 (a)  1° SITE: AP +1; L −2.1; DV −2.6. 
 (b)  2° SITE: AP +0.3; L −2.3; DV −2.4. 
  1.  Anesthetize the mouse. 
  2.  Perfuse the mice with cold physiologic solution at 35 rpm for 
2 min. 
  3.  Perfuse the mice with cold perfusion solution at 35 rpm for 
5 min. 
  4.  Carefully, extract the brain and post- fi x it in cold perfusion 
solution, overnight at 4°C. 
  5.  Discard the perfusion solution, wash the brain with PB and 
incubate with sucrose 30% for 24 h at 4°C. 
  6.  Cut the brain at 35  μ m with a microtome and stock the slices 
in antifreeze at −20°C. 
 3.4.  Proliferation 
Assays
 3.5.  In Vivo Lentiviral 
Injection
 3.6.  Brain Perfusion 
and Preparation 
of Free-Floating Slices
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  1.  Rinse the slices three times for 10 min in PBS. 
  2.  Preincubate the slices for 1 h at room temperature with block-
ing solution. 
  3.  Incubated overnight at 4°C with primary antibodies. 
  4.  Rinse the slices three times for 10 min in PBS. 
  5.  Incubated 1 h at room temperature with secondary 
antibodies. 
  6.  Rinse the slices three times for 10 min in PBS. 
  7.  Mount the slices on microscope slides, leave them dry and 
cover with a cover slip. Close it with the mounting medium. 
  1.  Prepare the ACSF solutions containing 20  μ M UO126 or the 
vehicle. Carboxygenate these solutions for at least 10 min and 
let them  fl ow into the brain slice chamber at a constant rate of 
2 ml/min at 32°C. The height of the perfusion  fl uid should be 
adjusted so that it forms a thin  fi lm over the slices. 
  2.  Anesthetize a mouse and decapitate it with scissors, rapidly 
remove the brain in ice-cold sucrose-based dissecting solution 
oxygenated with 95% O 2 and 5% CO 2 (see Note 6). 
  3.  Mount the brain on the vibratome stage on a drop of cyano-
acrylate glue. 
  4.  Cut 200  μ m-thick slices keeping the brain submerged in ice-
cold carboxygenated sucrose-based dissecting solution. The 
vibration rate of the blade should be fast and the speed nearly 
minimal. 
  5.  Transfer the slices into the brain slice chamber placing them 
upon a lens paper (up to four slices in every chamber) and let 
them recover for 1 h at 32°C, constantly perfusing carboxy-
genated ACSF in the presence of the inhibitor or the vehicle. 
  6.  After the recovery period, infuse 100  μ M glutamate in the 
chamber for 10 min. 
  7.  Remove the slices from the chamber and rapidly  fi x them in 4% 
PFA for 15 min at room temperature (see Note 7). 
  8.  Rinse extensively (three times for 20 min with gentle agitation) 
in 0.1 M sodium phosphate buffer pH 7.4 at room 
temperature. 
  9.  Incubate the slices in the cryoprotectant overnight at 4°C. 
Slices should not be incubated longer than overnight. 
  1.  Set the temperature of the cryostat chamber to −22°C. 
  2.  Mount a piece of embedding medium on a metal specimen 
holder and cut the surface to make it  fl at. 
  3.  Wrap a glass slide with para fi lm and place the slice on this sur-
face on a drop of embedding medium. 
 3.7.  Free Floating 
Immuno fl uorescence
 3.8.  Preparation 
of Acute Striatal Slices
 3.9.  Slices Sectioning
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  4.  Transfer the slice onto the embedding medium  fl at surface and 
let it freeze. 
  5.  Cut 18  μ m cryosections and collect them onto Superfrost 
slides. Store in the cryostat until the cutting is completed (see 
Note 8). 
  1.  Draw a hydrophobic ring around the slices using a PapPen. 
  2.  Rinse the slides with PBS three times for 10 min. 
  3.  Pipette 100–200  μ l blocking solution on each slide and incu-
bate for 1 h at room temperature in a humid chamber (see 
Note 9). 
  4.  Discard the blocking solution and pipette 100–200  μ l primary 
antibodies solution on each slide. Incubate in a humid cham-
ber overnight at 4°C. 
  5.  Rinse the slides with PBS three times for 10 min. 
  6.  Pipette 100–200  μ l secondary antibodies on each slide and 
incubate in a humid chamber for 1 h at room temperature. 
  7.  Rinse the slides with PBS three times for 10 min. 
  8.  Discard PBS without drying the sections and mount the cov-
erslips using the  fl uorescent mounting medium. 
  9.  Store the slides at 4°C overnight in the dark before the exami-
nation at the microscope. 
 Single and double-labeled images were obtained using a laser scanning 
confocal microscopy (Leica SP2), equipped with the corresponding 
lasers and the appropriate  fi lters sets to avoid the cross-talk between 
the  fl uorochromes. Images were obtained with a 40× and 63× 
objectives. Neuronal quanti fi cation was performed with ImageJ 
software by counting phospho-S6/phospho-H3 immunoreactive 
neurons among NeuN-positive neurons in each slice. Statistical 
analysis was performed using two-way  ANOVA and post-hoc com-
parisons between groups were made using Bonferroni test 
(**** p < 0.0001). 
 
  1.  Brain slices obtained from young animals are more viable. 
  2.  The height of the perfusion  fl uid in the brain slice chamber can 
be better regulated when the in fl ow and the out fl ow in the 
chamber are controlled by two independent pumps. 
  3.  Mouse embryonic  fi broblasts, prepared following this proto-
col, are cells with a relatively low proliferative potential and 
they should exclusively be used at low passages (maximum two 
 3.10.  Acute Striatal 
Slices 
Immuno fl uorescence
 3.11.  Microscopy 
and Image Analysis
 4.  Notes
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times after thawing) since they rapidly undergo senescence. We 
never refreeze MEF after the initial freezing. Although MEF 
normally grow at 10% FBS and can be starved at 0.5–1% FBS 
for inducing entering into the G 0 phase of the cell cycle, they 
can also be grown at 5% FBS, as done in our proliferation 
assays. Since MEF are resistant to plasmid transfection, we use 
for the experiments in Figs.  2 and  3 LV-assisted infection with 
the constructs described in Note 4. Using our infection condi-
tions (multiplicity of infection, MOI = 5), transduction 
ef fi ciency of MEF is very high (<90% of GFP-positive cells). 
  4.  All lentiviral vectors used for the MEF proliferation assays and 
in-vivo injections (Figs.  2 and  3 ) are self-inactivating, third-
generation vectors  ( 32 ) . The plasmids used for packaging, 
kindly provided by Luigi Naldini, were pREV (expressing REV 
protein), pVSVG (expressing the envelope: G glycoprotein of 
Vesicular Stomatitis Virus), and pRRE (expressing capsid, 
polymerase, protease, and integrase proteins). The lentiviral 
vector used as control in the MEF proliferation and in-vivo 
injection assay is pCCLsin.PPT.hPGK.eGFP.PRE  ( 33 ) . This 
vector allows the expression of eGFP under the human phos-
phoglycerate kinase (hPGK) promoter. The four LV used for 
overexpressing ERK1, ERK2, ERK1 > 2, and ERK2 > 1 were 
derived from the previously described constructs  ( 7 ) . The 
expression of the ERK constructs in the LV is under the hPGK 
promoter. 
  5.  At the proliferation assays, the following cell densities 
(mean ± SEM) were reached. For Day 4: control vector, 
5,338.06 ± 65.95 cells/mm 2 ; ERK1, 4,035.72 ± 116.09 cells/
mm 2 ; ERK2, 5,142.39 ± 99.53 cells/mm 2 ; ERK1 > 2, 
5,570.61 ± 56.04 cells/mm 2 ; ERK2 > 1, 3,310.61 ± 58.43 
cells/mm 2 . For Day 6: control vector, 5,453.83 ± 71.30 cells/
mm 2 ; ERK1, 4,681.61 ± 74.49 cells/mm 2 ; ERK2, 
5,700.06 ± 156.69 cells/mm 2 ; ERK1 > 2, 6,475.61 ± 94.57 
cells/mm 2 ; ERK2 > 1, 4,376.17 ± 68.44 cells/mm 2 . Statistical 
analysis was performed using two-way  ANOVA and post-hoc 
comparisons between groups was made using Bonferroni test 
(* p  £ 0.02). 
  6.  Speed is essential for good results: the brain should be removed 
within 1–2 min after the decapitation. 
  7.  The duration of  fi xation can be changed depending on the 
primary antibody and the brain region. 
  8.  The cryosections should not be stored too long in the freezer. 
Best results are achieved processing the sections for 
immuno fl uorescence immediately after cutting. 
  9.  The sections must never dry during the entire staining proce-
dure in order to avoid high levels of background  fl uorescence. 
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Noonan syndrome is a genetic condition characterized by con-
genital heart defects, short stature, and characteristic facial
features. Familial or de novo mutations in PTPN11, RAF1, SOS1,
KRAS, and NRAS are responsible for 60–75% of the cases, thus,
additional genes are expected to be involved in the pathogenesis.
In addition, the genotype–phenotype correlation has been hin-
dered by the highly variable expressivity of the disease. For all
these reasons, expanding the genotyped and clinically evaluated
case numbers will benefit the clinical community. A mutation
analysis has been performed on RAF1, SOS1, and GRB2, in 24
patients previously found to be negative for PTPN11 and KRAS
mutations. We identified four mutations in SOS1 and one in
RAF1, while no GRB2 variants have been found. Interestingly,
theRAF1mutationwas present in a patient also carrying a newly
identified p.R497Q familial SOS1 mutation, segregating with a
typical Noonan Syndrome SOS1 cutaneous phenotype. Func-
tional analysis demonstrated that the R497Q SOS1 mutation
leads to Jnk activation, but has no effect on the Ras effector Erk1.
We propose that this variant might contribute to the onset of the
peculiar ectodermal traits displayedby the propositus amidst the
more classical Noonan syndrome presentation. To our knowl-
edge, this is the first reported case of a patient harboring
mutations in two genes, with an involvement of both Ras and
Rac1 pathways, indicating that SOS1may have a role of modifier
gene that might contribute the variable expressivity of the
disease, evidencing a genotype–phenotype correlation in the
family.  2010 Wiley-Liss, Inc.
Keywords: Noonansyndrome; Jnkactivation; genotype–phenotype
correlation; SOS1; RAF1; GRB2; mutational analysis
INTRODUCTION
Noonan syndrome (NS [OMIM63950]) is an autosomal dominant
genetic condition, characterized by short stature, dysmorphic facial
features, skeletal abnormalities, and congenital heart defects. Its
estimated incidence ranges from 1/1,000 to 1/2,500 live births
[Allanson, 1987; Sharland et al., 1992]. Noonan syndrome is
diagnosed by a clinical-based scoring system, comprising major
and minor criteria [van der Burgt et al., 1994].
Noonan syndrome is genetically heterogeneous with four causal
genes identified to date. PTPN11 encodes a protein phosphatase
and it harbors gain-of-functionmutations in approximately 50%of
patients [Tartaglia and Gelb, 2005]. KRAS, SOS1, and RAF1 have
been recently implicated in aminority of patients [Carta et al., 2006;
Schubbert et al., 2006; Pandit et al., 2007; Razzaque et al., 2007;
Roberts et al., 2007; Tartaglia et al., 2007]. All genes so far identified
belong to the conserved Ras-MAPK signaling pathway. SOS1 is
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mapped to chromosome 2p22.1 and encodes for a 150 kDa Ras-
GEF (guanine exchange factor) protein. When a growth factor
binds to its tyrosine kinase receptor, SOS1, associated with the
adaptor GRB2, is recruited to the plasma membrane where it
participates in the activation of Ras by catalyzing the exchange of
GDP with GTP [Quilliam et al., 2002]. SOS1 is also known to
activate a distinct pathway mediated by Rac1, a GTPase belonging
to the Rho-family [Sini et al., 2004].
SOS1 mutations account for 10–13% of Noonan syndrome pa-
tients [Roberts et al., 2007].Thosepatientshavebeen reported to show
phenotypic elements reminiscent of cardiofaciocutaneous syndrome
[MIM115150], particularly concerning the dysmorphic features,
macrocephaly and peculiar ectodermal traits, although this observa-
tion lacks statistical significance [Tartaglia et al., 2007]. RAF1 was
identified as a causative gene for hypertrophic cardiomyopathy
(HCM) in Noonan syndrome and LEOPARD syndrome-2
[MIM611554], and accounts for about a third of PTPN11mutation
negative patients [Pandit et al., 2007; Razzaque et al., 2007]. RAF1 is a
knownoncogenemapped to3p25, andencodes fora serine–threonine
kinase downstream of Ras signaling pathway [Li et al., 1991].
Although different genes have been implicated in the pathogen-
esis ofNoonan syndrome, about 30%of patients remain genetically
uncharacterized, thus additional genes are expected to be involved
and should be searched for. In addition, the correlation between the
phenotypic traits and the specific genetic defect has been limited by
the highly variable expressivity of the disease and by the relatively
small number of published genotyped cases, thus further patients
should be genotyped.
We here report on the mutational study on SOS1, RAF1, in a
cohort of 24 patients affected with Noonan syndrome, who previ-
ously tested negative for PTPN11 and KRAS. Additionally, we
report the mutational screening of the candidate gene GRB2. We
found four SOS1mutations and one RAF1mutation, interestingly
shown by a patient also carrying a familial SOS1 mutation.
MATERIALS AND METHODS
Patients and Samples
Twenty-four patients affected by Noonan syndrome and negative
for PTPN11 and KRAS mutations were included in the study. All
matched thediagnostic criteria forNoonan syndrome, asdefinedby
vander Burgt et al. [1994] andwere referred as sporadic instances of
the disease at the time of referral. Genetic exams were performed by
experienced physicians (M.C., S.M., P.C.).
Peripheral lymphocyte DNA was obtained from patients,
parents, and controls using the QIAamp DNA Blood Mini Kit
(Qiagen,Valencia,CA), according tothemanufacturer’s instructions.
Mutation Screening
PCR products were bi-directionally sequenced using the Termina-
tor v3.1 Cycle Sequencing Kit (Applied Biosystems, Foster City,
CA), and run on an automated ABI-3130xl DNA genetic analyzer
(Applied Biosystems). Output data were analyzed by SeqScape
software v2.6 (Applied Biosystems). Sequencing was performed on
the nine exons of SOS1, and two exons of RAF1, where mutations
had been previously identified [Pandit et al., 2007; Roberts et al.,
2007; Tartaglia et al., 2007]. GRB2 mutation screening has been
carried out on the whole coding region by using the conditions
indicated in Table I.
Alternatively, PCR products were run on WAVE Nucleic Acid
Fragment Analysis System 3500HT (Transgenomic, Glasgow, UK),
and data analyzed byNavigator Software (Transgenomic). Prim-
er sequences are published elsewhere [Pandit et al., 2007; Tartaglia
et al., 2007].
Plasmids and Mutagenesis
hSOS1 was a kind gift of G. Scita (IFOMMilano); HA-JNK and HA-
ERK1 have been previously described [Innocenti et al., 1999]. The
hSOS1 plasmid was used as template for site-directed mutagenesis,
performed using the QuikChange Site-Directed Mutagenesis Kit
(Agilent Technologies, Santa Clara, CA) according to the
manufacturer’s instructions. Pairs of complementary mutagenic pri-
mers (R497Q-Fw: AAAAGTTTTTATGCAAAAGGTACAAATTA
and R497Q-Rev: TTAATTTGTACCTTTGCATAAAAAACTTTT;
M269R-Fw: AAGATACAGTAGAAAGGACAGATGAAGGCAG and
M269R-Rev: CTGCCTTCATCTGTCCTTTCTACTGTATCTT)
were designed.
Biochemical Analysis
HEK293 cells were grown in DMEMplus 10% FBS and antibiotics.
Cells were transiently transfected with equal amount of the full-
TABLE I. GRB2 Primers
EXON Primer Sequence Annealing temperature (C) Fragment size (bp)
2 EX2A 50-CGAGGCTGAAAAGAGG AAGA-30 58 467
EX2B 50-TGTGTGTAATCAGGGCGAAA-30
3 EX3A 50-CGAGTGAAACCGTTCACAGA-30 58 298
EX3B 50-TGACATCCATCCCAGTGATCT-30
4 EX4A 50-GGCTGGAT ATCCCGTTTCTT-30 56 250
EX4B 50-AACGGCTTCACAATTTGGAT-30
5 EX5A 50-ACCCTCGATTTGCCAAGTTA-30 58 [1,0]295
EX5B 50-CAGGAATGCACACTGAGGAG-30
6 EX6A 50-GGGAGATGGGAGGTGAGTTT-30 58 399
EX6B 50-AGAGGCAGCTTGTGGGTTTA-30
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length hSOS1 or of the mutated isoforms of hSOS1 and either
hemagglutinin (HA)-tagged c-Jun NH2-terminal kinase (JNK) or
HA-tagged extracellular regulated kinase1 (ERK1) using the JetPEI
(Polyplus, New York, NY) method according to manufacturer’s
instructions. Twenty-four hours after transfection themediumwas
replacedwith serumdeprivedmediumand left for 18 hr. Cells were
then stimulated with EGF (20 ng/ml) for the indicated intervals.
Cells were then collected in lysis buffer (Tris–HCl 50mM, pH 7.5,
NaCl 150mM, Triton X-100 1%, glycerol 10%, NaF 50mM,
NaVO3 1mM, and cocktail of proteases inhibitors) and equal
amount of proteins were immunoprecipitated using anti-HA anti-
bodies (BABCO,Richmond, CA) and subsequently incubatedwith
protein G slurry. Beads were washed and resuspended in SDS
sample buffer. Samples were run on SDS–PAGE and then trans-
ferred to nitrocellulose membranes. The membranes were then
immunodecorated with anti-HA, anti-pERK2 (Cell signalling,
Danvers, MA), pJNK (Cell signalling), or anti-SOS1 (Santa Cruz
Biotechnology, Santa Cruz, CA). Antibodies were visualized
by enhanced chemioluminescence detection (ECL; Amersham
Pharmacia Biotech, Milan, Italy) using horseradish peroxidase-
conjugated secondary antibodies (Jackson Immunoresearch Lab-
oratories, West Grove, PA). Band intensities were quantified by
densitometry with Scion Image Program (Scion Corporation,
Frederick, MD).
Bioinformatic Analysis
The potential effects of the novel SOS1 sequence variant were
analyzed using the following programs: ClustalX 2.0 (ftp://
ftp.ebi.ac.uk/pub/software/clustalw2) for multiple sequence align-
ment, NACCESS (http://www.bioinf.manchester.ac.uk/naccess/),
HBPLUS 3.0 (http://www.biochem.ucl.ac.uk/bsm/hbplus/
home.html), LIGPLOT 4.4.2 (http://www.biochem.ucl.ac.uk/bsm/
ligplot/ligplot.html), and PyMOL v1.1 (http://pymol.sourceforge.
net/) for theanalysis and thevisualizationofaminoacids interactions.
Three-dimensional structures of SOS1 domains were retrieved
from RCSB Protein Data Bank (http://www.rcsb.org/pdb/home/
home.do).
RESULTS
Mutation Analysis
We ascertained 24 carefully phenotyped patients with Noonan
syndrome, who were determined to be negative for PTPN11 and
KRASmutations. The clinical features of the propositi are detailed
in Table II. Following sequencing of SOS1 and RAF1 exons
implicated in Noonan syndrome pathogenesis, we identified two
novel heterozygous mutations, c.1430A>G (p.Q477R) and
c.1490G>A (p.R497Q), and two previously described mutations,
c.806T>C (p.M269T) and c.2104T>C (p.Y702H) [Tartaglia
et al., 2007; Zenker et al., 2007] in SOS1, and one knownmutation,
c.781C>T (p.P261S), inRAF1 [Pandit et al., 2007; Razzaque et al.,
2007] (Table III). It is noteworthy that both SOS1 p.R497Q and
RAF1 p.P261S mutations were present in the same patient. Muta-
tions p.M269T and p.Q477R were de novo, while p.R497Q and
p.Y702H were inherited. Segregation tests were run on every
propositus-parent group with a set of highly polymorphic micro-
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satellites, confirming paternity in every instance (data not shown).
The patients also underwent a mutational analysis of GRB2, a gene
encoding an adaptor protein with the function of recruiting and
activating SOS1 [Benfield et al., 2007], which has never been shown
tobe implicated inNoonan syndromeso far.GRB2wasnot found to
be mutated in the analyzed patients.
The SOS1 p.M269Tmutation was identified in Patient 2. This is
an already described pathogenetic variant [Zenker et al., 2007]
affecting a residue, which, if mutated, leads to increased levels of
RAS-ERK activation [Roberts et al., 2007]. The SOS1 p.Y702H
mutation, carried by Patient 8 and her mother, is also a known
change deemed as pathogenetic [Tartaglia et al., 2007; Zenker et al.,
2007].
Of the two novel mutations, the SOS1 p.Q477R change,
identified in Patient 7, is a non-conservative substitution and
affects a conserved amino acid. The same residue was found to be
mutated in a patient carrying the p.Q477H/P478L variants [Zenker
et al., 2007].
The secondnovelmutation,SOS1p.R497Q,was found inPatient
1, who turned out to bear also the known pathogenetic RAF1
p.P261S variant. This is the first instance of a Noonan syndrome
patient harboring mutations in two genes of the Ras-MAPK
pathway. In addition, Patient 1’s father and paternal grandfather
were found to share with the propositus the same SOS1 mutation
and to carry some cutaneous anomalies, typically observed in SOS1
mutated patients. DHPLC analysis on 300 control chromosomes of
unaffected individuals with matched geographic origin revealed
that the p.R497Q sequence variant is a private mutation in this
family. These findings prompted us to carry out functional studies
to characterize the p.R497Q mutation and to assess whether this
variant could contribute to Patient 1’s phenotype.
Functional Studies of SOS1 p.R497Q
Toinvestigatewhether theSOS1p.R497Qvariantcanactivate theRas
pathway, we transfected HEK293 cells with the wild type human
TABLE III. SOS1 and RAF1 Mutations
Patient Gene Mutation Inheritance
1 SOS1 c.1490G> A R497Q Familial
1 RAF1 c.781C> T P261S De novo
2 SOS1 c.806T> C M269T De novo
7 SOS1 c.1430A> G Q477R De novo
8 SOS1 c.2104T> C Y702H Familial
FIG. 1. Erk activation assay. A: hSOS1 (SOS WT) or M269R or R497Q together with HA-ERK1 were expressed in HEK293 cells. Cells were serum starved
and then stimulated with EGF (20 ng/ml) for the time indicated. HA-ERK1 was immunoprecipitated with anti-HA antibodies and the level of
phosphorylated ERK1 (A, upper row) and HA-ERK1 (A, middle row) in the immunoprecipitates was detected with pERKs and HA antibodies,
respectively. The level of the different SOS1 constructs was detected in total cell extracts with antibodies against SOS1 (A, bottom row). A
representative time course experiment is shown. B: Quantification of relative pERK1 level after normalization with HA-ERK1 intensity in the
immunoprecipitates. The quantification was done on three independent experiments and the data are expressed as fold increase over the basal
(unstimulated) condition for each SOS1 construct. Error bars represent SD, *P< 0.05 compared to the SOS1 wild type condition at 10min of
stimulation.
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SOS1, the mutant isoform p.M269R, previously reported to activate
the Ras-Erk pathway [Roberts et al., 2007], or the new p.R497Q
mutant. In Figure 1, we show that, after epidermal growth factor
(EGF) stimulation, the p.M269R mutant significantly activates Erk
signaling, as expected, while the p.R497Q substitution does not
induce Erk1 phosphorylation above the level of the wild type
(Fig. 1). As SOS1 is also involved in Rac1 pathway signal transduc-
tion,we sought todeterminewhether thispathwaymight be affected.
HEK293 cells transfected with the p.R497Q plasmid showed activat-
ed Jnk, after stimulation with EGF. On the contrary, Jnk is not
significantly activated under EGF stimulation in cells transfected
either with the wild type SOS1 or the p.M269R mutant (Fig. 2).
Structural Analysis of the SOS1 p.R497Q Variant
Inorder to characterize theSOS1p.R497Qmutant fromastructural
point of view, we performed a bioinformatic study. Conservation
analysis revealed that SOS1p.R497 is highly conserved in evolution,
from insects to Homo sapiens. The only exception is in worms,
where there is a conservative substitution fromarginine tohystidine
(Fig. 3A).
p.R497 lies within the PH domain of SOS1; based upon the
crystal structure of SOS1 PH-DH-cat domain (Protein Data Bank
entry 1XD4), it is oriented towards the outside of the protein and
face in the same direction as p.R552. Sondermann et al. [2005]
provided evidence, by means of a combined approach exploiting
computational docking, X-ray scattering and binding assays, that
p.R552 interacts with two aspartic residues (p.D140 and p.D169) of
SOS1 histone fold (HF) domain, whose crystal structure was
independently determined (Protein Data Bank entry 1Q9C). The
p.R552Gmutation resulted in increased and prolonged Ras activa-
tion and also in augmented pErk levels, and this effect is likely to be
caused by the disruption of p.R522 interaction with p.D140 and
p.D169 [Tartaglia et al., 2007].
We therefore wondered if p.R497 could also interact with a
negatively charged residue of SOS1 HF domain. According to the
validated docking model of HF domain onto DH-PH-cat domain,
p.R497 is located opposite to p.D174 in HF domain (Fig. 3B)
[Sondermann et al., 2005]. p.D174 is also a very conserved residue,
except in Caenorhabditis elegans, where, based on multiple align-
ments, there is glutamate [Innocenti et al., 2002]. The presence of
the two conservative substitutions p.Q174D and p.H497R in C.
elegans is suggestive of a functional interaction between the two
residues. The analysis of amino acids interactions, carried out by
means of HBPLUS 3.0 and LIGPLOT 4.4.2 programs, predicts that
p.R497 andp.D174 interact via hydrophobic bonds (see supporting
information which may be found in the online version of this
article). The analysis of themutated residue shows that p.Q497may
still hydrophobically interactwithp.D174but, unlike p.R497, it also
forms a hydrogen bond with p.M496 (Fig. 3C, and see supporting
information which may be found in the online version of this
article). This might lead to a conformational change of the sur-
FIG. 2. Jnk-activation assay. A: hSOS1 (SOS WT) or M269R or R497Q together with HA-JNK were expressed in HEK293 cells. Cells were serum starved
and then stimulated with EGF (20 ng/ml) for the time indicated. Ha-JNK was immunoprecipitated with anti-Ha antibodies and the level of
phosphorylated JNK (A, upper row) and HA-JNK (A, middle row) in the immunoprecipitates was detected with pJNK and HA antibodies, respectively.
The level of the different SOS1 constructs was detected in total cell extracts with antibodies against SOS1 (A, bottom row). A representative time
course experiment is shown (B) quantification of relative pJNK level after normalization with HA-JNK intensity in the immunoprecipitates. The
quantificationwas assayed on three independent experiments and the data is expressed as fold increaseover the basal (unstimulated) condition for
each SOS1 construct. Error bars represent SD, **P< 0.001 compared to the unstimulated condition for the same SOS1 construct.
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rounding region, altering the interaction between the HF and the
DH-PH domains, with a deleterious effect on the correct function-
ing of the protein.
DISCUSSION
We carried out the sequence analysis of SOS1, RAF1, and GRB2
genes in a cohort of 24 patients affected with Noonan syndrome,
previously found to be negative for PTPN11 and KRASmutations.
We found one patient with mutated RAF1 and four patients with
mutated SOS1, two of whom showing a new mutation (p.Q477R
and p.R497Q, respectively). Interestingly, this latter was inherited
and was present in the propositus, who also carries the identified
RAF1mutation, and in two unaffected relatives showing a peculiar
abnormal cutaneous phenotype. No GRB2 variants have been
identified.
The SOS1 p.Q477R change, identified in Patient 7, is a non
conservative substitution and affects a conserved amino acid. The
same residue was found to be mutated in a patient carrying the
p.Q477H/P478L variants [Zenker et al., 2007]. Together, these
findingsmight indicate thatp.Q477 is important for SOS1 function,
even if the amino acid is located in a PH domain loop, whose
function is unknown [Zenker et al., 2007].
The known p.Y702H SOS1mutation [Tartaglia et al., 2007] was
identified in Patient 8 and hermother, who had amedical history of
transitory GH deficiency treated with hormone replacement and
delayed puberty and was treated with replacement therapy. After
genetic counseling, it was agreed to extend the analysis to the
maternal uncle, born with cryptorchidism, and to both maternal
grandparents. The uncle and the maternal grandfather both har-
bored the p.Y702H mutation. The propositus’ family members
carrying the SOS1 mutation showed a subclinical Noonan syn-
drome phenotype, including facial features and medical history of
delayed puberty in all members, cryptorchidism in the uncle and
short stature as well as GH deficiency in the mother. This observa-
tion underlines the occurrence of milder phenotypes related to
SOS1 mutations. Subclinical phenotypes have previously been
reported in PTPN11 and SOS1 mutation carriers [Tartaglia
et al., 2007] that are usually parents diagnosed after their progeny
expressing the full phenotype.
Patient 1 was unusual in that he showed both a SOS1 and aRAF1
variant. This is the first instance of a Noonan syndrome patient
harboring mutations in two genes of the Ras-MAPK pathway.
The p.P261S RAF1mutation has been previously demonstrated
to increase RAF1 kinase activity downstream of EGFR in an
experimental cell model and is likely to be responsible for the
FIG. 3. Bioinformatic analysis of p.R497Q. A: Multiple sequence alignment of Sos1 orthologs, in the region surrounding p.R497 (black rectangle), as
computedbyClustalX2.0.6. B: Three-dimensional dockingmodel of SOS1HFdomain (PDB1Q9C, black) ontoSOS1PH-DH-cat domain (PDB1XD4, light
gray), showing the interaction between p.R497 and p.D174. C: Prediction of p.R497Q consequences. The PH domain p.R497 residue (light gray) is
predicted to contact theHFdomain p.D174 (black) via hydrophobic interactions. Themutated p.Q497 (dark gray) forms an additional hydrogen bond
with the flanking p.M496 (dashed line), which should cause a local conformational change affecting the interaction between PH-DH-cat and HF
domains. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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Noonan syndrome phenotype observed in the patient [Pandit et al.,
2007].
Patient 1, his father and the paternal grandfatherwere also found
to carry the novel SOS1 sequence variant p.R497Q. The lack of this
variant in a matched control population suggests that it is likely a
private mutation segregating within the family. The presence in the
propositus and in the two relatives of cutaneous anomalies peculiar
to SOS1mutated patients [Tartaglia et al., 2007] raised the hypoth-
esis that this substitution might have contributed to these ectoder-
mal features.
SOS1 functions as aGEF for bothRas andRac1. SOS1maybeRas
-specific, leading to Erk and Jnk activation, when alone or in
association with GRB2, or be Rac1 specific, causing Jnk activation
alone, when in complex with Eps8 and E3b1. SOS1 is therefore
involved in two separate and differentially regulated RTK initiated
signaling cascades [Innocenti et al., 2002; Khandhay et al., 2006].
The p.R497Q construct showed an increased activation of Jnk in
EFG-stimulated HEK293 cells, while wild type SOS1 and the
Noonan syndrome associated p.M269R mutant did not. As
p.R497Q substitution induces Erk1 phosphorylation to levels
comparablewith those inducedby thewild type (Fig. 1),wepropose
that the SOS1 p.R497Q mutation particularly affects the Rac1-Jnk
pathway, differently from the Ras-activating p.M269R mutation.
The in silico structural analysis suggests that the SOS1 p.R497
residue is important for the interaction between theHF and theDH
-PH domains. The p.R497Q mutant is likely to alter this function
and, unlike what has been seen for other SOS1mutations, it might
be that this variant affects only the regulation of the DH-PH
domain, which is known to be responsible for Jnk activation
through Rac1 stimulation [Nimnual et al., 1998], but not the
activity of the Rem-Cdc25 catalytic domain, which serves as
guanine nucleotide exchange factor for Ras, possibly explaining
why this mutation leads to Jnk but not Ras activation.
Within family 1 (Fig. 4), only the propositus, carrier of both
SOS1 p.R497Q andRAF1 p.P261Smutations, is consistent with the
diagnosis of Noonan syndrome. He displays a classic phenotype,
including the characteristic facial features (Fig. 4). Additionally, he
showed cutaneous xerosis and keratosis pilaris, a cafe-au-lait spot
on the abdomen, hypertrichosis, left foot fifth finger overlapping
the fourth finger and a mild thorax deformity. His cardiac pheno-
type was also consistent, and included pulmonary valve stenosis,
HCM, andmitral valve prolapse.RAF1mutations affecting theCR2
domain, like p.P261S, are thought to be frequently associated with
HCM [Pandit et al., 2007]. The finding of hyperpigmented cuta-
neous lesions inRAF1mutatedNoonan syndromepatients includes
multiple nevi, lentigines and cafe-au-lait spots. On the other hand,
Patient 1 also displays uncommon features in RAF1 mutated
patients, such as keratosis, hypertrichosis and left foot fifth finger
overlapping the fourth one (Fig. 4).
SOS1mutated patients typically have ectodermal abnormalities,
normal stature, and normal mental development [Tartaglia et al.,
2007]. In the relatives of Patient 1 who carry the private SOS1
p.R497Q mutation, we identified some ectodermal abnormalities.
A recently published mutational study on a different cohort de-
FIG. 4. Pedigree and clinical features of family 1: the black box indicates the fully penetrant Noonan syndrome phenotype in the propositus; gray boxes
indicate mild phenotype in his father and in his grandfather. A: Grandfather: keratosis pilaris on the trunk, left foot fifth finger overlapping the fourth
finger. B: Father:mildly lowset and posteriorly rotated ears, high arched and thick eyebrows, thick and prematurelywhite hair, keratosis pilaris of the
neck. C: Propositus: characteristic Noonan syndrome facial features, left foot fifthfinger overlapping the fourth finger, as observed in his grandfather,
keratosis pilaris.
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scribed a similarly looking keratosis pilaris rubra and additional
ectodermal features in a Noonan patient with a de novo SOS1
p.K170R mutation [Denayer et al., 2010].
Thepropositus’ fatherhasno clinical signs ofNoonan syndrome,
as determined by careful physical and dysmorphologic exam, with
the exception of mild lowset and posteriorly angulated ears, and
high arched and thick eyebrows (Fig. 4). Echocardiography showed
a borderline enlargement of the ventricular septum, which was
determined to be within range of normal upon further evaluation
by chest magnetic resonance. The father, however, displayed a
cutaneousphenotype characterizedby thick andprecociouslywhite
hair, since 20 years of age, and by keratosis pilaris of the neck skin
(Fig. 4). The grandfather of Patient 1, who also carries the SOS1
variant, has no clinical signs of Noonan syndrome. His heart is
normal examination by echocardiogram and electrocardiogram.
Like Patient 1, he has a left foot fifth finger overlapping the fourth
(Fig. 4). Multiple keratosis is also present on the chest. Both the
propositus and the family members carrying the SOS1 mutation
showed normal stature and normal mental development.
Although the full Noonan syndrome phenotype is clearly deter-
mined by the RAF1 p.P261S mutation in Patient 1, it seems
reasonable to hypothesize that the SOS1 p.R497Qmutation, which
we showed to activate the Rac1-Jnk pathway, have concurred in
determining the cutaneous anomalies also shared by his father and
grandfather, acting as amodifier gene for thepropositus phenotype.
It is worth noting that the activation of Jnk, through Rac1
pathway, might be related to the peculiar ectodermal phenotype
exhibited by some patients carrying a SOS1 mutation, raising the
possibility that some phenotypic characteristics of SOS1mutation
carriers may also be determined by alternative pathways and not
only by the canonical Ras pathway. Interestingly, Rac1 has been
reported to regulate the epidermal stem cell compartment, and
conditional epidermal deletion of Rac1 in mice generates an early
phenotype characterized by thickening of the interfollicular epi-
dermis with increased numbers of living and cornified cell layers
and expansion of the infundibulum [Benitah et al., 2005]. On the
basis of these findings we speculate that the abnormal cutaneous
traits, oftenexpressed inSOS1mutatedNoonan syndromepatients,
may be exacerbated by the concurrent activation of the Rac1-Jnk
pathway besides the Ras-Erk1 pathway. As a cautionary note, the
apparent incomplete penetrance reported for some SOS1 alleles
present in the undiagnosed parents of some patients [Tartaglia
et al., 2007; Zenker et al., 2007], might represent another known or
unknownmutated gene that is the real cause of Noonan syndrome.
In addition, the expression of atypical traits in the contest of a
classical Noonan phenotype might be explained by the co-occur-
rence of differentmutations in genes belonging to theRas-Erk1 and
related signalingpathways, onemajorpathogenetic variant, causing
per se the onset of the Noonan phenotype, and one minor variant,
that in such cases should act as modifier to the overall phenotype,
constituting a possible mechanism which contributes to the highly
variable expressivity of the syndrome. Although our hypothesis
needs to be substantiated by other similar cases, this may illustrate
the importance of a re-evaluation of the functional significance of
SOS1 variants that do not cause an overt Noonan syndrome
phenotype, extending the mutation screening to the other patho-
genetic genes, addressing genotype–phenotype correlation studies
that will ultimately improve genetic counseling and molecular
diagnosis of Noonan syndrome.
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Abstract 
 
Bidirectional long-term plasticity at the cortico-striatal synapse has been proposed as a central 
cellular mechanism governing dopamine (DA)-mediated behavioral adaptations in the basal ganglia 
system. A fine balance between the activity of medium spiny neurons (MSNs) of the direct and of 
the indirect striatal pathway is essential for normal striatal function. This balance is disrupted in 
Parkinson’s disease (PD) and in L-DOPA induced dyskinesia (LID), a common motor complication 
of current pharmacotherapy. Here we show that the Ras-ERK pathway, a signal transduction 
cascade previously implicated in behavioral plasticity, is essential for the induction of high 
frequency stimulation long-term potentiation (HFS-LTP) in the dorsal striatum but it is not needed 
for establishing long-term depression (HFS-LTD). In addition, in a mouse model, ablation of Ras-
GRF1 a neuronal specific activator of Ras proteins, causes a specific loss of HFS-LTP in the direct 
pathway MSNs, without affecting LTP in the indirect pathway. Furthermore, synapses of 6-OHDA 
unilaterally lesioned animals rendered dyskinetic with a repeated L-DOPA treatment cannot be 
depotentiated from a potentiated state to baseline levels, but in the Ras–GRF1 KO animals this form 
of synaptic plasticity is partially restored. These data demonstrate a central role for Ras-ERK 
signaling in striatal LTP and support at the cellular level, previous observations indicating that 
targeting of Ras-GRF1 and ERK may result in a significant attenuation of LID. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction  
Changes in the synaptic efficacy at the cortico-striatal synapse are believed to be central not only 
in the regulation of normal cellular functions of the basal ganglia system but also in pathological 
conditions such as Parkinson’s Disease (PD) and motor complications associated to prolonged 
dopamine (DA) replacement pharmacotherapy using L-DOPA or dopaminergic agonists (L-DOPA 
induced Dyskinesia, LID) (1-5). The synaptic correlates of these behavioral alterations most 
frequently studied in recent years are long-term potentiation (LTP) and long-term depression 
(LTD) in the dorsal striatum. Bidirectional synaptic plasticity can be induced in most medium 
spiny neurons (MSNs), the largest neuronal population of the striatum. MSNs are believed to 
consist of two distinct populations, the striatonigral (direct) pathway and the striatopallidal 
(indirect) pathway, which predominantly express dopamine (DA) D1-like and D2-like receptors, 
respectively. LTP and LTD can both be induced using repeated high frequency stimulation (HFS) 
protocol at 100 Hz. In order to induce LTP rather than LTD either magnesium (Mg2+) is removed 
from the extracellular medium or the neuron is depolarized to more positive potentials to allow 
stronger activation of glutamate NMDA receptors (1, 6-8). Importantly, while HFS-LTD seems to 
be dependent on both D1 and D2 receptors, HFS-LTP induction requires D1 receptors but it is 
blocked, most likely through an indirect mechanism, by D2 receptors antagonists. Both forms of 
long-term plasticity are lost in DA depleted experimental models, such as the unilateral 6-
hydroxydopamine (6-OHDA)-lesion system, and they can be promptly restored in chronically L-
DOPA administered animals. Two recently identified synaptic alterations have been specifically 
linked to abnormal involuntary movements (AIMs), the rodent correlate of LID. Firstly, striatal 
slices from highly dyskinetic animals fail to depotentiate, a condition normally obtained when a 
low frequency stimulation (LFS) protocol is applied after the induction of HFS-LTP (9, 10). 
Secondly, HFS-LTD cannot be restored in highly dyskinetic animals, unless phosphodiesterase 
(PDE) inhibitors are administered. PDE treatment also reduces LID formation (11). 
In recent years, the availability of transgenic mice expressing green fluorescent protein 
(GFP) under the control of BAC transgenes, has allowed several groups to specifically record, 
from individual MSNs belonging to either the striatonigral pathway or the striatopallidal pathway 
(12). Using this technology Surmeier’s group performed a number of studies using whole cell 
voltage-clamp recordings inducing different forms of synaptic plasticity, including a HFS-LTD 
protocol coupled to depolarization as well as spike-timing-dependent plasticity (STDP)(13, 14). In 
marked contrast with previous findings a study using HFS-LTD showed that this form of plasticity 
could only be induced in indirect-pathway MSNs (identified using BAC transgenic mice 
expressing EGFP under the D2R promoter) but not in direct pathway MSN (shown by means of 
M4-EGFP transgenic mice), (15). However, a more recent study suggests that the apparent lack of 
LTD in direct pathway detected in could be due to the electrophysiological abnormalities intrinsic 
to the D1-EGFP transgenic mice (16), shown by recordings in both EGFP-positive and EGFP-
negative MSNs of these BAC transgenic mice . 
At present, although intracellular mechanisms underlying synaptic plasticity in the dorsal striatum 
have been extensively investigated in physiological and pathological condition (5), little is known 
about the specific role of Ras-ERK signaling. This evolutionarily conserved signaling cassette has 
been implicated in a number of important cellular responses, including memory formation, synaptic 
plasticity and behavioral adaptations in the central nervous system, as well as in cell proliferation 
and survival in most cell types (17-24). In the striatum, the Ras-ERK pathway has been shown to 
control instrumental learning and memory, responses to drugs of abuse and to chronic L-DOPA in 
experimental models of LID (25-36) (37). Surprisingly, to date the role of Ras-ERK in cortico-
striatal plasticity has not been assessed; neither in normal conditions or in DA depleted animals 
subjected to chronic L-DOPA administration. Moreover, little attempt has been made to correlate 
changes in cellular plasticity in the dorsal striatum with behavioral alterations in experimental 
animal models of PD and LID. Here we show that ERK signaling is crucial in the induction of HFS-
LTP at the cortico-striatal synapse but it is not required for HSF-LTD. In addition, we identified a 
crucial brain specific component of this pathway, Ras-GRF1, which specifically modulates LTP in 
the direct striatal pathway and controls both LID onset and expression in both murine and non 
human primate (NHP) models of PD. 
 
 
Results 
ERK signaling is necessary for HFS-LTP at the cortico-striatal synapse. Recent evidence 
indicates that the Ras-ERK signaling pathway in the dorsal portion of the striatum is abnormally 
activated in responses to both drugs of abuse and L-DOPA (23, 38). Thus, hyperactivation of this 
signaling cascade may represent a key pathological factor for both drug addiction and LID, two 
conditions both relying on abnormal DA adaptations in the basal ganglia system. In particular, we 
recently showed that Ras-GRF1, a neuronal specific GDP/GTP Ras-exchange factor, plays a 
crucial role in the regulation of ERK mediated cellular and behavioral responses to 
psychostimulants, by sensing and integrating DA and glutamate (GLU) signaling in the striatum. 
In addition, Ras-GRF1 inhibition, both in murine and NHP models of LID, significantly improves 
the behavioral symptoms linked to repeated L-DOPA administration (30, 36). Thus, in order to 
identify the synaptic correlates of the observed behavioral responses in MSNs we investigated the 
role of Ras-GRF1 and ERK signaling in long-term plasticity at the cortico-striatal synapse. 
We first used extracellular field recordings on wild-type (WT) slices exposed to the MEK 
inhibitor U0126 (which blocks ERK signaling). This treatment did not affect basal synaptic 
responses which were consistent within a whole range of stimulus intensities (Fig. 1A: treatment 
effect, two way ANOVA, p>0.05). When HFS was delivered in the presence of physiological 
Mg2+ concentration, robust LTD was induced in both controls and U0126 treated slices (Fig. 1B: 
time effect, two way ANOVA, p<0.0001). Lack of U0126 effect was further confirmed by 
analyzing the mean amplitudes of 60 min post tetanic LTD (Fig1C: DMSO=69.58±2.5, 
U0126=74.03±3.5, Student’s t test, p>0.05). Interestingly, in the absence of magnesium, while 
HFS-LTP was efficiently induced in the control slices, this form of long-term plasticity was 
completely abolished by the pre-treatment with U0126 (Fig.1D: treatment effect, two way 
ANOVA, p<0.0001). Analysis of the post tetanic mean amplitudes (60min) further confirm the 
effect of U0126 treatment (Fig. 1E: DMSO=102.6±3.5, U0126=166±10.2, Student’s t test, 
p<0.0001). We obtained the same result using intracellular recordings where LTP induction in all 
recorded cells was abolished by 5µM U0126 treatment (Supplementary Fig 1A: time effect two 
way ANOVA, P>0.05, supplementary Fig 1B). Finally, when U0126 was applied 20 minutes after 
tetanus, it did not affect LTP expression (Fig. 1F: LTP pre= 178.4±16.1 vs. post=180.47±16.3 
U0126 application, Student’s t test, p>0.05). Altogether, these data indicate that ERK signaling is 
necessary for the induction of HFS-LTP in the dorsal striatum but it is not required either for LTP 
expression, for HFS-LTD and for basal synaptic transmission.  
Ras-GRF1 controls HFS-LTP in the striatonigral pathway. The data above suggest a specific 
role for ERK signaling in the induction of HFS-LTP but does not necessarily implicate Ras-GRF1 
in the striatal synaptic plasticity. In order to address this point, we performed electrophysiological 
recordings using intracellular sharp electrodes in slices from WT and Ras-GRF1 KO mice (6, 7, 
39). With physiological Mg2+ concentrations in the medium, HFS of cortical afferents induced a 
normal LTD in both WT and mutant mice (Fig. 2A: LTD time effect, two way ANOVA, p<0.001). 
Analysis of the 40 min post tetanic mean amplitudes confirm the lack of genotype effect (Fig. 2B: 
WT=60.3±4.3, Ras-GRF1 KO=58.3±6.1, Student’s t test, p>0.05). However, when Mg2+ was 
removed to unblock NMDA receptors, the same HFS protocol reliably induced LTP of cortico-
striatal synaptic transmission in WT mice, whereas approximately 50% of the striatal MSNs 
recorded from Ras-GRF1 KO mice did not potentiate (Fig. 2C: group effect, two way ANOVA, 
p<0.001). Comparison of the 40 min post tetanic mean amplitudes indicate that only one 
subpopulation of Ras-GRF1 KO MSNs significantly lack LTP (Fig. 2D: WT=143.0±4.52, Ras-
GRF1 first population=160.5±4.52, Ras-GRF1 second population=95.2±4.57)(WT vs. Ras-GRF1 
second population, Student’s t test, p<0.01; Ras-GRF1 KO first population vs. Ras-GRF1 KO-
second population, p<0.001). These data confirm that ERK signaling in the dorsal striatum is 
necessary for HFS-LTP but not for HFS-LTD and also indicate that Ras-GRF1 is likely to play a 
role in a specific subset of MSNs.  
Since we have previously established that the Ras-GRF1 is equally expressed in both 
striatonigral and striatopallidal MSNs, the pathway-specific involvement of Ras-GRF1 in LTP is 
likely due to its specific engagement by a subclass of these striatal cells (36). In order to clarify 
which subpopulation of MSNs is affected by the loss of Ras-GRF1, we took advantage of two types 
of bacterial artificial chromosome (BAC) transgenic mice expressing enhanced green fluorescent 
protein (EGFP) specifically in striatonigral or striatopallidal MSNs; M4-EGFP mice (striatonigral 
neurons, direct pathway) and adenosine receptor A2A-EGFP mice (striatopallidal neurons, indirect 
pathway) (12). In order to study the role of Ras-GRF1 in the two different subpopulations of MSNs 
we combined these BAC transgenic mutants with Ras-GRF1 KO mice, to obtain double mutants 
(M4-EGFP/Ras-GRF1-KO and A2A- EGFP/Ras-GRF1-KO).We first performed whole cell patch 
clamp recordings from M4-EGFP and A2A-EGFP single transgenics, to ensure that LTP could be 
reliably induced in  EGFP positive and EGFP negative cells in both transgenic lines. For this 
purpose, cells were visualized with a microscope with fluorescent and infrared imaging systems. 
Only cells with electrophysiological and morphological features typical for MSN were recorded. 
Fluorescent dye Alexa 594 was icluded in the patch pipette to allow the visualization of cell 
morphology during and after recordings (Fig. 3A and 3B). 
We were able to induce a robust LTP, with the similar amplitude and time course,  in the 
both fluorescent and non fluorescent MSNs from M4-EGFP mice (Fig. 3C: time effect, two way 
ANOVA, p<0.0001) (Fig. 3D: direct pathway MSNs=181.1± 4.1% vs. indirect pathway 
MSNs=187.4±14.5%, Student’s t test, p>0.05). Similarly, A2A-EGFP mice also showed robust 
LTP in both cell populations (Fig. 3E: time effect, two way ANOVA, p<0.0001) (Fig.3F: Direct 
pathway MSNs=172.3±14.7% vs. indirect pathway MSN=177.3±15.4%, Student’s t test, p>0.05). 
On the other hand, when we subsequently recorded in slices obtained from M4-EGFP/Ras-GRF1 
KO double mutants, LTP could only be induced in striatopallidal /indirect pathway MSNs (Fig. 3G: 
group effect, two way ANOVA, p<0.001) (Fig.3H: direct pathway MSNs=93.1±3.9% vs. indirect 
pathway MSNs=178.4±15.2%, Student’s t test p<0.001). As a further confirmation that Ras-GRF1 
is essential for LTP in the striatonigral MSNs, we also recorded from A2A-EGFP/Ras-GRF1 KO 
double mutants (Fig. 3I: group effect, two way ANOVA, p<0.0001) (Fig. 3J: direct pathway, 
MSNs=93.11±3.9% vs. indirect pathway MSNs=178.4±15.2%, Student’s t test, p<0.0001). This 
finding provides evidence of the selective involvement of Ras-GRF1 in the control of HFS-LTP in 
the direct striatal pathway.  
To further clarify the role of ERK and Ras-GRF1 in HFS-LTP induction we used 
immunofluorescence on acute cortico-straital slices to measure directly the phosphorilation levels of 
ribosomal protein 6S (p-6S), which is phosphorylated downstream of ERK, in response to HFS 
protocol. Phosphorilation levels were significantly higher in stimulated slices compared to controls 
(Supp. Fig 2. E:  HFS stimulated= 29.54±3.34%   vs. non stimulated slice= 11.05±3.15% of p-S6 
positive neurons over total number of neurons; Student’s t test, P<0.001). In the other hand in Ras-
GRF1 KO, the increase in S6 phosporilation was attenuated but still significant(HFS 
stimulated=19.10±6.05% vs. control=8.78±4.2% Student’s t test P<0.05). Furthermore we showed 
that the pre-treatment with 5µM U0126 prevents the increase in phosphorilation of S6 in response 
to HFS protocol, as expected ( Suplementary fig 2E: 6.7±3.2% of p-S6 positive cells over total 
number of NeuN pos cells ). 
 We used the same EGFP expressing mice, as in previous experiment, to distinguish 
between two different pathways. Even though the increase in p-S6 was significant in both pathways, 
the levels of p-S6 in the indirect pathway were substantially higher, either in basal conditions or 
after HFS stimulation (Supplementary fig 2 F,G: direct pathway, control 4.34±1.01%  vs. HFS 
8.71±1.49% stimulated P<0.01: indirect pathway control,  control 18±5.09%   vs. HFS  41±7.05% 
P<0.01; percentages are expressed as number of p-S6 positive cells over number of cells in direct or 
indirect pathway). Interestingly in M4-EGFP/Ras GRF1 KO mice only indirect pathway neurons 
showed significantly increased levels of p-S6 after HFS (Suppelementary fig 2 F,G: control  
3.02±1.10% vs. HFS 3.5±1.02 P>0.05; 18±5.09)  
 
Ras-GRF1 controls DA-mediated adaptations in the murine model of LID. Parkinson’s disease 
(PD) is a neurodegenerative disorder characterized by a slow and inexorable loss of substantia nigra 
pars compacta dopaminergic neurons and by an ensuing depletion of dopamine (DA) input to the 
striatum. DA replacement therapy, using the DA precursor L-DOPA, has been and remains the most 
effective treatment for PD, but its prolonged use is associated with a series of complications 
including motor fluctuations and abnormal involuntary movements (AIMs), also termed L-DOPA 
induced dyskinesia (LID), which can become treatment-limiting over time (40-43). Considering the 
central role played by Ras-GRF1 and ERK signaling in HFS-LTP, we then assessed the possibility 
that this intracellular pathway may be implicated in LID formation and in synaptic alterations in 
response to both DA depletion and replacement with L-DOPA. We first generated a unilateral 6-
hydroxydopamine (6-OHDA) lesioned model of PD and LID by injecting the neurotoxin into the 
right medial forebrain bundle of both Ras-GRF1 KO mice and littermate controls. Two weeks after 
surgery, we measured spontaneous ipsilateral rotations as an efficacy index of the lesion. The 
rotational behavior was similar in the two genotypes (Supplementary Fig 3A: 6-OHDA 
WT=24.7±1.4 vs. 6-OHDA Ras- GRF1 KO=28.1±2.5 turns/10 min, Student’s t test, p>0.05), 
suggesting an equivalent sensitivity to the neurotoxic damage .  
To elicit axial, limb, and orolingual AIMs, a validated model of LID in mice, we administered an 
ascending dose regimen of L-DOPA (1.5, 3, 6 mg/kg, twice daily) to both 6-OHDA-lesioned WT 
and Ras-GRF1 mutant animals for 9 consecutive days (36). Daily scoring of AIMs revealed a 
gradual development of dyskinetic symptoms in both genotypes, which affected the trunk, limb and 
orolingual regions on the side of the body contralateral to the lesion. However, for all doses of L-
DOPA, the AIMs scores were significantly reduced in Ras-GRF1 KO mice in comparison to their 
littermate controls (Supplementary Fig 3B: genotype effect, two way ANOVA,  p<0.001). Analysis 
of the cumulative AIMS over the 8 days time period confirm a significant reduction of LID in the 
Ras-GRF1 KO animals (Supplementary Fig 3C: WT + L-DOPA=42.6±3 vs. Ras-GRF1 KO + L-
DOPA=25.6±6.7, Student’s t test, p<0.05). These results are consistent with our previous data 
showing that the absence of Ras-GRF1 strongly attenuates LID induction in mice (36).  
At the electrophysiological level, following 6-OHDA lesion, all MSNs recorded either from 
WT or from Ras-GRF1 KO mice lost the ability to show LTP, an expected consequence of DA 
denervation (Fig. 4D) (Fig. 4E: mean 40 min after tetanus EPSP as % of control, WT=89.3±5.0 vs. 
Ras-GRF1 KO=86±8.1, Student’s t test, p>0.05) (6, 8). Chronic L-DOPA treatment has been shown 
to rescue LTP in DA-denervated animals but, concomitantly with the development of AIMs, 
depotentiation is occluded (9). We next examined the induction of LTP and its reversal by LFS in 
slices from Ras-GRF1 KO mice and WT littermates with 6-OHDA lesions and given chronic L-
DOPA treatment. As indicated in Figure 4B, Ras-GRF1 KO mice showed significantly lower AIM 
scores than the control WT group. Accordingly, all MSNs recorded from the mildly dyskinetic Ras-
GRF1 KO mice displayed normal LTP after HFS, and a significant but not complete depotentiation 
of the synaptic activity upon LFS (Fig. 4F), suggesting that cortico-striatal plasticity parallels the 
low dyskinetic profile of these mutants. Conversely, while LTP was normal in the highly dyskinetic 
WT controls, depotentiation was absent (Fig 4F; Dys Ras-GRF1 KO: pre vs. post LFS, Student’s t 
test, p<0.05; Dys WT vs. Dys Ras-GRF1 KO post LFS, post hoc Bonferroni, p<0.05).  
Thus, Ras-GRF1 KO mice, which showed less dyskinetic symptoms than the control WT 
animals, not only displayed normal LTP after HFS but also showed significant depotentiation upon 
low frequency stimulation (LFS), substantially different from the dyskinetic wild type animals 
which did not depotentiate. 
Discussion 
The striatum, as a part of basal ganglia circuit, receives a complex set of inputs comprising 
excitatory afferents from the cortex and the thalamus as well as midbrain dopaminergic 
innervation (3, 44, 45). For normal striatal function different neurotransmitter inputs, receptor 
activations and intracellular signaling cascades involved in the regulation of striatal plasticity need 
to be correctly balanced. Changes at the striatal synapses controlled by ERK signaling are believed 
to be crucial for learning of procedural actions as well as for habit formation and reward 
mechanisms (21, 24). In addition, alterations of striatal synaptic plasticity are linked to 
pathological states such as L-DOPA induced dyskinesia (9), drug addiction (46) and obsessive-
compulsive disorder (OCD) (47). 
The Ras-ERK signaling pathway is activated in MSNs by a combined engagement of DA 
and glutamate receptors, making it a suitable candidate for having a regulatory role in striatal 
synaptic plasticity (21, 23, 43). Importantly, it is now well established that distinct chemical stimuli 
are able to activate ERK signaling in specific MSN subpopulations. For example, psychostimulants 
in intact animals and L-DOPA in denervated animals selectively activate the ERK cascade in MSNs 
of the direct pathway. This activation involves DA D1-like receptors which also activate DARPP-
32, a known indirect activator of ERK signaling. Conversely, ERK activation in the indirect 
pathway MSNs can be achieved by a specific blockade of D2-like receptors through the 
administration of receptor antagonists and this effect also implicate the activation of adenosine A2A 
receptors, PKA and DARPP-32 (48-50). Our own data from the current study provides an initial 
evidence of a complex role of Ras-ERK signaling in cortico-striatal plasticity which highlights 
interesting differences from the defined role in drug-dependent plasticity. Firstly, ERK is vital for 
LTP in both cellular pathways, indicating that HFS at the cortico-striatal synapse is able to 
overcome the negative effect exerted by D2 receptors on ERK activation. Secondly, the mechanism 
of ERK activation in response to HFS is distinctly different in the two cell types. In fact, in 
striatonigral MSN, LTP is Ras-GRF1 dependent while in striatopallidal MSN LTP is Ras-GRF1 
independent. This evidence is rather unexpected since we previously demonstrated that Ras-GRF1 
is expressed in both MSN subpopulations (36). One possibility is that Ras-GRF1 loss in the indirect 
pathway is either compensated by other Ras specific exchange factors or that DARPP-32 activation 
is sufficient to increase ERK activity by acting downstream in the pathway, effectively bypassing 
Ras requirements. The third aspect to be highlighted is our observation that HSF-LTD does not 
require ERK signaling. In order to support this evidence we have provided data both using a 
chemical inhibition of ERK, U0126 and using Ras-GRF1 mutant mice. In both cases, HFS-LTD is 
spared. Interestingly, this form of plasticity is instead disrupted by blocking CREB function in the 
dorsal striatum (51). Considering that ERK signaling is a major determinant of CREB 
phosphorylation and is activated in many physiological conditions, our evidence suggests a 
differential regulation of the activity of this transcription factor in HFS-LTP and HFS-LTD, the 
latter being ERK independent. In addition, since both CREB inhibition and Ras-GRF1 loss in the 
striatum result in procedural memory impairment in operant conditioning tasks, but only LTP is 
impaired in both animal models, it is possible to hypothesize that this form of long-term plasticity is 
more relevant for striatum-dependent memory formation than LTD (30, 51). 
Finally, we believe that the role of Ras-GRF1 in controlling HFS-LTP in the dorsal striatum has 
profound consequences for our understanding of the cellular mechanisms underlying L-DOPA 
induced dyskinesia. We recently published that the loss of Ras-GRF1 functions in the striatum 
significantly attenuates LID both in a murine and in a non human primate (NHP) model of this 
disease. Although our recent report suggests that the inability of cortico-striatal synapses to rescue 
LTD correlates well with a highly dyskinetic status (11), it is also conceivable, based on our 
observation that Ras-GRF1 does not play a role in HFS-LTD. Moreover, we tend to confirm that 
occlusion of the scaling down of synaptic activity (loss of depotentiation and LTD) at the cortico-
striatal synapse plays an important role in LID, since in the Ras-GRF1 mutants an almost normal 
depotentiation is accompanied by a significant attenuation of abnormal involuntary movements, the 
rodent correlate of LID. Interestingly, while L-DOPA does not cause LID in the Ras-GRF1 
mutants, it does fully restore HFS-LTP in both direct and indirect MSNs pathways. Since LTP in 
the direct pathway is absent in naïve Ras-GRF1 mutants, we suggest that some L-DOPA dependent 
mechanism may occur in this subset of MSN upon DA denervation that may bypass the Ras-GRF1 
requirement. Once again, a likely possibility is that D1 receptor sensitization in the direct pathway 
of denervated animals may be responsible for that. Altogether, our findings strongly support the 
idea that the Ras-GRF1 plays an important role in LID by regulating both LTP and depotentiation at 
the cortico-striatal synapse.  
 
Materials and Methods 
Animals. Generation of Ras-GRF1 KO mice has been prevously described (30, 39). BAC-EGFP 
mice (M4-EGFP and A2A EGFP) were originally generated by the GENSAT (Gene Expression 
Nervous System Atlas) program at the Rockefeller University (www.gensat.org).Transgenic mice 
and littermate controls were kept in C57BL/6  background  and housed under a 12 hour-light-dark 
cycle with ad libitum access to the food.  
 
Lesion Surgery. Ras-GRF1 WT (n=20) and KO (n=20) mice were anesthetized with Isofluorane 
(Baxter Medical AB, Sweden) and secured in a stereotaxic frame equipped with a mouse adaptor. 
1µl of 6-OHDA-HCL (3µg/µl) was injected into the right ascending medium forebrain bundle 
(MFB) at the following coordinates according to the mouse brain atlas: AP -0.7; L -1.2; DV -4.7 
from dural surface using a glass capillary attached to a 10µl Hamilton syringe. Severity of DA 
denervation was assessed at the end of the experiments analyzing striatal levels of tyrosine 
hydroxylase (TH) and nigral cell loss using immunohistochemical labelling. 
 
Motor impairment and AIM induction. Two weeks after lesion, mice were evaluated in the open 
field in order to estimate the success rate of lesion. Starting from day 18, they were treated twice a 
day, for 9 consecutive days with an escalating L-DOPA dosing regimen (1.5, 3, 6 mg/kg) plus 
benserazide (12 mg/kg) (Ras-GRF1 wt, n=9 and Ras-GRF1 KO, n=9) or with saline (Ras-GRF1 wt, 
n=6 and Ras-GRF1 KO, n=6). Abnormal involuntary movements were scored using a 0-4 rating 
scale according to validated mouse model of LID (36). At the end of treatment respectively (n=7) 
WT mice and (n=7) KO develops dyskinetic movements. Every morning, mice were individually 
placed in large transparent boxes and observed for 1 min  
 
Electrophysiology  
Extracellular recordings. Coronal brain slices (350µm) from 35-50d old male C57BL/6 mice were 
cut in ice-cold modified artificial cerebrospinal fluid (aCSF) containing the following (in mM): 87 
NaCl, 2.5 KCl, 1 NaH2PO4, 75 Sucrose, 7 MgCl26H2O, 24 NaHCO3, 11 D-glucose, and 0.5 CaCl2. 
Slices where then transferred into incubating chamber, submerged in a normal aCSF containing in 
mM 130 NaCl, 3.5 KCl, 1.2 NaH2PO4, 1.3 MgCl26H2O, 25 NaHCO3, 11 D-glucose, 2mM CaCl and 
constantly provided with 95%O2 and 5%CO2 at room temperature. Slices were stored in this 
condition for at least 1h before registration. During registrations, slices were transferred in a 
submerged recording chamber, perfused at a constant rate of 2ml/min with aCSF, maintained at 
constant temperature of 28-30 ºC and constantly bubbled with 95%O2 and 5%CO2. Extracellular 
field recordings of glutamate driven population spikes (PS) were obtained in the dorsolateral 
striatum using glass micropipettes filled with 3M NaCl. Stimuli were delivered via a Constant 
Voltage Isolated Stimulator (Digitimer Ltd., Welwyn Garden City, UK) through bipolar twisted 
Ni/Cr stimulating electrodes placed in the proximity of the white matter overlaying the dorsal 
striatum. Data were amplified and filtered (low filter 10Hz, high filter 3kHz) by a DAM 80 AC 
Differential Amplifier (World Precision Instruments, Sarasota, FL), and digitized at 10 KHz by a 
Digidata 1322 (Axon Instruments, Sunnyvale, CA) (Molecular Devices, Foster City, CA). LTP and 
LTD were induced by the following high-frequency (HFS) stimulation protocol: 4 trains, 1s 
duration, 100 Hz frequency, 10s inter-train interval. During LTP experiments Mg2+ ions were 
omitted from the medium and the concentration of Ca2+ ions was 2.4 mM . 
Intracellular recordings. Corticostriatal coronal slices (270-300µm thickness) were prepared from 
tissue blocks of brain from WT and Ras-GRF1 KO mice with the use of a vibratome (Leica 
VT1200S, Heidelberger, Germany). A single slice was transferred to a recording chamber and 
submerged in a continuously flowing artificial CSF (ACSF) solution (32°C, 2±3ml/min) gassed 
with 95% O2/5% CO2. The composition of the ACSF solution was (in mM): 126 NaCl, 2.5 KCl, 
1.2 MgCl2, 1.2 NaH2PO4, 2.4 CaCl2, 11 glucose and 25 NaHCO3. Intracellular current clamp 
recordings were performed to study the synaptic plasticity of striatal spiny neurons (46, 52, 53). The 
sharp electrodes were filled with 2 M KCl (30–60MΩ). An AxoClamp 2B amplifier (Axon 
Instruments, USA) was used for recordings in current clamp mode. The headstage signal was 
continuously monitored on a separate oscilloscope. Traces were displayed on an oscilloscope and 
stored on a digital system (pClamp 9, Axon Instruments, USA). For synaptic stimulation, bipolar 
electrodes were used and were located in the white matter between the cortex and the striatum. 
Mg2+ ions were omitted from the medium to better disclose the NMDA-mediated component of the 
evoked excitatory post synaptic potential (EPSP). Under this experimental condition, high 
frequency stimulation (HFS; 3 trains, 3 s duration, 100 Hz frequency, 20 s inter-train interval) of 
corticostriatal fibres was used as a long term potentiation (LTP)-inducing protocol. The same HFS 
protocol in the presence of 1.2mM Mg2+ was used to induce the long term depression (LTD) in 
striatal spiny neurons. Quantitative data on EPSP modifications induced by tetanic stimulation are 
expressed as a percentage of the controls, the latter representing the mean of responses recorded 
during a stable period (15–20 min) before the tetanus. 
Whole cell recordings. Coronal corticostriatal brain slices (300 µm thick) were transferred to a 
submerged recording chamber and constantly perfused with the ACSF at a rate of 2 ml/min. ACSF 
was constantly bubbled with the 95% O2 and 5% CO2. Cells were visualized with the 40X water 
immersion objectives using Olympus BX51WI upright microscope equipped with the reflected 
fluorescence as well as IR/DIC (infrared/ differential interference contrast) observation systems. 
Whole cell recordings were performed using borosilicate patch pipettes (6-8 MΩ) filled with a 
solution containing (in mM): 115 K-gluconate, 20 KCl, 10 HEPES, 2 MgCl2, 2 Mg-ATP, 2 Na2-
ATP, 0.3 GTP (pH 7.3). A bipolar twisted Ni/Cr stimulating electrode was used to evoke the 
responses. All patch clamp experiments were peformed in current clamp mode. For LTP 
experiments Mg2+ was removed from the bath solution and the Ca2+ was increased to 2.5 mM. After 
a stable evoked EPSP has been recorded for at least 10 min, high frequency induction protocol 
consisting of 3 trains of 1s at 100 Hz with 20 s intervals between trains was used to induce LTP. 
The stimulation intensity during HFS was transiently increased to the superthreshold levels if 
necessary. Data were acquired using a Multiclamp 700B amplifier and pClamp 10 software 
(Molecular Device), and sampled at 10 kHz with a Digidata 1322 (Molecular Device) 
 
Fluorescence imaging. During electrophysiological recordings neurons were filled, through patch 
pipette, with the fluorescent dye Alexa fluor 594 hydrazide sodium (invitrogen). Brain slices were 
post-fixed with 4% paraformaldehyde at 4ºC in phosphate buffer solution (PBS) for 20 min, and 
washed in PBS. Slices were then left overnight at 4ºC in PBS and mounted on slides using ProLong 
Gold antifade reagent (Invitrogen). Images were acquired with Leica TCS-SP2 laser-scanning 
confocal microscope. 
 
Statistical analyses.  
Electrophysiological data given in the text and in the figures are mean ± SEM of changes in the 
respective cell populations. Statistical analysis of the time courses was done using two way 
ANOVA for repeated measures, followed by Bonferroni’s test for post-hoc comparison, in the case 
interactions were significant. Paired Student’s t test was used to compare mean amplitudes of post 
HFS responses. These analyses were done using Prism 4.0 software.  
Global AIMs scores were analyzed by two way ANOVA for repeated measures and relevant 
differences within or between groups were analyzed pairwise by Tukey’s HSD test. These analyses 
were done using Statistics. 
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 Figure legends 
 
Fig. 1. Characterization of synaptic responses and long term plasticity in  striatal slices 
treated with the MEK inhibitor U0126 (extracellular recordings). (A) Application of 5µM 
U0126 had no effect on the basal transmission measured as input/output response (DMSO, n=7; 
U0126, n=7). (B) LTD induced with HFS of corticostriatal synapses in the presence of 
physiological concentration of Mg+2 was not significantly affected by  pre-incubation (20min) with 
U0126 (5µM) in the bath solution (DMSO, n=6; U0126, n=6). (C) Field amplitudes as % of 
baseline 60 min after LTD induction were not affected by the U0126 treatment. (D) HFS-LTP 
induction was blocked by the pre-treatment with 5µM U0126 (DMSO, n=7; U0126, n=7; post hoc 
Bonferroni, **p<0.001, ***p<0.0001). (E) Field amplitudes as % of baseline 60 min after LTP 
induction indicate a significant effect of U0126 treatment, ***p<0.0001. (F) U0126 (5µM) does not 
affect the LTP maintenance when applied 20 min after the HFS induction (n=4).  
 
Fig. 2. Electrophysiological analysis of the corticostriatal synaptic plasticity recorded from 
WT and Ras-GRF1 KO mice (intracellular recordings) (A) High frequency stimulation protocol 
induced a normal long term depression (LTD) in both WT and mutant mice (WT n=8; Ras-GRF1 
KO n=9; pre HFS vs. 40 min after HFS, Student’s t test, p<0.05). (B) The histogram shows the 
EPSPs amplitude as % of control, measured at 40 min after tetanus, both in WT and mutant mice  
(C) A long-lasting potentiation (LTP) was induced only in half of the striatal spiny neurons (MSNs) 
recorded from Ras-GRF1 KO mice (WT, n=5; Ras-GRF1 KO first MSNs population, n=8; Ras-
GRF1 KO second MSNs population, n=9; Ras-GRF1 KO first MSNs population vs. Ras-GRF1 KO 
second MSNs population, post hoc Bonferroni, ***p<0.001; WT vs. Ras-GRF1 KO second MSNs,  
##p<0.01, ###p<0.001). (D) The histogram shows the means of EPSP amplitude as % of control, 
for all three cell populations, Student’s t test, **p<0.01, ***p<0.001.  
 
Fig. 3. HFS-LTP is absent in the direct pathway MSNs from Ras-GRF1 KO (whole cell 
recordings). (A) Representative example of MSN filled with Alexa fluor 594 in the post processed 
slices from M4 –EGFP and (B) A2A-EGFP mice (scale bar 20 µm). (C) HFS stimulating protocol 
induced LTP in fluorescent (n=5) and non fluorescent cells (n=5) from M4-EGFP mice. (D) EPSPs 
amplitudes 40 min after HFS as % of baseline. (E) Time course of HSF-LTP in fluorescent (n=4) 
and non fluorescent (n=5) cells from A2A-EGFP mice. (F) Histogram representing the EPSP 
amplitude as % of baseline 40 min after HFS (G) In M4-EGFP/Ras-GRF1 KO LTP was blocked in 
the direct pathway (direct pathway MSNs vs. indirect pathway MSNs, post hoc Bonferroni, 
**p<0.001, ***p<0.0001) (H) EPSP amplitudes 40 min after HFS as % of baseline (direct pathway 
MSN, n=5, vs indirect pathway MSN, n=5, ***p<0.0001). (I) HFS-LTP was blocked in the direct 
pathway MSNs from A2A-EGFP/Ras-GRF1 KO (direct pathway MSNs vs. indirect pathway 
MSNs, post hoc Bonferroni, ***p<0.0001). (J) EPSP amplitudes 40 min after HFS as % of baseline 
(direct pathway MSNs, n=6 vs. indirect pathway MSNs, n=4, ***p<0.0001) 
  
Fig. 4. Analysis of LTP in Parkinsonian and dyskinetic Ras-GRF1 KO and WT mice 
(intracellular recordings). (A) The MSNs recorded from both WT and Ras-GRF1 KO mice 
lesioned with 6-OHDA lose the capability to show LTP. (B) The histogram shows the mean EPSP 
amplitude as % of control, both in WT and lesioned mutant mice. (C) L-DOPA treated Ras-GRF1 
KO mice presented a normal LTP after HFS. The subsequent LFS protocol induced a significant 
depotentiation for all (pre vs post LFS Dys Ras-GRF1 KO, Student’s t-test, #p<0.05; Dys WT (n=4) 
vs. Dys Ras-GRF1 KO (n=4), post hoc Bonferroni *p<0.05, **p<0.01, ***p<0.001).  
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Supplementary Information 
 
Methods 
 
Immunofluorescence ex-vivo. Acute slices (250µm thick) from M4-EGFP, A2A-EGFP 
or M4-EGFP-GRF1KO mice, were cut and incubated for one hour in the way described 
in the extracellular filed recordings methods section.  Using extracellular recordings, LTP 
was induced in the Mg+2 free ACSF, using HFS protocol. After the LTP induction (10 
min) slices were fixed in ice cold 4% PFA for 20 min and stored in 30% sucrose 
overnight. Controlateral slices were fixed after 20 min perfusion with Mg+2 free ACSF 
and used as controls. The following day slices were re-sliced into thinner sections (18µm) 
using the cryostat. These sections were incubated overnight with primary antibodies 
(NeuN 1:500 MAB-377, Chemicon, anti-phosphoS6 1:300, Cell Signaling or anti-
phospho (Ser10)-acetyl (Lys14)-histone H3, 1:1000, Upstate) and then 1h with the 
secondary antibody (cy3 goat anti rabbit, Jackson Immuno Research 1:200, Alexa 406  
1:200 ). Images were acquired with a Leica TCS SP2 laser scanning confocal 
microscope. We acquired 3 different fields in the proximity of the stimulation, and 3 
fields in the same position in the control, non stimulated slice. Fluorescent cells were 
counted using Image J software.  
Immunohistochemistry. Brains were perfused with 4% PFA in PBS, post-fixed and 35 
µm thick sections were cut and kept in cryoprotective solution at -20°C. Free-floating 
sections were incubated overnight at 4°C with primary antibody Phospho-p44/42 Map 
Kinase (1:200, Cell Signalling) and then incubated with biotinylated secondary antibody 
Goat anti-rabbit IgG BA-1000 (1:200, Vector Labs) for 2 hours. Tissue sections were 
further processed using Vectastain ABC kit (1:200, Vector Labs) and DAB detection. 
Quantification of p-ERK positive neurons was performed from dorsolateral striatum, in 4 
sections per mouse, bilaterally, using the Image J software. All visible positive nuclei or 
cell bodies within a field were counted and expressed as number of cells per square 
millimeter.  
Immunofluorescence post-mortem. Sections from M4- and A2A-EGFP mice were 
mounted on slides and incubated overnight with antibodies NeuN (1:1000 Chemicon) and 
anti-phosphoS6 ribosomal protein (Ser235/236) (1:200, Cell Signaling). Following 1 
hour incubation with appropriate secondary antibodies cy3 goat anti rabbit (1:200, 
Jackson Immuno Research) and Pacific Blue F(ab)2 fragment of goat anti-mouse (1:200, 
Invitrogen) slides were rinsed and incubated again with primary antibody anti GFP Alexa 
fluor 488 conjugated (1:200, Invitrogen) for 5 hours at 4°C in order to visualize EGFP-
labeled neurons.  Slides were then coverslipped with Dako fluorescent mounting medium 
(Dako) and kept at 4°C. Images were acquired with a Leica TCS SP2 laser scanning 
confocal microscope.  
 
Figure legends 
 
Supplementary fig. 1. MEK inhibitor U0126 abolishes LTP in striatal slices 
(intracellular recordings) (A) LTP was abolished in all tested cells when recordings 
were performed in presence of 5µM U0126 (n=5). (B) The histogram shows that EPSPs 
amplitude is not significantly different measured before and 30 min after tetanus p=0.89. 
(EPSPs amplitude is expressed as % of control). 
 
Supplementary fig. 2. Ribosomal protein S6 phosphorylation is increased 10 min 
after LTP inducing stimulus. In all images immunofluorescence of p-S6 is represented 
in red, EGFP in green and neuronal nuclear labeling NeuN in blue. (A) Representative 
images of non-stimulated, control slices (upper panels) and HFS stimulated slices (lower 
panels) from M4-EGFP, (B) A2A-EGFP and (C) M4-EGFP/ Ras-GRF1 KO mice. (D) 
No increase in p-S6 levels was observed in slices pre-treated with 5µM U0126. Scale 
bars 20 µm. (E) Graph showing the percentage of p-S6 positive neurons over the total 
number of NeuN-positive cells in M4-EGFP, A2A-EGFP and M4-EGFP/Ras-GRF1 KO, 
in non-stimulated and HFS stimulated slices (M4-EGFP, A2A-EGFP control (n=13) vs. 
HFS stimulation (n=15) **P<0.001; M4-EGFP/Ras-GRF1 KO control n=8 vs. HFS 
stimulation n=8, Student’s t test *p<0.01). Graph also shows that the increase in p-S6 
levels 10 min after HFS protocol is prevented by application of 5 µM U0126 in the bath 
solution (n=3). (F) Percentage of p-S6 positive cells over the number of cells in direct 
pathway in control and HFS stimulated slices from M4-EGFP (control n=7, HFS n=8; 
Student’s t test p<0.05*) and M4-EGFP/Ras-GRF1 KO mice (control n=9 vs. HFS n=8, 
Student’s t test *p>0.05). (G) Percentage of p-S6 positive cells over the number of cells 
in indirect pathway, in control and HFS stimulated slices from A2A-EGFP mice (control 
n=6 vs. HFS n=7, Student’s t test *p<0.01) and M4-EGFP/Ras-GRF1 KO mice (control 
n=8 vs. HFS n=8, Student’s t test *p<0.01). Data are means ± SEM.    
 
Supplementary fig. 3.  Attenuated Abnormal Involuntary Movements (AIMs) after 
L-dopa treatment in Ras-GRF1 KO mice (A) Spontaneous turning evaluation after 6-
OHDA denervation in Ras GRF1 KO and wt mice. (B) Chronic L-DOPA treatment 
induces mild abnormal involuntary movements (AIMs) in Ras GRF1 KO mice (n=7) 
compared to WT (n=7) animals. Genotype effect, two way ANOVA, p<0.001. (C) The 
histogram shows the AIMs amplitude in Ras GRF1 KO compared to WT L-DOPA-
treated groups measured in the last session test, Student’s t-test, *p<0.05. 
 
Supplementary fig 4 
(A) Representative photomicrographs of phospho-ERK1/2 immunoreactive cells in the 
dorsolateral part of the striatum after 9 days of L-dopa treatment. An aberrant phospho-
ERK activation was observed in dyskinetic WT animals while a severe reduction was 
seen in Ras-GRF1 KO animals. (B) Quantification of p-ERK1/2 positive cells 
(mean±sem) in the striatum of Ras-GRF1 mutants and control animals. Two–way 
ANOVA revealed a significant reduction in the number of pERK positive cells in 
lesioned striatum of Ras-GRF1 mutants (n=8) in comparison to littermate controls (n=8) 
(Tukey’s HSD test, *p<.001 genotype effect). (C) Immunofluorescence of citoplasmatic 
p-S6 (red), and neuronal nuclear labeling NeuN (blu) of MSNs of dyskinetic Ras-GRF1 
mutants and control animals. The graph provided quantitative data of the percentage 
number of p-S6 positive cells over the total NeuN-positive neurons. 
(D) Immunofluorescence of nuclear p-H3 (red), and nuclear NeuN (blu) of MSNs of Ras-
GRF1 mutants and control animals. (WT n=7 vs. Ras-GRF1 KO n=9, Student’s t test 
*p<0.05). 
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